netFormulary
 Report : A-Z of formulary items 23/09/2018 07:59:06
[Back]
 
Section Name Details
06.04.01.01 Continuous combined HRT patch Evorel® Conti
06.02.01 Liothyronine 
  • Liothyronine 20mg tablets
    • In line with British Thyroid Association (BTA) guidance, where levothyoroxine has failed, liothyronine may be recommended for individual patients after a carefully audited trial of at least 3 months duration of liothyronine.
    • Existing patients should be reveiwed, as appropriate, by an endocrinologist to ensure the continuing need for liothyronine. Patients shouldn't have treatment stopped without review by an endocrinologist.     
  • Liothyronine 20microgram injection. Red Traffic Light
13.02.01.01 Oilatum® Bath Emollient  
13.05.02 5-Methoxypsoralen 20mg tablets 
13.05.02 8-Methoxypsoralen 10mg tablets 
05.03.01 Abacavir 
05.03.01 Abacavir & Lamivudine 
05.03.01 Abacavir & Lamivudine & Dolutegravir 
05.03.01 Abacavir & Lamivudine & Zidovudine 
10.01.03 Abatacept Orencia®
  • Abatacept 250mg injection is approved for:
    • Juvenile idiopathic arthritis in patients aged six years and above (licensed) and under six years. It should only be prescribed with informed consent.
    • People aged 6 years and older to treat polyarticular juvenile idiopathic arthritis (JIA) whose diease has responded inadequately to other DMARDs, including at least one tumour necrosis factor (TNF) inhibitor in accordance with NICE.
    • Rheumatoid arthritis after the failure of a TNF inhibitor in line with NICE.
    • Treatment in adults with severe rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed in accordance with NICE.

  • Abatacept 125mg SC injection (prefilled syringe) is approved for moderate to severe rheumatoid arthritis in accordance with NICE.
02.09 Abciximab 
09.06.07 Abidec® 
  • Drops containing in each 0.6ml dose ascorbic acid 50mg, ergocalciferol
    400 units, nicotinamide 5mg, pyridoxine HCL 500micrograms, riboflavin
    400 micrograms, thiamine 1mg & vitamin A 1,333 units.
    To be used in children and adults.
08.03.04.02 Abiraterone 
  • Approved for castration-resistant metastatic prostate cancer in line with NICE.
  • Approved for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated in line with NICE and NHS England Commissioning Policy.
04.10.01 Acamprosate 
06.01.02.03 Acarbose 
04.08.01 Acetazolamide 
11.06 Acetazolamide 

250mg tablets Green Traffic Light
500mg injection Red Traffic Light

12.01.01 Acetic Acid 2% spray Earcalm ®
19 Acetic acid 5% 
  • T o be diluted to 2.5%
    - approved for the use in the detection of dysplasia/ neoplasia
    in Barrett’s oesophagus
11.08.02 Acetylcholine Chloride 
  • 20mg in 2ml injection.
03.07 Acetylcysteine 
  • 600mg plain and effervescent tablets.
  • For use on specialist advice in the treatment of idiopathic pulmonary fibrosis.
  • For the prevention of x-ray contrast media induced renal damage Red Traffic Light.
16 Acetylcysteine 2gram in 10ml injection 

Paracetamol overdose


11.08.01 Acetylcysteine 5% eye drops and preservative eye drops 
11.08.01 Acetylcysteine 5% with Hypromellose 0.35% 
05.03.02.01 Aciclovir 
11.03.03 Aciclovir 3% eye ointment  
13.10.03 Aciclovir 5% cream 
11.03.03 Aciclovir 800mg Tablets 
  • For the treatment of ophthalmic zoster.
12.03.02 Aciclovir tablets and suspension 

see section 05.03.02

13.05.02 Acitretin Neotigason®
  • 10mg and 25mg capsules 
03.01.02 Aclidinium Eklira Genuair®
03.01.04 Aclidinium & formoterol inhaler Duaklir Genuair®
  • Alternative LABA/LAMA for COPD.
18.03.03 Acticoat® Flex 3 

Conformable antimicrobial barrier dressing consisting of polyester core between low adherent silver-coated high density polyethylene mesh.

  • Specialist initiation only 
18.03.03 Acticoat® Flex 7 

Conformable antimicrobial barrier dressing consisting of polyester core between low adherent silver-coated high density polyethylene mesh.

  • Specialist initiation only
18.10 Acti-glide® 
18.09.01 Actilymph® 
18.03.03 Actisorb Silver 220 

Knitted fabric of activated charcoal with one-way stretch, with silver residues, within spun-bound nylon sleeve

18.06.01 ActiV.A.C.® 
18.09.01 Activa® hosiery 
16 Activated charcoal Actidose Aqua Advance®, Carbomix®
  • Actidose Aqua Advance® – 50g in 240ml suspension
  • Carbomix® - 50g powder supplied in a bottle to which
    water is added to prepare a suspension
16 Activated Charcoal Actidose Aqua Advance®, Carbomix®
  • Actidose Aqua Advance® – 50g in 240ml suspension
  • Carbomix® - 50g powder supplied in a bottle to which
    water is added to prepare a suspension
18.02.05 ActivHeal Foam 

Polyurethane Foam Film Dressing without Adhesive Border

18.02.06 ActivHeal® Alginate  

Calcium sodium alginate dressing

18.02.06 ActivHeal® Aquafiber 

Non-woven, calcium sodium alginate dressing

18.02.01 ActivHeal® Hydrogel 
  • 8g only
18.08.02 Actiwrap® Latex-free Bandage 

Polyamide and Cellulose Contour Bandage, BP 1988

 

01.05.03 Adalimumab Humira®
  • Only approved for use in accordance with NICE guidance. 
10.01.03 Adalimumab Humira®
  • Adalimumab is approved for:
    • The treatment of adults with severe rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed in accordance with NICE 
    • Rheumatoid arthritis after the failure of a TNF inhibitor in accordance with NICE.
    • Treatment of severe active ankylosing spondylitis in adults whose disease has responded inadequately to, or who cannot tolerate, non-steroidal anti-inflammatory drugs in accordance with NICE.
    • Psoriatic arthritis in accordance with NICE.
    • As a second-line anti-TNF therapy in children with juvenile idiopathic arthritis and uveitis.
    • Children and adults aged 2 years and older to treat polyarticular juvenile idiopathic arthritis (JIA) whose disease has responded inadequately to 1 or more DMARD in accordance with NICE.

11.04.02 Adalimumab  Humira®
  • 40mg Injection
  • Approved for the treatment of children with Severe Refractory Uveitis in line with interim NHS England Clinical Commissioning Policy.
  • Approved for the treatment of adults with Severe Refractory Uveitis in line with interim NHS England Clinical Commissioning Policy.
  • Approved for the treatment of non-infectious uveitis in line with NICE and NHS England Commissioning Policy (replaces interim policy for adalimumab for adults with severe refractory uveitis from 24th October 2017)
13.05.03 Adalimumab Humira®
  • Approved for psoriasis in line with NICE.
  • Approved for the treatment of moderate to severe hidradenitis suppurativa in line with NICE and NHS England Commissioning Policy
  • Approved for the treatment of plaque psoriasis in children and young people in line with NICE
13.06.01 Adapalene 0.1% and benzoyl peroxide 2.5%  Epiduo® Gel
13.06.01 Adapalene 0.1% gel and cream Differin®
18.02.03 Adaptic® Touch 

Non-adherent soft silicone wound Contact Dressing

16 Adder Snakebite Antiserum 
02.03.02 Adenosine 
  • 6mg in 2ml injection
  • 25mg in 5ml injection unlicensedunlicensed
  • 30mg in 10ml injection for infusion - NHCT only
  • 130mg in 130ml IV infusion unlicensedunlicensed
02.07.03 Adrenaline (epinephrine) 
  • 1 in 1,000 injections in 1ml syringes and 1ml & 10ml ampoules.
  • 1 in 10,000 injections in 1ml & 10ml ampoules & syringes.
03.04.03 Adrenaline / Epinephrine Emerade®
  • Approved for use in the emergency treatment of anaphylaxis for patients with a BMI of >40 or who have required more than one auto-injector previously to control symptoms. Specialist immunologist initiation only Green Traffic Light.
  • Approved for use by NUTH Community Dental Team in anaphylaxis boxes Red Traffic Light.
03.04.03 Adrenaline / Epinephrine Jext® & Jext Junior®
03.01.05 AeroChamber Plus® 
08.01.05 Afatinib  
  • Approved as a possible treatment for adults with locally advanced or metastatic non-small-cell lung cancer if their cancer tests positive for the epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation and they have not had an EGFR-TK inhibitor before NICE and additional NHS England criteria.
11.08.02 Aflibercept 4mg/0.1ml injection Eylea®
  • Approved for wet age related macular degeneration in line with NICE.
  • Approved for macular oedema – central retinal vein occlusion in line with NICE.
  • Approved for diabetic macular oedema in line with NICE.
  • Approved for treating visual impairment caused by macular oedema after branch retinal vein occlusion in line with NICE.
  • Approved as an option for treating visual impairment because of myopic choroidal neovascularisation in adults in line with NICE
04.03.04 Agomelatine 
  • NETAG approved for the treatment of depression only following an adequate trial of at least three alternative antidepressant drugs at maximally tolerated doses (as described by NICE and as stated in the BNF).

 

  • Prescribing and monitoring should be initiated by specialist mental health physicians. After a minimum of 12 weeks, prescribing may be transferred to primary care. 
02.03.02 Ajmaline 
  • For use as a diagnostic test of Brugada syndrome.
05.05.01 Albendazole 
13.11.01 Alcohol hand rub gel 
13.11.01 Alcohol impregnated wipes 

Containing 70% isopropyl alcohol or methylated spirit (e.g. Clini-wipes®, Alcowipes®)

11.09 Alcon Optifree® Express System 
08.02.03 Alemtuzumab 
  • Alemtuzumab 30mg in 1ml concentrate for IV infusion is approved for use in, lymphocytic leukaemia & prevention of graft vs. host disease in bone marrow transplant patients, and high-risk kidney and pancreas transplantation.
  • Alemtuzumab 12mg in 1.2ml concentrate for IV infusion is approved for treating adults with active relapsing– remitting multiple sclerosis in line with NICE and NHS England commissioning policy. 
06.06.02 Alendronic Acid 
  • Approved alendronic acid formulations include:
    • 10mg tablets (taken daily)
    • 70mg tablets (taken once weekly) – preferred
    • 70mg effervescent tablets (Binosto®) - for use only in patients with documented swallowing difficulties

  • Alendronic acid is approved for the primary prevention of osteoporosis in postmenopausal women in line with NICE
  • Approved for the secondary prevention of osteoporotic fragility fractures in postmenopausal women who are confirmed to have osteoporosis primary in line with NICE.
  • Approved for the treatment of osteoporosis in line with NICE
09.06.04 Alfacalcidol 
  • 250 nanogram & 1 microgram capsules
  • 2 microgram/ml sugar-free oral drops – one drop containing approx. 100 nanograms of alfacalcidol 
  • 1 microgram in 0.5ml & 2 micrograms in 1ml injections
15.01.04.03 Alfentanil 
  • 1mg in 2ml, 5mg in 10ml & 5mg in 1ml injections - approved for initiation by specialists in palliative care
07.04.01 Alfuzosin 2.5mg tablets and 10mg XL tablets 
18.03.01 Algivon® 

Absorbent, non-adherent calcium alginate dressing impregnated with medical grade manuka honey

  • Specialist use only
15.01.04.01 Alimeazine 
  • 30mg/5ml syrup.
    • see section 03.04.01 for other formulations.

03.04.01 Alimemazine 
  • Hospital only for the following indications
    • Enteral sedation in paediatric ITU setting
    • Use in patients where promethazine has failed

  • Existing patients can continue to be prescribed in primary care until a treatment review has taken place  
02.12 Alirocumab 
  • Only approved for use in accordance with NICE guidance.
02.05.05.03 Aliskiren 
  • Only approved for use in the treatment of hypertension in patients who have failed to respond adequately to, or not tolerated, other treatments (including thiazide diuretics, calcium channel blockers, ACE inhibitors, angiotensin receptor blockers and beta-blockers).
  • Aliskiren has NOT been approved for use in combination with other drugs to maximise suppression of the renin angiotensin system in patients with diabetes and/or renal disease.
13.05.01 Alitretinoin Toctino®
  • Approved for adults with severe chronic hand eczema that have not responded to potent topical corticosteroids in line with NICE.
18.02.05 Allevyn® Adhesive  

Polyurethane Foam Film Dressing with Adhesive Border

 

18.02.03 Allevyn® Gentle 

Soft Polymer Wound Contact Dressing with Polyurethane Foam Film Backing

18.02.03 Allevyn® Gentle Border  

Silicone gel wound contact dressing, with polyurethane foam film backing

18.02.03 Allevyn® Gentle Border Lite 

Silicone gel wound contact dressing, with polyurethane foam film backing

  • Podiatry only
18.02.03 Allevyn® Life 

Soft silicone wound contact dressing, with central mesh screen, polyurethane foam film backing and adhesive border

10.01.04 Allopurinol 
  • An allopurinol 100mg in 5ml suspension (unlicensedunlicensed) is also approved for use. 
10.01.04 Allopurinol 
  • An allopurinol 100mg in 5ml suspension (unlicensedunlicensed) is also approved for use. 
06.01.02.03 Alogliptin  
06.01.02.03 Alogliptin / metformin 
09.06.05 Alpha Tocopherol Vedrop®
  • 50mg in 1ml oral solution - approved for the treatrment of children with vitamin E deficiency due to fat malabsorption syndromes.
09.06.05 Alpha Tocopheryl Acetate 
  • 500mg in 5ml suspension
  • 134mg (200 unit) capsules
13.05.02 Alphosyl HC® cream 
  • Cream containing coal tar extract 5%, hydrocortisone 0.5% and allantoin 2%
07.04.05 Alprostadil Vitaros® & Muse®
  • Vitaros® 3mg/g cream
  • Muse® 250microgram, 500microgram, and 1mg.
07.04.05 Alprostadil Caverject® & Viridal Duo®
  • Approved as the second choice intracavernosal injection option.
  • Caverject® 10, 20 & 40 microgram injections (Caverject® dual chamber injections are easier to use and less expensive than the vials).
  • Viridal Duo® 10, 20 and 40 microg starter pack and dual chamber injection (approved for use whilst supply issues surrounding Caverject® are ongoing).
01.01.01 Altacite plus 
02.10.02 Alteplase 
  • 10mg, 20mg, and 50mg injections.
  • Also approved for stoke in accordance with NICE guidance. 
  • 2mg in 2ml injection - approved for unblocking intravenous lines, mainly in paediatric dialysis patients.

 

18.09.01 Altiform® Hosiery 
18.09.01 Altipress® 
13.12 Aluminimum Chloride  Driclor®, Anhydrol Forte®
  • Aluminium chloride hexahydrate 20% solution in an alcoholic basis
04.09.01 Amantadine 
  • For use on the advice of neurologists.
02.05.01 Ambrisentan 
  • Approved for pulmonary hypertension - in accordance with NHS England Commissioning policy. 
05.01.04 Amikacin 
  • Restricted for use on microbiology/infectious diseases advice, or as agreed in Trust Guidelines.
02.02.03 Amiloride Hydrochloride 
02.11 Aminocaproic acid 
  • Approved for the use in paediatric patients undergoing extracorporeal membrane oxygenation (ECMO).
03.01.03 Aminophylline 
  • COPD: intravenous aminophylline of limited benefit.
  • Injection used in hospital for acute asthma not responding to steroids and continuous inhaled bronchodilators.
  • Plasma levels need to be checked before administration if patient has previously taken theophylline/ aminophylline.
02.03.02 Amiodarone 
  • 100mg & 200mg tablets Green Traffic Light
  • 50mg in 5ml suspension is also approved Green Traffic Light unlicensedunlicensed
  • 150mg/3ml & 300mg/10ml injection Red Traffic Light

 

04.02.01 Amisulpride 
04.03.01 Amitriptyline 
04.07.03 Amitriptyline 
04.07.04.02 Amitriptyline 
06.01.05 Amitriptyline 
07.04.02 Amitriptyline  
  • 10mg, 25mg and 50mg tablets
  • 25mg in 5ml sugar-free oral solution is also approved for use.
02.06.02 Amlodipine 
  • Preferred calcium channel blocker for treating hypertension.
    • If a 10mg dose is not tolerated e.g. due to leg/ankle
      oedema, consider reducing dose before changing to an
      alternative such as lercanidipine.

13.10.02 Amorolfine 5% nail lacquer cream Loceryl®
05.01.01.03 Amoxicillin 
05.02.03 Amphotericin 
  • 50mg injection (Fungizone®)
  • 50mg liposomal injection (Ambisome®)
12.03.02 Amphotericin 100mg/1ml oral suspension 
  • Approved for specialist use in chronic mucocutaneous candidiasis unlicensedunlicensed.
11.03.02 Amphotericin B Preservative-free 
  • 0.1% and 0.3% eye drops.
08.01.05 Amsacrine  
09.01.04 Anagrelide 
  • For the treatment of thrombocythemiaas a 2nd line agent in patients poorly/non-responsive tohydroxycarbamide therapy.
10.01.03 Anakinra Kineret®
  • Approved for:
    • Use by specialists in Systemic onset Juvenile Idiopathic Arthritis (SoJIA) and Chronic Infantile Neurocutaneous Arthritis (CINCA) and Muckle-Wells Syndrome (unlicensedunlicensed indications).
    • The treatment of severe gout in patients who have not responded to other treatment and for patients with pseudogout who have failed to respond to conventional treatment or unable to tolerate conventional treatment.
    • Adult onset still’s disease (diagnosed prior to November 2013).

08.03.04.01 Anastrozole 
18.08.08 AndoFlex® TLC  
  • Specialist use only
18.08.08 AndoFlex® UBZ 
  • Specialist use only
05.02.04 Anidulafungin 
01.01.02 Antacid with oxetacaine 
  • Used to relieve symptoms in patients who have had radiotherapy and may be of value in some patients with acute oesophagitis. Not for routine use as an antacid.
11.04.02 Antazoline 0.5% with Xylometazoline 0.05% Otrivine-Antistin®
14.05.03 Anti-D (Rh0) Immunoglobulin Rhophylac®
  • Approved for the prevention of RhoD sensitisation in
    women in line NICE.
  • Approved for use by haematologists in appropriate patients with immune thrombo-cytopenia. The 1,500 and 5,000 unit vials (WinRho) are much more expensive than the other formulations and should only be used on advice from haematologists. It is the only formulation licensed for use in immune thrombocytopaenia.
14.05.03 Anti-D (Rh0) Immunoglobulin WinRho SDF®
  • Approved for the prevention of RhoD sensitisation in
    women in line NICE.
  • Approved for use by haematologists in appropriate patients with immune thrombo-cytopenia. The 1,500 and 5,000 unit vials (WinRho) are much more expensive than the other formulations and should only be used on advice from haematologists. It is the only formulation licensed for use in immune thrombocytopaenia.
08.02.02 Antithymocyte immunoglobulin (horse)  Thymoglobuline®
  • NETAG approved for aplastic anaemia in adults (unlicensedunlicensed).
08.02.02 Antithymocyte immunoglobulin (rabbit)  Thymoglobuline®
  • Used in the management of transplant rejection.
01.07.01 Anusol ® 

Cream and Suppositories

01.07.02 Anusol®HC 
01.07.02 Anusol-HC 
02.08.02 Apixaban 
  • Only approved for use in accordance with NICE guidance. 
04.09.01 Apomorphine 
  •  Apomorphine 10mg lozenges are also approved (RVI) unlicensedUnlicensed
18.07.02 Appeel® Single Use Wipes 
  • Specialist use only 
11.08.02 Apraclonidine 
  • 0.5% and 1% ophthalmic solution.
10.01.03 Apremilast Otezla®
  • Approved for the treatment of psoriatic arthritis in line with NICE
13.05.03 Apremilast Otezla®
  • 10mg, 20mg & 30mg tablets
  • To be used in accordance with NICE guidance
04.06 Aprepitant 
  • For the prevention of chemotherapy induced nausea and vomiting (CINV) in high risk patients in accordance with North of England Cancer Network: CINV Guidelines in adult oncology and haematology patients
02.11 Aprotinin 
  • For limited use in cardiothoracic surgery.
A2.03.01 Aptamil 
18.02.04 Aquacel® 

Soft non-woven pad containing hydrocolloid-fibres

18.03.03 Aquacel® Ag Extra 
18.02.04 Aquacel® Extra 

Soft sterile non-woven pad containing hydrocolloid fibres.

  • Provides greater tensile strength compared to aquacel 
18.02.04 Aquacel® Foam 

Soft non-woven pad containing hydrocolloid-fibres with foam layer, without adhesive border

18.02.04 Aquacel® Foam Border 

Soft non-woven pad containing hydrocolloid-fibres with foam layer, with adhesive border

18.02.04 Aquacel® Surgical cover dressing 
  • Not to be prescribed on FP10
13.02.01 Aquamax® 
  • Approved for used in radiotherapy only.
13.02.01 Aqueous Cream BP 
  • Due to the SLS content to be used as a soap substitute only.
01.06.03 Arachis Oil 
02.08.01 Argatroban 
  • For use on advice of haematologists in patients with heparin induced thrombocytopenia.
06.05.02 Argipressin 20units in 1ml injection 
04.02.01 Aripiprazole 
  • Approved for schizophrenia in people aged 15 to 17 years in line with NICE.
  • Approved for moderate to severe manic episodes in young people aged 13 and older with bipolar I disorder NICE. 
  • Aripriprazole 10mg & 15mg orodispersible tablets are approved for doses over 5mg for those patients who have difficulty swallowing. 
  • Aripiprazole 1mg in 1ml oral solution is only for doses of 5mg or less, or when titrating patients on doses of increments of less than 5mg, in patients who have difficulty swallowing tablets.
  • To be used in accordance with NICE criteria
  • Note: Aripiprazole 7.5mg/ml IM Injection is approved for use in rapid tranquilisation in patients with acute psychosis. Red Traffic Light NTW use only.
04.02.02 Aripiprazole Abilify Maintena®
  • NTAG approved for the treatment of schizophrenia as per its licensed indication and as outlined in the Guidance on the Use of Antipsychotic Long-acting Injections in the North of England.
08.01.05 Arsenic Trioxide  
  • NECDAG approved relapsed or refractory acute promyelocytic leukaemia (APL).
05.04.01 Artesunate 
  • Approved for severe malaria in in line WHO guidance.
15.02 Articaine Hydrochloride with Adrenaline 
  • Articaine 4% & adrenaline 1 in 100,000 injection
    • approved for mandibular procedures in patients in whom nerve blocks are contraindicated.

12.03.05 AS Saliva Orthana® 
  • preferred to Glandosane® as it is less likely to damage tooth enamel.
09.06.03 Ascorbic Acid Vitamin C
  • 50mg, 100mg, 200mg & 500mg tabs
  • 500mg in 5ml injection unlicensedunlicensed
11.08.02.04 Ascorbic acid 10% Preservative-free eye drops 
18.03.03 Askina® Calgitrol 15g Paste 
  • Specialist use only
02.09 Aspirin 
  • 75mg dispersible tablets
  • Note: 75mg e/c tablets – no longer recommended for use.
04.07.01 Aspirin 
04.07.01 Aspirin 
04.07.04.01 Aspirin 
02.09 Aspirin 500mg in 5ml injection 
  • For specialist use in the endovascular treatment of cerebral
    aneurysms
10.02.01 Ataluren Translarna®
  • Approved for the treatment of Duchenne Muscular Dystrophy in children -in line with NICE a nd NHSE commissioning policy (SSC 1633).
05.03.01 Atazanavir 
  • For limited use as part of triple therapy where other protease inhibitors are unsuitable
05.03.01 Atazanavir sulfate and cobicistat 

To be used in accordance with NHS England Clinical Commissioning Policy (SSC1614).

02.03.02 Atenolol 
02.04 Atenolol 
08.01.05 Atezolizumab 
  • 1200mg/20mL concentrate for solution for infusion
  • Approved for treating locally advanced or metastatic non-small-cell lung cancer (NSCLC) in adults who have had chemotherapy (and targeted treatment if they have an EGFR- or ALK‑positive tumour). CDF
  • Approved for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma after disease progression following one prior platinum-containing chemotherapy regimen. CDF 
04.04 Atomoxetine 
  • 10mg, 18mg, 25mg, 40mg, 60mg, 80mg & 100mg capsules
  • 4mg/1ml oral solution - approved for patients with more complex needs e.g. younger patients and those with swallowing difficulties.
02.12 Atorvastatin 
  • Note: atorvastatin 10mg and 20mg chewable tablets should be used instead of simvastatin suspension where solid dosage forms cannot be used. 
07.01.03 Atosiban 
  • Approved formulations include:
    • 6.75mg in 0.9ml injection
    • 37.5mg in 5ml (7.5mg/ml) concentrate for IV infusion.

05.04.08 Atovaquone 
  • Approved for use in patients intolerant of co-trimoxazole
15.01.05 Atracurium 
  • 25mg in 2.5ml
  • 50mg in 5ml  
  • 250mg in 25ml injection
18.01.01 Atrauman  
01.02 Atropine  
  • Approved formulations include 600microgram tablets and 500microgram in 5ml mixture (unlicensedunlicensed).
11.05 Atropine 
  • 1% eye drop.
    1% ointment.
    1% preservative-free eye drops unlicensedunlicensed.
15.01.03 Atropine 600microgram injection 
15.01.03 Atropine pre-filled syringes minijet®
  • 1mg in 5ml and 3mg in 30ml injections in prefilled syringes used in cardiac resuscitation.
11.05 Atropine Sulphate Single Use Minims® 
07.04.05 Avanafil 
  • Approved only for second line use after intolerance to, or failure of sildenafil
13.02.01 Aveeno® Cream
07.04.05 Aviptadil 25microgram/phentolamine 2mg solution for injection Invicorp®
  • Approved as first choice intracavernosal injection option.
  • Aviptadil 25microgram/phentolamine 2mg solution for injection.
08.01.05 Axitinib  
  • Approved as treatment for adults with advanced renal cell carcinoma when tyrosine kinase inhibitors or cytokines have not worked in line with NICE.
08.01.03 Azacitidine  
  • Approved for myelodysplastic syndromes, CLL and AML - in line with NICE guidance.
01.05.03 Azathioprine 
01.05.03 Azathioprine 
08.02.01 Azathioprine 
  • An azathioprine 50mg in 5ml suspension (unlicensedunlicensed) is also available.
10.01.03 Azathioprine 
  • See section 8.2.1
13.06.01 Azelaic Acid  
  • 15% (Finacea®) and 20% (Skinoren®) gel 
12.02.01 Azelastine Hydrochloride 140microgram nasal spray Rhinolast®
05.01.05 Azithromycin 
05.01.02.03 Aztreonam 
  • Restricted for use on microbiology/infectious diseases advice, or as agreed in Trust Guidelines.
05.01.02.03 Aztreonam nebuliser solution Cayston®
  • To be used in accordance with NHS England Commissioning Policy   
10.02.02 Baclofen 
  • The following baclofen intrachecal injections (unlicensedunlicensed) are also approved; 36mg in 12ml, and 72mg in 12ml intrathecal injections.Red Traffic Light
11.08.01 Balanced Salt Solution 
  • Sterile solution containing sodium chloride 0.64%, sodium acetate 0.39%, sodium citrate 0.17%, calcium chloride 0.048%, magnesium chloride 0.03%, potassium chloride 0.075% in 15ml bottles and 500ml bags.
  • For intra-ocular or topical irrigation during surgical procedures.
13.02.01.01 Balneum® Bath Additive 
13.02.01 Balneum® Plus cream 
01.05.01 Balsalazide Sodium 

Alternatives

10.01.03 Baricitinib Olumiant®
  • 2mg & 4mg film-coated tablets
  • Approved for the treatment of moderate to severe rheumatoid arthritis in adults in line with NICE
08.02.02 Basiliximab 
  • Approved for limited use in adult renal transplant patients with high risk of acute organ rejection.
  • Approved for severe graft versus host disease post haematopoietic stem cell transplantation.
  • Approved for induction therapy in renal transplantation in children and adolescents in with combinations that include ciclosporin in line with NICE.
11.09 Bausch & Lomb contact lens solution Boston®
11.09 Bausch & Lomb saline Salette®
08.02.04 BCG 81mg vial (connaught) 
03.02 Beclometasone 
  • QVAR® MDI, QVAR® Easibreathe, QVAR® Autohaler
  • Clenil Modulite®
  • Easyhaler®

Note: CFC-Free beclometasone must be prescribed by brand name. 50 mcg QVAR is equivalent to 100 mcg for a conventional inhaler & 100 mcg is equivalent to 250 mcg conventional beclometasone. 

03.02 Beclometasone and formoterol Fostair®
  • Third Choice ICS/LABA combination
    • CFC-free MDI (Fostiar®)
    • DPI (Fostair NEXThaler®)

      Note:
      100 mcg of beclometasone in Fostair® is equivalent to a 250 mcg dose in a conventional beclometasone metered dose inhaler (e.g. Becloforte, Beclazone and Clenil Modulite).

12.02.01 Beclometasone Dipropionate 50 microgram nasal spray 
05.01.09 Bedaquiline 
  • To be used in accordance with NHS England Commissioning Policy 
03.04.02 Bee and Wasp Allergen Extracts Pharmalgen®
  • For use in adults and children by adult and paediatric immunologists only. Only approved for use in accordance with NICE guidance. 
10.01 Belimumab 

Approved for the treatment of active autoantibody-positive systemic lupus erythematosus in line with NICE.

10.01.03 Belimumab Benlysta®
  • Approved for the treatment of active autoantibody-positive systemic lupus erythematosus in accordance with NICE.
08.01.01 Bendamustine  
  • Approved for the first line treatment of CLL (Binet stage B or C) in, patients for whom fludarabine combination chemotherapy is not appropriate in line with NICE. 
  • NECDAG approved for use in combination with rituximab for patients with CLL not fit for FCR chemotherapy and not fit for alemtuzumab. 
  • Approved for Low Grade Non-Hodgkins Lymphoma in line with NICE - not recommended for (low grade) non-Hodgkin's lymphoma that is refractory to rituximab or a rituximab-containing regimen NICE.
02.02.01 Bendroflumethiazide 2.5mg tablets 
  • Current patients should continue on bendroflumethiazide
  • Bendroflumethiazide 5mg tablets are available but not recommended for general use.
12.03.01 Benzocaine 
12.03.03 Benzocaine 1.5mg spray 
12.03.01 Benzocaine/Dequalinium Dequacaine®
13.06.01 Benzoyl Peroxide 10% Aquagel and 5% gel PanOxyl®
13.06.01 Benzoyl Peroxide 4% cream Brevoxyl®
13.06.01 Benzoyl Peroxide 5% Gel Acnecide®
13.06.01 Benzoyl Peroxide 5% with Clindamycin 1% Duac®
12.03.01 Benzydamine Mouthwash & Spray Difflam®
05.01.01.01 Benzylpenicillin 
11.03.01 Benzylpenicillin 0.3% Eye drops 
05.01.01.01 Benzylpenicillin Benzathine 
02.11 Beriplex - P/N® 
  • Approved for reversing the effects of oral anticoagulants in patients with life or limb threatening bleeding in accordance with a regional protocol.
04.06 Betahistine Dihydrochloride 
13.04 Betamethasone (as Dipropionate) 0.05% with Salicylic Acid 2% Diprosalic®
  • Scalp application
13.04 Betamethasone (as Dipropionate) 0.05% with Salicylic Acid 3% Diprosalic®
  • Ointment
13.04 Betamethasone (as Valerate) 0.025% Betnovate-RD®

MODERATELY POTENT

  • Cream and ointment
13.04 Betamethasone (as Valerate) 0.1% 

POTENT

  • Cream, ointment & scalp application
13.04 Betamethasone (as Valerate) 0.1% with Clioquinol 3% Betnovate C®

POTENT

  • Cream and ointment
13.04 Betamethasone (as Valerate) 0.1% with Fucidic Acid 2% Fucibet®

POTENT

13.04 Betamethasone (as Valerate) 0.1% with Neomycin Sulphate 0.5% was Betnovate-N®

POTENT

Cream and ointment

13.09 Betamethasone 0.05%, salicylic acid 2% Diprosalic ®
13.09 Betamethasone 0.1% 
12.01.01 Betamethasone 0.1% ear/eye/nose drops 
  • First choice corticosteroid ear drops.
11.04.01 Betamethasone 0.1% eye drops & eye ointment 
12.02.01 Betamethasone 0.1% eye/ear/nose drops 
12.01.01 Betamethasone 0.1% with neomycin 0.5% ear drops Betnesol N®
  • Alternative choice compound antibacterial/corticosteroid ear drop.
11.04.01 Betamethasone 0.1% with Neomycin 0.5% eye drops 
06.03.02 Betamethasone 4mg in 1ml 
11.08.02 Bevacizumab 1.25mg/0.5ml intravitreal injection 
  • NETAG approved for use in the management of macular oedema
    secondary to retinal vein occlusion. This is considered a more cost
    effective treatment option in RVO compared with ranibizumab.
  • NTAG approved for age related macular degeneration.
02.12 Bezafibrate 
18.02.03 Biatain® Silicone 

Silicone gel wound contact dressing, with polyurethane foam film backing

18.02.03 Biatain® Silicone Lite 

Silicone gel wound contact dressing, with polyurethane foam film backing

08.03.04.02 Bicalutamide 

Initiate with specialist advice.

11.06 Bimatoprost eye drops 
11.06 Bimatoprost with Timolol eye drops 
  • For use as a second/third-line agent in patients insufficiently responsive
    to monotherapy with a prostaglandin analogue or beta blocker
19 BioGaia® 
12.03.05 Biotene Oralbalance® gel 
19 Biotin 5mg tablets 
12.03.05 BioXtra® 
  • The gel, but not the toothpaste, is prescribable on the NHS in primary care as a
    Borderline Substance
06.01.01.02 Biphasic Insulin Aspart NovoMix® 30
  • Approved NovoMix® 30 formulations include:
    • 5x3ml cartridges (for use with Novopen® and Novopen® Penmate injection devices)
    • 5x3ml Flexpen® pens. 

06.01.01.02 Biphasic Insulin Lispro Humalog® Mix 25 amd Mix 50
  • Humalog® Mix 25 and Mix 50 formualtions approved include:
  • 5x3ml cartridges;
  • 5x3ml Kwikpen®.
06.01.01.02 Biphasic Isophane Insulin Mixtard® 30
  • Approved Mixtard® 30 formulations include:
    • 10ml vials;
    • 5x3ml cartridges (for use with Novopen and Novopen Penmate injection devices);
    • 5x3ml Innolet® pens. 

06.01.01.02 Biphasic Isophane Insulin Humulin® M3
  • Approved Humulin®M3 formulations include:
    • 10ml vials;
    • 5x3ml cartridges;
    • 5x3ml pens. 

01.06.02 Bisacodyl 
12.02.03 Bismuth Subnitrate and Iodoform (B.I.P.P.)  1.25cm x 100cm & 2.5cm x 100cm impregnated gauze
13.10.05 Bismuth Subnitrate and Iodoform (B.I.P.P.) Paste 
  • For use in ENT surgery & epistaxis
    1.25cm x 100cm & 2.5cm x 100cm impregnated gauze
02.04 Bisoprolol 
  • 5mg & 10mg tablets.
  • 1.25mg, 2.5mg, 3.75mg & 7.5mg tablets - for use in the treatment of heart failure only. The 5mg and 10mg tablets should be used where possible - cheaper than other strengths.
02.08.01 Bivalirudin 
  • Approved for preventing thrombosis in patients undergoing percutaneous coronary artery interventions.
  • For use instead of abciximab in some low risk patients.
  • Approved in combination with aspirin and clopidogrel for the treatment of adults with ST segment elevation MI undergoing percutaneous coronary intervention, in accordance with NICE guidance. 
08.01.02 Bleomycin  
  • Also approved for use in intralesional sclerotherapy in the treatment of low-flow vascular lesions. unlicensedunlicensed indication
08.02 Blinatumomab Blincyto®
  • 38.5 micrograms powder for concentrate and solution for solution for infusion
  • Approved for use in previously treated Philadelphia-chromosome-negative acute lymphosblastic leukaemia in line with NICE and NHS England Commissioning Policy
13.11.06 Bonney's Blue Paint 
  • For limited use in some operating theatres only.
12.02.03 Boric Acid & Povidone Iodine 
08.01.05 Bortezomib  
  • Approved for:
    • Relapsed multiple myeloma in line with in line with NICE.
    • Combination with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma in line with NICE. 
    • Induction therapy for multiple myeloma in line with NICE.
    • Treatment of adults with mantle cell lymphoma that has not been treated before, if haemotopoietic stem cell transplantation is not suitable, in line with NICE.

02.05.01 Bosentan 
  • Approved for pulmonary hypertension - in accordance with NHS England Commissioning policy.
  • Approved for systemic sclerosis with ongoing digital ulcer disease (to reduce number of new digital ulcers) - in accordance with NHS England Commissioning policy.
08.01.05 Bosutinib Bosulif®
  • Approved as an option for the treatment of chronic, accelerated blast phase Philidephia chromosome positive chronic myeloid leukaemia in adults when they have previously had 1 or more tyrosine kinase inhibitor and imatinib, nilotinib and dasatanib are not appropriate in line with NICE.
04.09.03 Botulinum Toxi Type A injection Xeomin ®
  • Similar potency to Botox®, and may be less expensive (depending on price agreements/ contracts), but not licensed for the full range of indications.
01.07.04 Botulinum toxin type A 
  • Approved for use by specialists as an alternative to surgery in patients failing other treatments. Also approved for use in paediatrics but there must be documented informed consent from patients/carers.
04.07.04.02 Botulinum Toxin Type A 
  • Only approved for use in accordance with NICE guidance. 
04.09.03 Botulinum Toxin Type A Botox®
  • Botox also approved for use in paediatric patients with severe bladder over- activity and neuropathic bladder who have not responded to other treatment.
  • Prescribe by brand name.
04.09.03 Botulinum Toxin Type A Vistabel®
  • Restricted to use in private patients receiving aesthetic treatment. 
  • Prescribe by brand name.
04.09.03 Botulinum Toxin Type A Dysport®
  • Prescribe by brand name.
13.12 Botulinum toxin type A  
04.09.03 Botulinum Toxin Type B NeuroBloc®
08.01.05 Brentuximab vedotin Adcetris®
  • 50mg powder for concentrate for solution for infusion
  • Approved for the treatment of relapsed or refractory systemic anaplastic large cell lymphoma in line with NICE and NHS England Commissioning Policy.
  • Approved for the treatment of CD30-positive Hodgkin lymphoma in patients:
    • if they have already had autologous stem cell transplant
    • if they have already had at least 2 previous therapies when autologous stem cell transplant or multi-agent chemotherapy are not suitable. CDF

 

13.06.01 Brimonidine Tartate 0.33% gel Mirvaso®
  • For specialist initiation for the treatment of severe rosacea. Following specialist review of effectiveness, primary care can continue supply.
11.06 Brimonidine Tartrate 0.2% eye drops 
11.06 Brinzolamide 
  • 1% eye drops.
11.06 Brinzolamide 10mg/ml & brimonidine 2mg/ml Simbrinza®
  • Approved as a third line agent as an “add-on” in patients at the very end of medical management.
04.08.01 Brivaracetam 
  • Approved for use as adjunctive therapy in patients with severe/intractable partial onset seizures e.g. a sezuire frequency of 1 per week following failure of first-line adjunctive therapy. Response must be assessed within 3-6 months before transferring prescribing to primary or stopping treatment, as appropriate.
13.05.03 Brodalumab Kyntheum®

 

  • 210mg/1.5ml solution for injection in pre-filled syringes.
  • Approved for the treatment of moderate to severe plaque psoriasis in line with NICE 

 

04.09.01 Bromocriptine 
06.07.01 Bromocriptine 2.5mg tablets 
01.05.02 Budesonide 

Alternative

  • Budenofalk® (3mg capsules enclosing e/c pellets)
  • Entocort® (3mg capsules enclosing e/c m/r pellets)
  • For use on consultant gastroenterologist advice only
01.05.02 Budesonide 
  • 2mg foam enema
  • Equal first choice with hydrocortisone foam enema  
03.02 Budesonide 
  • Turbohaler® 
  • Easyhaler®
  • Nebules
03.02 Budesonide and formoterol 
  • First Choice ICS/LABA combination
    • Duroresp Spiromax®: First choice budesonide/formoterol preparation.
    • Symbicort Turbohaler®: Second choice budesonide/formoterol preparation.

02.02.02 Bumetanide 
15.02 Bupivacaine Hydrochloride 
  • 0.25% & 0.5% injection 10ml
  • 0.25% & 0.5% + adrenaline 1 in 200,000 inj. 10ml
  • 0.5% in glucose 8% injection (Marcain Heavy)
  • 0.1% & 0.125% unlicensedunlicensed in sodium chloride 0.9% infusions
04.07.02 Buprenorphine 
  • 200microgram sublingual tablets
  • 300microgram in 1ml injection
  • Buprenorphine patches (Preferred brand - Butec®) are approved for use in palliative care when fentanyl 12 microgram/hr transdermal patches exceed the patient’s analgesic requirements.
  • To be initiated by a specialist
04.10.03 Buprenorphine 400 microgram, 2mg, and 4mg sublingual tablets 
  • Only approved for use in accordance with NICE guidance. 
  • In the treatment of substance misuse the 400microgram strength should be prescribed as Subutex® to avoid a product licensed for pain relief being supplied
04.10.03 Buprenorphine and Naloxone Suboxone®
04.10.02 Bupropion Hydrochloride 
08.03.04.02 Buserelin 
  • Approved formulations include:
    • 5mg in 5ml injection;
    • 150 microgram metered dose nasal spray.

06.07.02 Buserelin 150microgram nasal spray 
08.01.01 Busulfan 
  • Approved formulations include:
    • 2mg tablets;
    • 25mg capsules (unlicensedunlicensed);
    • 60mg in 10ml injection.

03.04.03 C1 Esterase Inhibitor 
  • Approvded for the treatment and pre-procedure prevention of angioedema attacks in patients with hereditary angioedema (HAE).
  • Approvded for the routine prevention of angioedema attacks in adults and adolescents years old with severe and recurrent attacks of HAE.

 

08.01.05 Cabazitaxel  
  • Approved for the treatment of hormone relapsed metastatic prostate cancer treated with with docetaxel in line with NICE.
06.07.01 Cabergoline 500microgram and 1mg tablets 
08.01.05 Cabozantinib Cometriq®
  • Approved for use in the treatment of renal cell carcinoma in line with NICE and NHS England Commissioning Policy
  • Approved for the treatment of medullary thyroid cancer in line with NICE and NHS England Commissioning Policy
03.05.01 Caffeine Citrate 
  • 50mg in 5ml injection (equivalent to 25mg caffeine base in 5ml).
  • 50mg in 5ml oral solution.
03.05.01 Caffeine Citrate 

50mg in 5ml injection (equivalent to 25mg caffeine base
in 5ml)
50mg in 5ml oral solution

13.03 Calamine lotion 
13.05.02 Calcipotriol 50mcg/g  Dovonex®
  • 0.005% Cream and ointment
  • 0.005% scalp application

13.05.02 Calcipotriol 50mcg/g with Betamethasone 0.05% 
  • Gel and ointment (Dovobet®)
    • approved for the treatment of scalp and mild to moderate non scalp plaque psoriasis vulgaris in adults.

  • 60g cutaneous spray (Enstilar®)
    • Approved for the treatment of plaque psoriasis 

13.09 Calcipotriol 50micrograms in 1ml 
09.05.01.02 Calcitonin Salmon®
  • 400 units in 2ml injection - see section 6.6.1 for 200 units/dose nasal spray.
06.06.01 Calcitonin 400units in 2ml  
09.05.01.01 Calcium 2.55mmol/5mL syrup 
09.05.02.02 Calcium Acetate Phosex®, Renacet®
  • Phosex® 1g tablets (containing 250mg, 6.2mmol of calcium) 
  • Renacet® 475mg (containing 120.25mg, 3mmol of calcium) &
    950mg tablets (containing 240.5mg, 6mmol of calcium)
09.06.04 Calcium and Ergocalciferol Tablets 
  • Second choice combination
    • Calcium lactate 300mg, calcium phosphate 150mg (Ca 97mg, 2.4 mmol) & ergocalciferol 10 micrograms (400 units).

09.05.01.01 Calcium Carbonate 
  • 1.25g chewable tablets (500mg, 12.6 mmol calcium).
  • 2.5g chewable tablets (1g, 25 mmol calcium).
  • 500mg in 5ml suspension unlicensedunlicensed.
09.05.02.02 Calcium Carbonate 
  • 1.25g & 2.5g chewable tablets (Calcichew)
    (Other formulations e.g. Remegel, Rennies, Rennie Soft gel and Settler’s.
    Tums are also stocked at the RVI for use in paediatric renal patients)
09.06.04 Calcium Carbonate 1.5g and Colecalciferol 10micrograms (400iu) Evacal®
  • Second Choice combination
    • Chewable tablet containing calcium carbonate 1.5g and colecalciferol 10 micrograms (400 units) approved as chewable option and also to be used in patients with peanut and soya allergy.

09.06.04 Calcium Carbonate 1.5g and Colecalciferol 10micrograms (400iu) Accrete®
  • First Choice combination
    • Film coated tablet containing calcium carbonate 1.5g and colecalciferol 10 micrograms (400 units)

09.05.01.01 Calcium Chloride 
  • 5 mmol in 5ml & 10 mmol in 10ml injections.
  • 10% 10ml injection in syringes also used in some resuscitation boxes at Freeman Hospital - under review
08.01 Calcium Folinate 
  • Approved for methotrexate-induced mucositis and myelosuppression. The following formulations are approved:
    • 15mg tablets.
    • 3mg, 15mg, 30mg, and 300mg injections
    • A calcium folinate 1mg per ml mouthwash can be prepared if needed.unlicensedunlicensed

09.05.01.01 Calcium Gluconate 
  • 10% 10ml injection (approx. 2.2mmol, 89mg calcium).
09.06.04 Calcium Phosphate 3.1g and Colecalciferol 20micrograms (800iu)  Calfovit D3®
  • Second choice combination
    • Powder in sachets – calcium phosphate 3.1g (1.2g calcium) & Vitamin D3 800 units

09.02.01.01 Calcium Resonium® 
  • Powder (Calcium polystyrene sulphonate)
13.02.01 Calmurid® emollient 
A2.04.01.02 Calogen®  
06.01.02.03 Canagliflozin 
  • Only approved for use in accordance with NICE guidance. 
02.05.05.02 Candesartan 
08.01.03 Capecitabine  
  • Only approved for use in accordance with NICE guidance.
12.03.01 Caphosol® 
  • For limited use in patients having chemo-radiotherapy or radiotherapy to malignancies of the oral cavity, hypopharynx and oro-pharynx.
04.07.03 Capsaicin 
  • Qutenza® cutaneous patch approved for the treatment of neuropathic pain as fourth line agent for neuropathic pain and in line with the attached regionally agreed pathway. Red
  • 0.075% cream (Axsain®) approved for post hepatic neuralgia and peripheral diabetic neuropathy Green plus
10.03.02 Capsaicin 
  • 0.025% cream
    • approved for use as an adjunct to core treatment for knee and hand osteoarthritis as per NICE
02.05.05.01 Captopril  
  • Treatment should only be on the advice of a hospital paediatrician.
  • 5mg in 5ml suspension are also approved for use.
  • 2mg capsules are also approved for use unlicensedunlicensed.
04.02.03 Carbamazepine 
04.07.03 Carbamazepine 
  • Restricted use in treatment of trigeminal neuralgia only.
04.08.01 Carbamazepine 
  • Carbamazepine 200mg and 400mg MR tablets (Tegretol® retard) are available on consultant request for those in whom conventional carbamazepine has been shown to be unsuitable Green Traffic Light
06.02.02 Carbimazole 
03.07 Carbocisteine 
  • 375mg capsules.
  • 750mg/10ml oral solution in sachets: first choice liquid preparation for adult patients.
  • 250mg in 5ml syrup.
11.08.01 Carbomer 980 eye drops 
  • Viscotears® eye drops
  • GelTears® single unit dose eye drops
08.01.05 Carboplatin  
07.01.01 Carboprost 250microgram in 1ml  
08.01.05 Carfilzomib Kyprolis®
  • 10mg, 30mg & 60mg powder for solution for infusion
  • Approved for use in previously treated multiple myeloma in line with NICE and NHSE Commissioning Policy
11.08.01 Carmellose sodium  
  • 0.5% and 1% eye drops.
12.03.01 Carmellose Sodium paste Orabase®
08.01.01 Carmustine 
  • Approved formualtions include 100mg injection and 7.7mg implants.
  • Approved for newly diagnosed glioblastoma multiforme (GBM) in line with NICE.
09.08.01 Carnitine  
  • 30% oral solution
  • 1g in 5ml injection
A2.05.02 Carobel, Instant®  
02.04 Carvedilol 
  • For use in the treatment of heart failure only.
05.02.04 Caspofungin 
07.04.04 Catheter Patency Solutions 
  • Chlorhexidine 0.02% (1 in 5,000) solution in 100ml sachets.
07.04.04 Catheter Patency Solutions 
  • Sodium chloride 0.9% solution in 100ml sachets.
07.04.04 Catheter Patency Solutions Urotainer Twin Suby G®
  • Solution G 2 x 30ml sachets (citric acid 3.23%, magnesium oxide 0.38%,
    sodium bicarbonate 0.7%, disodium edetate 0.01%)
07.04.04 Catheter Patency Solutions Urotainer Twin Solution R®
  • Solution R 2 x 30ml sachets (citric acid 6%, gluconolactone 0.6%, magnesium carbonate 2.8%, disodium edetate 0.01%)
05.01.02.01 Cefalexin 
05.01.02.01 Cefixime 
  • Restricted for use on microbiology/infectious diseases advice, or as agreed in Trust Guidelines.
  • 200mg tablets
  • 100mg in 5ml paediatric suspension: also approved for the prevention of irinotecan induced diarrhoea, specialist use only Red Traffic Light.
05.01.02.01 Cefotaxime 
  • Restricted for use on microbiology/infectious diseases advice, or as agreed in Trust Guidelines.
05.01.02.01 Ceftaroline 
  • Restricted for use on microbiology/infectious diseases advice, or as agreed in Trust Guidelines.
05.01.02.01 Ceftazadime / avibactam Zavicefta ®
  • 2.5g injection
  • Approved for use only on the advice of Microbiology/Infectious Diseases for the treatment of infections with carbapenemase-producing organisms for which treatment options are very limited, toxic and not particularly effective.
05.01.02.01 Ceftazidime 
05.01.02.01 Ceftobiprole 
  • Approved for the treatment of hospital acquired pneumonia and other infections on the advice of microbiology/infectious disease physicans.
05.01.02.01 Ceftolozane & tazobactam 
  • Approved for use in multiple antibiotic resistant strains of enterobacteriaceae, pseudomonas and acinetobacters on the advice of microbiology/infectious disease physicians.
05.01.02.01 Ceftriaxone 
  • Restricted for use on microbiology/infectious diseases advice, or as agreed in Trust Guidelines. Red Traffic Light
  • Approved for use in primary care (i.e. care homes) to treat patients with conditions such as UTIs and pneumonia, at risk of sepsis in line with local guidance and microbiology input Green Traffic Light
05.01.02.01 Cefuroxime 
11.03.01 Cefuroxime 5% eye drops 
10.01.01 Celecoxib 
  • Only to be initiated by rheumatology.
02.04 Celiprolol Hydrochloride 
  • For specialist use in the treatment of patients who cannot tolerate other beta-blockers. Treatment should only be intiated on the advice of a cardiologist. 
08.01.05 Ceritinib  
  • Approved for use in previously treated anaplastic lymphoma kinase positive non-small-cell-lung cancer in line with NICE and NHS England Commissioning Policy.
  • Approved for untreated ALK-positive non-small-cell lung cancer in line with NICE and NHS England Commissioning Policy
10.01.03 Certolizumab Pegol Cimzia®
  • Approved for:
    • Adults with severe rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed in accordance with NICE.
    • Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor in accordance with NICE.
    • Severe active ankylosing spondylitis in adults whose disease has responded inadequately to, or who cannot tolerate, non-steroidal anti-inflammatory drugs in accordance with NICE.
    • Psoriatic arthritis in accordance with NICE.

12.01.03 Cerumol® 
03.04.01 Cetirizine 
13.02.01 Cetraben® 
13.02.01.01 Cetraben®Bath additive 
06.07.02 Cetrorelix 
08.01.05 Cetuximab  
  • Approved for the first-line treatment of metastatic colorectal cancer in combination with FOLFOX in line with NICE (monotherapy or combination chemotherapy is not recommended for the treatment of people with metastatic colorectal cancer that has progressed after first-line chemotherapy -  as per NICE). 
  • NECDAG approved for K-RAS wild type metastatic colorectal cancer; second line use in combination with chemotherapy in patients that have progressed on previous chemotherapy; third line use as a single agent in patients who have failed oxaliplatin- and irinotecan based therapy and who are intolerant to irinotecan. 
  • Approved for locally advanced squamous cell carcinoma of the head and neck in line with NICE. 
  • Approved for previously untreated metastatic colorectal cancer in line with NICE.
  • Approved for the treatment of metastatic and/or recurrent squamous cell carcinoma of the head and neck (oral cavity only) in line with NICE and NHS England Commissioning Policy
  • Note: cetuximab is not approved in combination with platinum-based chemotherapy for recurrent and/or metastatic squamous cell cancer of the head and neck as per NICE.
12.03.03 Cetylpyridinium chloride 1.4mg Lozenges Merocet®
09.08.01 Chenodexoycholic acid Xenbilox®
  • 250mg capsules
    • Approved for the treatment of Cerebrotendinous Xanthomatosis in line with NHS Commissioning Policy. NHS England will commission this drug for patients who are currently being treated (April 2017)

04.01.01 Chloral Hydrate 
04.01.01 Chloral Hydrate 500mg in 5ml mixture 
08.01.01 Chlorambucil  
05.01.07 Chloramphenicol 
  • Restricted for use on microbiology/infectious diseases advice, or as agreed in Trust Guidelines.
12.01.01 Chloramphenicol 
11.03.01 Chloramphenicol 0.5% eye drops & ointment 
  • Preservative-free eye drops are also approved for use:
    • 0.5% preservative-free Minims® - first choice.
    • 0.5% preservative-free eye drops unlicensedunlicensed - approved only for patients who are unable to use Minims®due to dexterity problems

12.01.01 Chloramphenicol 5% and 10% ear drops 
04.01.02 Chlordiazepoxide 
04.10.01 Chlordiazepoxide 
12.03.04 Chlorhexidine  
  • 0.2% mouthwash.
  • 0.2% mint flavoured spray.
  • 1% dental gel.
  • 2% oral gel unlicensedunlicensed.
    • For hospital use in the prevention of ventilator-associated pneumonia in adult patients who are ventilated (for >48 hours).

13.11.02 Chlorhexidine CX Antiseptic Dusting Powder®
  • 1% chlorhexidine acetate dusting powder.
13.11.02 Chlorhexidine 0.015% with Cetrimide 0.15% 
13.11.02 Chlorhexidine Gluconate 
  • 0.02% & 0.05% solutions, 25ml & 100ml sachets 
  • 0.5% solution in 70% methylated spirit (pink, colourless & red staining)
  • 2.5% in 70% methylated spirit wipes
  • 0.5% hand rub (contains 70% isopropyl alcohol + emollients)
  • 4% surgical scrub
  • 2% in 70% isopropyl alcohol wipes (Sanicloth® & Clinell®)
  • Skin swabs & skin cleanser
  • 3ml & 10.5ml applicators (Chloraprep®)
  • 1% Obstetric cream
12.02.03 Chlorhexidine Hydrochloride 0.1%, Neomycin Suphate 0.5% Naseptin®
19 Chlorhexidine impregnated sponge Biopatch®
05.04.01 Chloroquine 
  • 200mg tablets (=150mg chloroquine base) Green Traffic Light Not NHS Not NHS. 
  • 68mg in 5ml syrup (=50mg in 5ml chloroquine) Green Traffic Light Not NHS Not NHS
    272.5mg in 5ml injection (=200mg in 5ml chloroquine) unlicensedunlicensed Red Traffic Light.
02.02.01 Chlorothiazide 250mg in 5ml suspension 
  • Treatment should only be on advice from paediatric cardiology.
03.04.01 Chlorphenamine 
04.02.01 Chlorpromazine 
04.02.01 Chlorpromazine 
04.06 Chlorpromazine 
12.03.01 Choline Salicylate Bonjela® Adult
07.04.04 Chondroitin sulfate Gepan Instill®
  • Approved the treatment of:
    • Interstitial cystitis/painful bladder syndrome
    • Radiation cystitis
    • Recurring bacterial cystitis
    • Overactive bladder
06.05.01 Choriogonadotropin Alfa Ovitrelle®
  •   Fertility treatment Red Traffic Light
  •   Hypogonadism Green Traffic Light
01.05.03 Ciclosporin 
01.05.03 Ciclosporin 
  • 50mg/1ml continuous infusion.
08.02.02 Ciclosporin Sandimmun®
  • Approved Sandimmun® formulations include:
    • 50mg in 1ml & 250mg in 5ml concentrate (oily) for IV infusion. Red Traffic Light
    • 25mg & 100mg capsules (unlicensedunlicensed). Amber Traffic Light
    • 100mg in 1ml sugar-free oral solution (oily). Amber Traffic Light

  • Note: original oral formulations Sandimmun® supplied on request for patients who cannot take Neoral®.
08.02.02 Ciclosporin Neoral®
  • Neoral® is the preferred product for most indications.
  • Approved formulations include:
    • 10mg, 25mg, 50mg, and 100mg capsules;
    • 100mg in 1ml sugar free oral solution (oily).

10.01.03 Ciclosporin 
  • See section 8.2.2
13.05.03 Ciclosporin 
  • Capsules & SF Solution 
    See section 8.2.2
11.04.02 Ciclosporin 0.1% (1mg/1ml) Eye Drops Ikervis®
  • Approved as a possible treatment for people with dry eye disease that has not improved despite treatment with artificial tears NICE.
  • A 0.2% eye ointment is also approved as an alternative to eye drops for this indication Red Traffic Light  and unlicensedunlicensed.
05.03.02.02 Cidofovir infusion 
  • For use in the prevention and treatment of cytomegalovirus infection. 
  • For limited use by ENT Surgeons in the treatment of selected
    patients with respiratory papillomatosis (unlicensedunlicensed)
01.03.01 Cimetidine 
09.05.01.02 Cinacalcet 
  • Approved for the treatment of secondary hyperparathyroidism in patients with end stage renal disease on maintenance haemodialysis where parathyroid gland surgery has failed or is inappropriate. Red Traffic Light
  • Also for short term use to control symptoms prior to a second attempt at more definitive surgery. Red Traffic Light
  • Approved for patients with primary hyperparathyroidism (after January 2017Red Traffic Light
  • For use in existing patients with primary hyperparathyroidism (commenced prior to January 2017) for whom parathyroidectomy would be indicated based on serum calcium levels, symptoms and end – organ damage, but in whom parathyroidectomy is either not clinically appropriate or is contraindicated. It should be clearly documented as to why surgery is not an appropriate treatment option for the particular patient. Amber Traffic Light
04.06 Cinnarizine 
04.06 Cinnarizine 
05.01.12 Ciprofloxacin 
  • 250mg, 500mg & 750mg tablets
  • 250mg in 5ml suspension
  • 100mg & 200mg, 400mg intravenous infusions Red Traffic Light.
12.01.01 Ciprofloxacin 0.3% eye drops 
  • To be used in the ear unlicensedunlicensed indication.
15.01.05 Cisatracurium Nimbex®
  • 20mg in 10ml (2mg/ml) injection
  • 150mg in 30ml (5mg/ml) injection
08.01.05 Cisplatin  
04.03.03 Citalopram 
  • Please note maximum doses
    • Adults = 40mg
    • Elderly = 20mg
19 Citrasate® 
08.01.03 Cladribine 
  • 10mg in 10ml solution for preparing infusions; 2mg in 1ml subcutaneous injection 
  • Approved for Hairy cell leukaemia only.

  • 10mg tablets
  • Approved for treating highly active multiple sclerosis in adults in line with NICE
05.01.05 Clarithromycin 
11.09 Clens 100® 
05.01.06 Clindamycin 
  • 150mg capsules.
  • 75mg in 5ml suspension unlicensedunlicensed.
  • 300mg in 2ml & 600mg in 4ml injections.
13.06.01 Clindamycin  Dalacin T®
  • 1% topical solution (alcohol – water basis)
  • 1% lotion (aqueous)
07.02.02 Clindamycin 2% vaginal cream 
04.08.01 Clobazam 
13.09 Clobetasol 0.05% 
13.04 Clobetasol Propionate 0.05% Dermovate®

VERY POTENT
Cream, ointment & scalp application

13.04 Clobetasol Propionate with neomycin and nystatin Dermovate-NN®

VERY POTENT

Ointment

13.04 Clobetasone Butyrate 0.05% Eumovate®

MODERATELY POTENT

Cream, ointment & scalp application

04.01.01 Clomethiazole 
  • Alcohol withdrawal - chlordiazepoxide is preferred in the management of alcohol withdrawal.
06.05.01 Clomifene Citrate 
04.03.01 Clomipramine 
04.08.01 Clonazepam 
  • Clonazepam 500microgram in 5ml sugar-free oral solution is also approved unlicensedunlicensed
04.08.02 Clonazepam 
  • For intiation by neurologists only.
04.07.04.02 Clonidine 
  • Clonidine is not generally recommended for migraine prophylaxis; may aggravate depression/cause insomnia.
02.05.02 Clonidine 100 microgram tablets 
  • Treatment should be on the advice of a cardiologist/nephrologist.
02.05.02 Clonidine 150 microgram in 1ml injection 
  • For use in paediatric cardiac ITU and in adult ITU patients with delerium and agitation, often around extubation unlicensedunlicensed.
02.09 Clopidogrel 
  • Approved for use in cardiac patients being fitted with stents/acute coronary syndromes and where aspirin is contraindicated/not tolerated, despite its use in combination with acid suppressants e.g. omeprazole.
  • Approved ischaemic stroke; in peripheral arterial/multivascular disease; or after MI only if aspirin not suitable in line with NICE.
  • The North of Tyne APC recommends the use of generic 75mg clopidogrel tablets in all the approved indications for clopidogrel.
  • Care should be taken to ensure that the brand supplied is suitable if it is to be packed into monitored dosage systems.
02.09 Clopidogrel 75mg in 5ml suspension 
  • Approved for use in paediatric patients with Berlin Heart devices.
07.02.02 Clotrimazole 
13.10.02 Clotrimazole 1% cream 
12.01.01 Clotrimazole 1% solution 
04.02.01 Clozapine 
19 Coagucheck XS 
13.05.02 Coal tar 2% and salicylic acid 2% ointment 
13.09 Coal Tar Extract 5% shampoo Alphosyl 2 in 1®
13.05.02 Coal tar in emulsifying ointment solution 
  • 1% unlicensedunlicensed
  • 2% unlicensedunlicensed
  • 5% unlicensedunlicensed
13.05.02 Coal tar lotion 1% Exorex®
02.02.04 Co-amilofruse (furosemide and amiloride) 
05.01.01.03 Co-Amoxiclav 
18.08.07 Coban® 2 Comfort Foam Layer 
  • Used in lymphoedema
  • Specialist use 
18.08.07 Coban® 2 Compression Layer 
  • Used in lymphoedema
  • Specialist use 
18.08.08 Coban® 2 Layer 
  • Specialist use only
18.08.08 Coban® 2 Layer Lite 
  • Specialist use only
04.09.01 Co-Beneldopa 
05.03.01 Cobicistat Tybost®
15.02 Cocaine 
  • 4% nasal solution (drops) unlicensedunlicensed
    25% paste (1g syringe pack) unlicensedunlicensed
15.02 Cocaine with Adrenaline 
  • 4% solution with adrenaline unlicensedunlicensed
04.09.01 Co-Careldopa 
04.09.01 Co-Careldopa and Entacapone 
04.07.04.01 Co-codamol 8/500 
13.05.02 Cocois® 
07.03.01 Co-Cyprindiol 2000/35 - cyproterone Acetate 2mg with ethinylestradiol 35micrograms 
  • Co-cyprindiol should be reserved for those women requiring treatment for the androgenic conditions such as severe acne or moderately severe hirsutism. It is recommended that treatment be withdrawn 3 to 4 cycles after the androgenic condition(s) has/have completely resolved and that it is not continued solely to provide oral contraception. Venous thromboembolism occurs more frequently in women taking co-cyprindiol than those taking a low-dose combined oral contraceptive. Repeat courses may be given if the androgen-dependent condition(s) recur.
  • Note: generic co-cyprindiol is much cheaper than Dianette®
13.06.02 Co-Cyprindiol 2000/35
(Cyproterone Acetate 2mg with Ethinylestradiol 35micrograms)
 
  • Tablets containing cyproterone acetate 2mg & ethinylestradiol 35 micrograms
    generic co-cyprindiol is much cheaper than Dianette®
13.06.02 Co-Cyprindiol 2000/35
(Cyproterone Acetate 2mg with Ethinylestradiol 35micrograms)
 
  • Tablets containing cyproterone acetate 2mg & ethinylestradiol 35 micrograms.
  • Note: generic co-cyprindiol is much cheaper than Dianette®
13.09 Co-Cyprindiol 2000/35
(Cyproterone Acetate 2mg with Ethinylestradiol 35micrograms)
 
  • Tablets containing cyproterone acetate 2mg & ethinylestradiol 35 micrograms.
  • Note: generic co-cyprindiol is much cheaper than Dianette®
01.06.02 Co-danthramer 
  • Note: Co-danthramer and Co-danthrusate are generally restricted to use in the treatment of constipation in terminally ill patients. A combination of Senna and Docusate is normally preferred.
01.06.02 Co-danthrusate 
  • Note: Co-danthramer and Co-danthrusate are generally restricted to use in the treatment of constipation in terminally ill patients. A combination of Senna and Docusate is normally preferred.
01.04.02 Codeine 
04.07.02 Codeine 
  • The following codeine preparations are unlicensedunlicensed and approved for use:
    • codeine 30mg in 1ml injection CD
    • codeine 2mg, 3mg, 6mg, 15mg;
    • 30 mg suppositories.

03.09.01 Codeine Phosphate 
  • 15mg in 5ml linctus.
10.01.04 Colchicine 
09.06.04 Colecalciferol 
  • 20microgram (800 units) capsules or tablets
    • For first line use in the long term maintenance treatment of patients with documented vitamin D deficiency following high strength therapy and also for use in patients with symptoms and insufficient levels. 

  • 500 microgram (20,000 units) capsules
    • For use in patients requiring high strength therapy for vitamin D deficiency. 

  • 2740iu/ml oral solution (Fultium®-D3 Drops) 
  • 1000iu and 3000iu buccal spray (DLux®) unlicensedunlicensed Red Traffic Light
    • Approved for use in paediatric parenteral nutrition patients with short bowel syndrome and adults with metabolic bone disease who have vitamin D deficiency despite previous treatment.

01.09.02 Colesevelam 
  • Approved for second line use (after Colestyramine) for the treatment of bile malabsorption that results in diarrhoea.
02.12 Colesevelam 
  • For initiation in lipid clinic only in patients with familial hypercholesterolaemia and/or those with substantial cardiovascular risk and who are unable to tolerate existing treatments.
01.09.02 Colestyramine 
  • Also approved for the treatment for leflunomide toxicity Red Traffic Light
02.12 Colestyramine 
  • For initiation in lipid clinic only in patients with familial hypercholesterolaemia and/or those with substantial cardiovascular risk and who are unable to tolerate existing treatments.
  • Also approved for the treatment of leflunomide toxicity Red Traffic Light.
05.01.07 Colistimethate 
  • 1 million-unit vial for nebulisation/intravenous injection
    • Nebulised therapy for bronchiectasis Green Traffic Light.
    • Nebulised therapy for CF Red Traffic Light.
    • Intravenous therapy Red Traffic Light.

  • Dry powder for inhalation (Colobreath®) Red Traffic Light.
    • To be used for treatment of Cystic Fibrosis in accordance with NHS England Commissioning Policy/NICE Guidance.      

10.03.01 Collagenase Xiapex®
  • Approved for treating Dupuytren’s contracture in line with NICE
13.10.05 Collodion Flexible BP 
  • 2.5% castor oil & colophony 2.5% in a collodion base.
01.01.01 Co-magaldrox Maalox®
  • Mucogel is first choice in the community due to cost.   
01.01.01 Co-magaldrox Mucogel®
  • First choice in the community due to cost.
07.03.01 Combined Hormonal Contraceptive - patch Evra
  • Evra® are self-adhesive patches releasing approximately 20 micrograms ethinylestradiol and 150 micrograms norelgestromin/24 hours.
    Approved for use by a small number of women with gastrointestinal absorption problems or with compliance issues.
07.03.01 Combined Hormonal Contraceptives - oral 
  • Logynon®;
  • Logynon® ED;
  • Tri-Regol®;
  • Trinovum®
07.03.01 Combined Hormonal Contraceptives - oral 

First Choice

  • Rigevidon® (ethinylestradiol 30 microgram/levonorgestrel 150microgram).

Alternatives

  • Cilest® (ethinylestradiol 35 microgram/norgestimate 250 microgram).
  • Cilique® (ethinylestradiol 35 microgram/norgestimate 250microgram).
  • Femodene® (ethinylestradiol 30 microgram/gestodene 75 microgram).
  • Femodene® ED (ethinylestradiol 30 microgram/gestodene 75 microgram).
  • Gedarel 30/150® (ethinylestradiol 30 microgram/desogestrel 150
    microgram).
  • Levest® (ethinylestradiol 35 microgram/norgestimate 250microgram).
  • Lizinna® (ethinylestradiol 35 microgram/norgestimate 250 microgram).
  • Loestrin 30® (ethinylestradiol 30 microgram/ norethisterone 1.5mg).
  • Lucette® (ethinylestradiol 30 microgram/drospirenone 3mg).
  • Marvelon® (ethinylestradiol 30 microgram/desogestrel 150
    microgram).
  • Microgynon® 30 (ethinylestradiol 30 microgram/levonorgestrel 150 microgram).
  • Microgynon® ED (ethinylestradiol 30 microgram/levonorgestrel 150 microgram).
  • Millinette 30/75® (ethinylestradiol 30 microgram/ gestodene 75 microgram).
  • Ovranette® (ethinylestradiol 35 microgram/norgestimate 250microgram).
  • Ovysmen® (ethinylestradiol 35 microgram/norethisterone 500 microgram).
  • Yasmin® (ethinylestradiol 30 microgram/drospirenone 3 mg).
07.03.01 Combined Hormonal Contraceptives - oral 
  • Femodette® (ethinylestradiol 20 microgram/gestodene 75 microgram).
  • Gedarel® 20/150 (ethinylestradiol 20 microgram/desogestrel 150 microgram).
  • Loestrin 20® (ethinylestradiol 20 microgram/ norethisterone 1.5mg).
  • Mercilon® (ethinylestradiol 20 microgram/desogestrel 150 microgram).
  • Millinette® 20/75 (ethinylestradiol 20 microgram/estodene 75 microgram).
07.03.01 Combined Hormonal Contraceptives - vaginal ring NuvaRing®
  • Vaginal ring releasing ethinylestradiol approximately 15 micrograms/24 hours and etonogestrel approximately 120 micrograms/24 hours.
  • To be initiated by a specialist in contraceptive services for patients who are unable to tolerate progesterone-only contraceptives, have experienced skin irritation with the transdermal patch, and are unable to take oral contraceptives due to allergy.
06.04.01.01 Continuous combined HRT tablets Climagest, Elleste-duet Conti, Kliofem, Kliovance, Femoston Conti, Premique-low dose, Premique
18.01.02 Cosmopor E® 

Absorbent Perforated Dressing with Adhesive Border

05.01.08 Co-trimoxazole 
  • 480mg tablets (plain or dispersible), 960mg tablets, 240mg in 5ml & 480mg in 5ml suspensions Green Traffic Light.
  • 480mg in 5ml ampoules for IV infusion Red Traffic Light.    
05.04.08 Co-trimoxazole 
  • 480mg/5ml injection Red Traffic Light.
18.08.03 Cotton Stockinette Bleached BP 1988 Comfi-gauz®
08.01.05 Crizotinib  
  • Approved in accordance with NICE and NHS England Commissioning Policy.
13.03 Crotamiton Eurax®
13.11.06 Crystal Violet 0.5% Paint 
  • For limited use in some operating theatres/critical care areas only.
18.02.02 C-View® Post-Op 
04.06 Cyclizine 
11.05 Cyclopentolate Eye drops 
  • 0.5% and 1%.
11.05 Cyclopentolate Single Use Minims® 
  • 0.5% and 1%.
08.01.01 Cyclophosphamide 
08.03.04.02 Cyproterone 
06.04.02 Cyproterone Acetate 50mg and 100mg tablets 
  • Approved for use on the advice of a urologist.
08.01.03 Cytarabine  
  • A cytarabine 50mg vial - intrathecal injection (cytarabine encapsulated in liposomes) is also approved for use. 
02.08.02 Dabigatran 
  • Only approved for use in accordance with NICE guidance. 
08.01.05 Dabrafenib  Tafinlar®
  • Approved for the treatment of unresectable or metastatic BRAF V600 mutation-positive melanoma in line with NICE 
08.01.05 Dacarbazine  
05.03.03.02 Daclatasvir  
  • Approved for the treatment of chronic hepatitis C in line with NICE and NHS England Commissioning Policy.  
08.02.04 Daclizumab Zinbryta®
  • 150mg subcutaneous injection
  • Approved for the treatment of highly active relapsing-remitting mutiple sclerosis that has failed to respond to other treatment in adults in line with NICE and NHS England Commissioning Policy. 
  • Subject to restricted use by EMA
08.01.02 Dactinomycin  
05.01.07 Dalbavancin Xydalba ®
  • 500mg injection
    • approved for the treatment of significant deep soft tissue infections such as joint, discitis and spinal infection, on the advice of infectious disease physicians or microbiology.

09.06.07 Dalivit® 
  • Drops containing in each 0.6ml dose ascorbic acid 50mg, ergocalciferol
    400 units, nicotinamide 5mg, pyridoxine HCl 500 micrograms, riboflavin
    400 micrograms, thiamine 1mg & vitamin A 5,000 units)
    • Dalivit drops are to be retained for use in patients requiring a full supplement of vitamin A.

02.08.01 Danaparoid 
  • For use on advice from haematologists in patients who develop thrombocytopenia with heparins - cross reactivity with heparin antibodies is thiought to be <10%. 
03.04.03 Danazol 
  • For use on the advice of an immunologist in the prophylaxis, treatment hereditary angioedema associated with C1-esterase inhibitor deficiency.
     
06.07.02 Danazol 100mg and 200mg capsules 
10.02.02 Dantrolene 
15.01.08 Dantrolene Sodium Dantrium Intravenous®
  • 20mg injection
06.01.02.03 Dapagliflozin 
  • Only approved for use in accordance with NICE guidance. 
05.01.10 Dapsone 
  • Used in the treatment of leprosy and some skin conditions (e.g. dermatitis herpetiformis, pemphigoid on the advice of dermatologists).
05.01.07 Daptomycin 
09.01.03 Darbepoetin Alfa 
  • 10, 15, 20, 30, 40, 50, 60, 80, 100, 150 & 300 microgram injections in prefilled syringes 
  • 20, 40, 60, 80, 100 & 300 microgram Sureclick® pens - approved for management of cancer treatment-induced anaemia in women receiving platinum-based chemotherapy for ovarian cancer 
  • Shared care arrangement in place for monitoring to be undertaken in primary care
07.04.02 Darifenacin  
  • To be given following tolterodine (when oxybutynin is not appropriate e.g. frail elderly patients or those with cognitive impairment).
05.03.01 Darunavir 
05.03.01 Darunavir and Cobicistat 

To be used in accordance with NHS England Clinical Commissioning Policy (SSC1614).

05.03.03.02 Dasabuvir Exviera®
  • Approved for the treatment of chronic hepatitis C in line with NICE and NHS England Commissioning Policy.
08.01.05 Dasatinib Sprycel®
  • Approved for use in accordance with NICE and NHS Commissioning Policy
08.01.02 Daunorubicin 
  • The following formualtions are approved:
    • 20mg injection;
    • 10mg, 15mg, 35mg;
    • 40mg prefilled syringes.

19 DC beads 
18.05 Debrisoft® 

Polyester fibres with bound edges and knitted outer surface coated with polyacrylate

  • Specialist initiation only
13.02.02 Deegan's ointment 
09.01.03 Deferasirox 
  • Approved for iron chelation in patients with myelodysplastic syndromes (MDS) - (as per NECN Haematology Group Guidelines) and recommended for use in patients when treatment with desferrioxamine is no longer considered to be appropriate due to progressive iron overload despite maximally tolerated doses of desferrioxamine. 
02.08 Defibrotide 
  • Approved for use in severe veno-occlusive disease following stem cell transplant - in accordance with NHS England commissioning policy. 
08.03.04.02 Degarelix 
  • Approved formulations include 80mg and 120mg vials (with diluent).
  • Approved for the first line treatment of advanced hormone dependant prostate cancer with a PSA > 20ng/l at presentation 
    • -approved as an option for treating advanced hormone-dependent prostate cancer in people with spinal metastases in line with NICE.

04.12 Dehydrated alcohol 100% BP for Injection 
  • Approved for intrathecal neurolysis treatment of intractable pain due to cancer in terminally ill patients
05.01.09 Delamanid 
  • To be used in accordance with NHS England Commissioning Policy 
05.01.03 Demeclocycline 
  • For the treatment of inappropriate antidiuretic hormone secretion. Treatment is initiated by specialists only.
06.05.02 Demeclocycline 

Treatment to be intitated by specialist.

06.06.02 Denosumab 
  • Denosumab 60mg in 1ml solution in prefilled syringe is approved for use in the treatment of postmenopausal osteoporosis in line with NICE. Also approved for male patients who dont tolerate isphosphonates or strontium ranelate. 
  • Denosumab 70mg in 1ml (120mg) vial is approved for the prevention of skeletal-related events in adults with bone metastases from solid tumours in line with NICE 
  • Note: denosumab is not approved for therapy induced bone loss in non- metastatic prostate cancer (NICE).
18.04.02 Dermatix® 15g Gel 

Silicone gel

  • For use by the Burns Team
13.02.01.01 Dermol 600® Bath Additive 
13.02.01 Dermol® 
13.02.01.01 Dermol® 200 Shower emollient 
13.02.01.01 Dermol® 500 Lotion 
16 Desferrioxamine 
  • 500mg vials (for preparing injection & oral solution)
09.01.03 Desferrioxamine Mesilate 
15.01.02 Desflurane Suprane®
  • For use in neurosurgery patients as an alternative to sevoflurane or desflurane and in the following groups of patients as an alternative to sevoflurane/ isoflurane in:
    • Bariatric surgery. 
    • Prolonged procedures over 2 hours e.g. oesophagectomy. 
    • Surgery in the elderly where there are concerns of cognitive impairment. 
    • Major surgery in the elderly with or without cognitive dysfunction.

  • Subject to the following limitations: 
    • Desflurane is not for use in day surgery unless the patient is morbidly obese. 
    • There is no role at present for its use in paediatrics or cardio-thoracic surgery.
    • Desflurane must be used in conjunction with low fresh gas flow.

  • Its use should be monitored and audited.
03.04.01 Desloratadine 
06.05.02 Desmopressin 
  • The following desmopressin  formualtions are approved for use:
    • 10 microgram/dose nasal spray.
    •  2.5 & 150 microgram/dose nasal sprays Red Traffic Light(unlicensedunlicensed).
    • 100 microgram/ml nasal drops.
    • 100 microgram & 200 microgram tablets.
    • 120 microgram sublingual tablets.
    •  4 microgram in 1ml injection and 15 microgram in 1ml injectionRed Traffic Light

07.04.02 Desmopressin 
  • The following formulations are approved:
    • 100microgram and  200 microgram tablets;
    • 120 microgram sublingual tablets. 

  • Note: nasal formulations no longer licensed for treating nocturnal
    enuresis (see section 6.5.2 for other formulations).
06.03.02 Dexamethasone  
  • 500microgram & 2mg tablets
  • 500microgram soluable tablets
  • 2mg in 5ml oral solution and 5mg in 5ml oral solution  is also approved. unlicensedunlicensed
06.03.02 Dexamethasone 
12.01.01 Dexamethasone 0.05% with framycetin 0.5% ear drops Sofradex®
  • Alternative choice compound antibacterial/corticosteroid ear drop.
11.04.01 Dexamethasone 0.1% eye drops Maxidex®
  • Preservative-free eye drops are also approved.
    • 0.1% Minims® - first choice.
    • 0.1% preservative free eye drops unlicensedunlicensed - approved only for patients who are unable to use Minims®due to dexterity problems.

11.04.01 Dexamethasone 0.1% Preservative-free 

First choice

Unit dose vials (Minims®)

Alternative

Eye drops (unlicensed) - only for patients who are unable to use Minims® due to dexterity problems

12.01.01 Dexamethasone 0.1% with neomycin 0.5% spray Otomize®
  • Alternative choice compound antibacterial/corticosteroid ear drop.
06.03.02 Dexamethasone 3.3mg in 1ml and 6.6mg in 2ml 
  • Note: there are two different strength preparations of dexamethasone injection available in the UK (3.8mg/ml and 3.3mg/ml) where traditionaly a 4mg/ml preparation was available and prescribed as such. To avoid confusion the 3.3mg/ml strength is the preparation of choice in the acute Trusts. Where previously a 4mg dose would have prescribed it is appropriate to prescribe a 3.3mg dose (or multiples thereof). This is because the range of doses given in clinical practice varies widely and subsequent doses tend to be adjusted to reflect clinical response. If 4mg is required please ensure that the appropriate volume of 3.3mg/ml is (e.g. 1.2ml) prescribed (or mulitples thereof).
11.04.01 Dexamethasone 700 microgram intravitreal implant Ozurdex®
  • Approved for macular oedema following central retinal vein occlusion
    in line with NICE.
  • Approved for treating diabetic macular oedema in line with NICE.
  • Approved for the treatment of non-infectious uveitis in line with NICE and NHS England Commissioning Policy
11.04.01 Dexamethasone with Neomycin and Polymyxin B sulphate Maxitrol®
  • Eye drops and eye ointment
04.04 Dexamfetamine 
  • 5mg tablets
  • Approved for narcolepsy and ADHD. 
  • Note: For narcolepsy doses >30mg daily Red Traffic Light
15.01.04.04 Dexmedetomidine  Dexdor®
  • 100 micrograms in 1ml injection approved for use in patients:
    • with traumatic brain injury, have no respiratory problems but require prolonged ventilatory support due to severe agitation, confusion and requirement for propofol/midazolam; and
    • who are difficult to sedate e.g. with overdose of MDMA/PMA/”legal highs” or who have pre-existing drug or alcohol dependence or who have failed conventional methods of treatment.
    • Paediatric patients undergoing cardiac surgery with a high risk of post-operative Junctional Ectopic Tachyarrhythmia (JET) or those suitable for fast-track surgery.
  • 100 micgrograms in 1ml injection (intranasal) unlicensedunlicensed route
    • approved for pre-operative sedation in anxious children at risk of respiratory depression in whom midazolam is contraindicated or those who have failed pre-operative sedation with other agents.
08.01 Dexrazoxane  Savene®
  • For use in line with NECN extravasation.
09.02.02.02 Dextran 40/Sodium Chloride 
  • 10%/0.9% 
04.07.02 Diamorphine 
  • Intranasal diamorphine (unlicensedunlicensed) is approved for use in children for the relief of severe pain due to clinically suspected limb fractures, burns and significant fingertip injuries. Appropriate risk assessments are to be conducted by each organisation in order to determine formulation of choice (e.g. ampoules or intranasal spray).
  • Note: intranasal diamorhine Red Traffic Light  
04.01.02 Diazepam 
  • Diazepam 2mg tablets: are the preferred strength in primary care. 
  • Diazepam 10mg tablets: should no longer be used. 
  • Diazepam 10mg in 2ml injection (plain & emulsion): only approved for use in epilepsy (see section 4.8.2).
04.08.02 Diazepam 
10.02.02 Diazepam 
  • Note: diazepam 10mg tablets are no longer on the formulary. 
15.01.04.01 Diazepam 
  • 2mg, 5mg tablets – 10mg tablets should no longer be used.
  • 2mg in 5ml oral solution.
  • 10mg in 2ml injection (plain & emulsion) Red Traffic Light.
    • For use in epilepsy see section 4.8.2 and use in anxiety see
      section 4.1.2.

02.05.01 Diazoxide 
06.01.04 Diazoxide 
  • Diazoxide suspensions can be obtained/prepared if needed. unlicensedunlicensed
19 Dibotermin Alfa Inductos®
04.07.01 Diclofenac 
  • Oral diclofenac is restricted to short-term use for post operative pain.
  • If long-term use is required diclofenac is only approved for 4th line treatment (see below):
    • Ibuprofen low dose – first line treatment.
    • Naproxen low dose – second line treatment.
    • Naproxen high dose – third line treatment.
    • Diclofenac – fourth line treatment.

04.07.04.01 Diclofenac 
10.01.01 Diclofenac 
  • The use of oral diclofenac is restricted. It can be used short-term for post operative pain, or as a fourth line choice for long-term use.
  • 75mg in 2ml injection is also available - this is mainly for use in post-operative analgesia. Red Traffic Light
  • Topical formulations are NOT on the formulary
11.08.02 Diclofenac 
  • 0.1% eye drops and unit dose eye drops.
  • For post-operative inflammation limited to patients where corticosteroids are unsuitable.
15.01.04.02 Diclofenac 75mg/1ml injection Dyloject
  • Mainly for use in post-operative analgesia - see section 10.01.01 for other formulations
16 Dicobalt edetate 
  • 300mg in 20ml injection
01.02 Dicycloverine 
05.03.01 Didanosine 
08.03.01 Diethylstilbestrol 
  • Should be initiated with specialist advice.
02.01.01 Digoxin 
  • 62.5, 125 & 250 microgram tablets Green Traffic Light.
  • 50 microgram per ml elixir Green Traffic Light.
  • 500 microgram in 2ml injection Red Traffic Light.
  • 100 microgram in 1ml injection unlicensedunlicensed Red Traffic Light.
02.01.01 Digoxin specific antibody fragments Digifab®

For the treatment of life threatening digoxin toxicity only, requests must be cleared by an appropriate clinician.

 

 

04.07.02 Dihydrocodeine 
  • Note: the use of dihydrocodeine 30mg tablets & 10mg in 5ml oral solution is no longer recommended for regular use. Codeine is the preferred weak opioid analgesic.
  • Dihydrocodeine is only approved for use in breast feeding mothers immediately postdelivery/ c-section where adequate pain relief has not been achieved using paracetamol and NSAIDs. Patients requiring contunation of dihydrocodeine following discharge (post delivery/c-section) can have dihydrocodeine prescribed in primary care (for short-term use only).
05.04.02 Diloxanide 
02.06.02 Diltiazem 
  • Preferred calcium channel blocker for angina.
  • Zemtard® is the formulary brand of choice for starting new patients on long acting diltiazem.
01.07.04 Diltiazem 2% 
  • The most effective formulation is to be prescribed
16 Dimercaprol 
  • 100mg in 2ml injection
08.02.04 Dimethyl fumarate Tecfidera®
  • Approved as a option for treating adults with active relapsing-remitting multiple sclerosis that isn’t highly active or rapidly evolving severe relapsing-remitting multiple sclerosis NICE and NHS England Commissioning Policy. 
13.05.03 Dimethyl fumarate Skilarence®
  • 120mg tablets
  • Approved for the treatment of moderate to severe plaque psoriasis in line with NICE
13.02.02 Dimeticone Siopel®
13.10.04 Dimeticone 4% lotion Hedrin®
07.01.01 Dinoprostone 
  • The following formulations are approved:
    • 0.75mg in 0.75ml injections;
    • 3mg vaginal tablets;
    • 10mg pessaries.

09.02.01.02 Dioralyte® Oral Rehydration Salts 
13.02.01 Diprobase® 
13.02.01.01 Diprobath® Bath Additive 
13.05.02 Diprosalic ointment 
  • 0.05%/3%
02.09 Dipyridamole 
  • Only approved for use in accordance with NICE guidance.
  • 50mg in 5ml sugar free suspension alos avialable unlicensedunlicensed.
11.08.02.04 Disodium edetate 0.37% solution  
09.05.01.02 Disodium Pamidronate  
  • 30mg injection
06.06.02 Disodium Pamidronate 30mg injection 
02.03.02 Disopyramide 
04.10.01 Disulfiram 
13.05.02 Dithranol cream 
  • 0.1%, 0.25%,0.5%,1%, & 2% 
13.05.02 Dithranol in Full Strength Lassar's Paste BP 
  • 0.1%, 0.2%, 0.4%, 0.6%, 0.8%, 1%, 2%, 4%, 6% & 8%.
13.05.02 Dithranol pomade 
  • 0.2%, 0.4% & 0.6% unlicensedunlicensed
13.05.02 Dithranol with salycyclic acid 0.5% 
  • 0.1%, 0.2%, 0.4%, 0.6%, 0.8%, 1%, 2%, 4%, 6%, 8% & 16%in emulsifying base.
02.07.01 Dobutamine 
08.01.05 Docetaxel  
  • Approved for early node-positive breast cancer in line with NICE. 
  • Approved for hormone refractory metastatic prostate cancer in line with NICE.
01.06.02 Docusate sodium 
05.03.01 Dolutegravir 
01.02 Domperidone 
04.06 Domperidone 
  • Approved for use as a galactagogue to re-establish breastfeeding on specialist advice and following a cardiovascular risk assessment in light of MHRA advice.
04.11 Donepezil 
  • Only approved for use in accordance with NICE guidance. 
02.07.01 Dopamine 
05.01.02.02 Doripenem 500mg injection  
  • For use as a 2nd line alternative to meropenem in patients known to be infected with organisms resistant to meropenem, or with those organisms with raised MICs to meropenem. Should only be on the advice of microbiology or infectious disease consultants.
03.07 Dornase Alfa 
11.06 Dorzolomide 
  • 2% eye drops.
  • 2% unit dose eye drops.
11.06 Dorzolomide 2% with Timolol 0.5%  
  • Eye drops and unit dose eye drops
  • Approved for use in patients with confirmed allergy presenting as
    conjunctival changes or skin allergy. To be initiated by ophthalmologists
    only. The ophthalmologists must clearly document that signs and
    symptoms of preservative allergy have been demonstrated in their
    patient prior to initiation.
13.02.01 DoubleBase®gel 
03.05.01 Doxapram 
15.01.07 Doxapram 
  • 100mg in 5ml injection
  • 2mg/ml 500ml intravenous infusion in glucose 5%
    see section 03.05.01
02.05.04 Doxazosin 
  • 1mg, 2mg & 4mg tablets
07.04.01 Doxazosin 1mg, 2mg and 4mg tablets 
  • 1mg, 2mg and 4mg tablets
  • MR formulations are Non-Formulary 
08.01.02 Doxorubicin 
  • Doxorubicin 50mg injection - includes use with DC Beads for use in transcatheter arterial chemoembolisation (TACE) therapy in patients with hepatocellular cancer. 
  • Doxorubicin 20mg & 50mg pegylated liposomal injection - approved for second-line (or subsequent) treatment in advanced ovarian cancer in line with NICE. 
  • Approved for the treatment of recurrent ovarian cancer in line with NICE.
05.01.03 Doxycycline 
12.03.01 Doxycycline 20mg tablets 
  • Treatment of periodontitis.
13.02.02 Drapolene® 
13.02.02 Drapolene® 
13.10.05 Drapolene® cream 
18.02.07 DrawTex® 

Super absorbent hydroconductive dressing with absorbent, cross-action structures of viscose, polyester and cotton

18.07.01 Dressit® 

Contains vitrex gloves, large apron, disposable bag, paper towel, soft swabs, absorbent pad and sterile field.

  • Second choice on FP10. 
02.03.02 Dronedarone 
  • Approved for patients who are unsuitable for or not tolerant of amiodarone. Treatment should be initiated by a cardiologist.
02.03.02 Dronedarone Multaq®
06.01.02.03 Dulaglutide Trulicity®
  • 0.75mg and 1.5mg prefilled syringes
  • Approved for use in patients who require once-weekly GLP-1 receptor agonist therapy. 
  • This has replaced once-weekly exenatide. Existing patients can continue to receive exenatide until reviewed by a specialist
04.03.04 Duloxetine 
  • For use on advice of psychiatrists as a third-line antidepressant - but only for use in patients who cannot tolerate high-dose (>150mg daily) venlafaxine, or patients with hypertension, established CHD or other cardiovascular risk factors which would make the use of high-dose venlafaxine undesirable.
    Also approved for third-line use (after drugs such as the tricyclic antidepressants and gabapentin) in the treatment of neuropathic pain on the advice of pain specialists.
04.07.03 Duloxetine 
  • For third-line use (after drugs such as the tricyclic antidepressants and gabapentin) in the treatment of neuropathic pain on the advice of pain specialists.
06.01.05 Duloxetine 30mg and 60mg capsules 
A2.04.01.02 Duocal® Super Soluble 
18.02.04 DuoDERM® Extra Thin 

Semi-permeable hydrocolloid dressing

11.08.01 Duolube® eye ointment 
11.08.02 Duovisc® Injection 
  • Injection for use in cataract surgery containing VisCoat (1% sodium hyaluronate) and ProVisc (3% sodium hyaluronate, 4% chondroitin sulphate).
13.02.01 E45® 
13.02.01.01 E45® Bath Additive 
18.05 Eakin® Wound Pouches 
18.01.02 Eclyspe® adherent 

Soft silicone wound contact layer with absorbent pad and film-backing

  • Specialist initiation only
11.03.02 Econazole 1% Eye drops 
09.01.03 Eculizumab  
  • For use in accordance with NICE and NHS England commissioning policies.
02.08.02 Edoxaban 
  • Only approved for use in accordance with NICE guidance. 
15.01.06 Edrophonium 
  • 10mg in 1ml injection
10.02.01 Edrophonium Chloride 
05.03.01 Efavirenz Sustiva®
13.09 Eflornithine 11.5% cream Vaniqa®
  • Approved for use as a second-line treatment of facial hirsutism in patients where co-cyprindiol is ineffective, contra-indicated or considered inappropriate. Treatment should be initiated by or on the specific advice of an appropriate specialist - endocrinologist (or gynaecologist).
18.08.03 Elasticated Tubular Bandages BP 1993 Comfigrip®
18.08.03 Elasticated Viscose Stockinette Comfifast® range
18.08.03 Elasticated Viscose Stockinette Clinifast® range
05.03.03.02 Elbasvir & grazoprevir Zepatier®
  • Approved for the treatment of chronic hepatitis C in line with NICE and NHS England Commissioning Policy.
A2.01.01.02 Elemental 028® Extra 
09.08.01 Elosulfase alfa 
  • 5mg/5ml concentrate for solution for infusion -approved as a possible treatment for people with mucopolysaccharidosis type IV a (MPS IVa).
09.01.04 Eltrombopag 
  • For the treatment of adults with chronic immune (idiopathic) thrombocytopenia purpura in line with NICE.
01.04.02 Eluxadoline Truberzi®
  • 75mg & 100mg film-coated tablets
  • Approved for the treatment of irritable bowel syndrome with diarrhoea in line with NICE
06.01.02.03 Empagliflozin 
  • Only approved for use in accordance with NICE guidance. 
05.03.01 Emtricitabine 
13.02.01 Emulsifying Ointment BP 
02.05.05.01 Enalapril  
  • For use in breastfeeding mothers only. Breastfeeding mothers should be converted to ramipril when they are no longer breastfeeding. 
05.03.01 Enfuvirtide 
02.08.01 Enoxaparin 
  • Only approved for use in the treatment of acute coronary syndromes.
02.01.02 Enoximone 
  • As per licensed indication
  • Injection given orally. Approved for the treatment of severe heart failure in adults and children to wean from IV milrinone as a bridge to transplant and to reduce the need for ventricular assist devices (VADs) unlicensedunlicensed
04.09.01 Entacapone 
05.03.03.01 Entecavir 
15.01.02 Entonox® 

50% nitrous oxide and 50% oxygen mixture used for analgesia

08.03.04.02 Enzalutamide 
  • Approved for use in adults with metastatic hormone-relapsed prostate cancer, who have not had chemotherapy in line with NICE.
13.02.01 Epaderm® emollient 
  • Hydromol® Ointment is made to the same formula and is more cost effective.
02.07.02 Ephedrine 
  • 30mg in 1ml injection 
  • 30mg in 10ml syringe unlicensedunlicensed.
  • 15mg tablets.
12.02.02 Ephedrine 
  • 0.5% and 1% nasal drops.
03.01.01.02 Ephedrine Hydrochloride 
13.02.01 Epimax® 
08.01.02 Epirubicin  
  • Note: epirubicin 100mg injection is unlicensedunlicensed.
02.02.03 Eplerenone 
  • For use in post-acute myocardial infarction patients with left ventricular dysfunction and heart failure. Only to be used in patients who are unable to tolerate the estrogenic side effects of spironolactone. Treatment should only be on advice from a cardiologist.
09.01.03 Epoetin alfa Eprex®
  • Prefilled syringes (various strengths)
    • Approved for management of cancer treatment-induced anaemia in
      women receiving platinum-based chemotherapy for ovarian cancer
    • No longer regularly used in NUTH

09.01.03 Epoetin beta NeoRecormon®
  • Cartridges for use in RecopensPrefilled syringes
    • Approved for management of cancer treatment-induced anaemia
      in women receiving platinum-based chemotherapy for ovarian cancer.
    • No longer regularly used in NUTH.

  • Shared care arrangement in place for monitoring to be undertaken in primary care
02.05.01 Epoprostenol 
  • Approved for pulmonary hypertension - in accordance with NHS England Commissioning policy. 
02.08.01 Epoprostenol 
  • For pulmonary hypertension see section 2.5.1 
19 Eptotermin alfa Osigraft®
09.06.04 Ergocalciferol 
  • 250 microg. (10,000 units) & 1.25mg (50,000 units) tablets.
    • A 3000 units in 1ml suspension (unlicensedunlicensed) may be supplied if colecalciferol oral solution is not available.

  • 7.5mg (300,000 units) in 1ml injection.
07.01.01 Ergometrine Maleate 500micrograms in 1ml 
07.01.01 Ergometrine Maleate and Oxytocin Syntometrine®
08.01.05 Eribulin Halaven®
  • Approved for the treatment of locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens  in accordance with NICE and NHS England Commissioning Policy
08.01.05 Erlotinib 
  • Also approved for second line use, as an alternative to docetaxel, in NSCLC in line with NICE.
  • Monotherapy not approved for maintenance after platinum chemotherapy in advanced or metastatic NSCLC NICE.
  • Approved for the treatment of locally advanced or metastatic nonsmall-cell lung cancer that has already been treated with non-targetted chemotherapy because of delayed confirmation of epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation status if; their cancer tests positive for EGFR-TK mutation; it is not know if the cancer is EGFR-TK mutation- positive because of problems with the test, and the cancer is very likely to be EGFR-TK mutation-positive and it responds to the first 2 cycles of treatment with erlotinib - in line with NICE.
05.01.02.02 Ertapenem 
05.01.05 Erythromycin 
11.03.01 Erythromycin 0.5% Eye ointment 
13.06.01 Erythromycin 2% topical solution Stiemycin®
13.06.01 Erythromycin 40mg with Zinc Acetate 1.2% topical solution Zineryt®
04.08.01 Eslicarbazepine 
  • Approved for use by specialists only in those patients for whom intolerance of carbamazepine is a major concern and when use of this agent is more cost effective than alternatives available.
02.04 Esmolol 
07.02.01 Estradiol 10 microgram vaginal tablets 
06.04.01.01 Estradiol 1mg and 2mg tablets 
06.04.04 Estradiol 1mg and 2mg tablets 
06.04.01.01 Estradiol patches/gel 
  • Twice weekly matrix patches releasing approximately 25, 50, 75 & 100 microgram/24 hours (e.g. Evorel®, Femseven®, Estraderm® MX);
  • Once weekly matrix patches releasing approx. 50 & 100 microgram estradiol/24 hours (Progynova TS®)
  • Oestrogen 0.1% gel (Sandrena®).
08.01.01 Estramustine Phosphate  
07.02.01 Estriol  
  • The following topical estriol formulations are approved:
  • 0.01% cream (Gynest®) 80g;
  • 0.1% cream (Ovestin®)
  • Gynest® is the preferred choice.
10.01.03 Etanercept 
  • Prescribe by brand name.
  • Approved formulations include 10mg (Enbrel®) 25mg injection (Enbrel®, Benepali® & Erelzi®), 50mg injection (Enbrel®, Benepali® & Erelzi®). 
  • Approved for:
    • Treatment in adults with severe rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed in line with NICE.
    • Rheumatoid arthritis after the failure of a TNF inhibitor in line with NICE.
    • Psoriatic arthritis in accordance with NICE.
    • Treatment of severe active ankylosing spondylitis in adults whose disease has responded inadequately to, or who cannot tolerate, non-steroidal anti-inflammatory drugs in accordance with NICE.
    • The treatment of juvenile idiopathic arthritis (JIA) in people 2 years or older whose disease has responded inadequately to, or who are intolerant of methotrexate in line with NICE.
    • Treatment of Juvenile Scleroderma (Its use will be subject to informed consent and specialists using etanercept in this indication should collect data on patient outcomes. If after a six month trial, treatment were found to be beneficial, it would be continued for two years. If unsuccessful after six months, treatment should be discontinued).
    • People aged 2 years and older to treat polyarticular juvenile idiopathic arthritis (JIA) whose diease has responded inadequately to, or who are intolerant of methotrexate in line with NICE.

13.05.03 Etanercept Enbrel®, Benapali® & Erelzi®
  • Approved for psoriasis in line with NICE
  • Approved for the treatment of plaque psoriasis in children and young people in line with NICE
09.05.01.02 Etelcalcetide Parsabiv®
  • 2.5mg/0.5ml, 5mg/1ml & 10mg/2ml solution for injection
  • Approved for the treatment of secondary hyperparathyroidism in line with NICE and NHS England Commissioning Policy
05.01.09 Ethambutol  
11.08.02 Ethanol 20% eye drops. 
  • For use in the debridement of the corneal epithelium in patients with
    recurrent corneal erosion syndrome.
02.13 Ethanolamine Oleate 
06.04.01.01 Ethinylestradiol 2microgram and 10microgram tablets 
  • Note: ethinylestradiol 2microgram tablets are unlicensedunlicensed.
04.08.01 Ethosuximide 
15.02 Ethyl Chloride Spray 
10.01.01 Etodolac 
15.01.01 Etomidate 20mg/10ml injection 
07.03.02.02 Etonorgestrel 68mg implant Nexplanon®
  • Replaces Implanon® and differs in that it is impregnated with radio opaque material.
08.01.04 Etoposide 
  • The following formulations are approved for use:
    • 50mg capsules & 100mg capsules;
    • 100mg in 5ml injections;
    • 500mg in 25ml injections.

10.01.01 Etoricoxib 
05.03.01 Etravirine Intelence®
13.09 Eucerin 5% Dry Scalp Shampoo 
13.02.01 Eucerin® Intensive 
08.01.05 Everolimus Afinitor®, Votubia®
  • 2.5mg, 5mg & 10mg tablets (Votubia®)
    • Approved for the treatment of angiomyolipomas associated with tuberous sclerosis in accordnace with NHS England Commissioning Policy.
    • Approved for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in accordnace line with NHS England Commissioning Policy.

  • 5mg & 10mg tablets (Afinitor®)
    • Approved, in combination with exemestane, for the treatment of advanced human epidermal growth factor receptor 2 (HER2)-negative, hormone-receptor-positive breast cancer in postmenopausal women in accordance with NICE.
    • Approved for the treatment of advanced breast cancer after endocrine therapy in line with NICE.
    • Approved for the treatment of advanced renal cell carcinoma after previous treatment in line with NICE.
    • Approved for the treatment of unresectable or metastatic neuroendocrine tumours in people with progressive disease in line with NICE and NHS England Commissioning Policy

02.12 Evolocumab 
  • Approved for use in accordance with NICE guidance for treating primary hypercholesterolaemia.
  • Approved for the treatment of homozygous familial hypercholesterolaemia in line with NHS England Commissioning policy.
08.03.04.01 Exemestane 
06.01.02.03 Exenatide 
  • 5 microgram and 10 microgram per dose are prefilled injection pens containing a 250microgram/ml solution for subcutaneous injection.
  • 2mg once weekly pre-filled pen. Non-formulary (October 2017) Existing patients can continue to receive exenatide until reviewed by a specialist
  • Only approved for use in accordance with NICE guidance Treatment must be initiated by a consultant diabetologist and use is limited to overweight patients with type 2 diabetes in line with NICE guidelines.
02.12 Ezetimibe 
  • Only approved for use in accordance with NICE guidance.
  • For further information refer to FATS7. 
02.11 Factor VIIa (Recombinant) 
10.01.04 Febuxostat Adenuric®
  • Approved for patients where allopurinol is not tolerated or contraindicated in line with NICE.
02.12 Fenofibrate 

For initiation in lipid clinic only in patients with combined hyperlipidaemias and severe hypertriglycerideamia.

04.07.02 Fentanyl 
  • Fentanyl 200 microgram lozenges with oromucosal applicator are only approved for limited short-term use in RVI burns unit and for the treatment of very severe incident pain on the advice of pain/palliative care specialists Green plus
  • Fentanyl sublingual tablets (Abstral®) are also approved but only for patients experiencing incident pain during radiotherapy, restricted to palliative care use only Red.
  • 12, 25, 50, 75 & 100 microgram/hour transdermal patches (First choice brand - Matrifen®Green Traffic Light.
15.01.04.03 Fentanyl 
  • 100 microgram in 2ml & 500 microgram in 10ml injections Green Traffic Light
  • 2.5mg in 50ml (50 micrograms/ml) syringe unlicensedunlicensed Red Traffic Light
09.01.01.02 Ferric Carboxymaltose 100ml in 2ml & 500mg in 10ml injections Ferinject®
  • For use as an alternative to iron dextran or iron sucrose. Approved for
    use by renal physicians, gastroenterologists and haematologists.
  • Unlicensed for use in children under 14 years of age. If used in this age-group, use should only be on the advice of a consultant with the informed consent of the patient and/or his/her parents/carers.
09.01.01.01 Ferric maltol 30mg hard capsules Ferracru®
  • For the treatment of iron deficiency anemia in patients with inflammatory bowel disease.
09.01.01.01 Ferrous Fumarate 
  • First Choice oral liquid iron preparation140mg in 5ml syrup (45mg iron/5ml).
  • 210mg tablets (68mg iron/tablet).
09.01.01.01 Ferrous Gluconate 

300mg tablets (35mg iron)

09.01.01.01 Ferrous Sulphate 
  • 200mg tablets (65mg iron).
07.04.02 Fesoterodine  
  • Specialist Initiation or GP Initiation (in patients who do not wish to be referred to secondary care and have failed first/second line treatments).
03.04.01 Fexofenadine 
13.10.05 Fibrin sealant (Artiss®) 
  • 2ml, 4ml & 10ml prefilled syringe.
  • For use in plastic surgery to close dead spaces, adhere skin graft, close simple wounds and stabilise bone grafts.
13.10.05 Fibrin sealant (Bioglue®) 
  • For use in neurosurgery and vascular surgery.
13.10.05 Fibrin sealant (Evicel® Human Fibrin Glue) 

2ml and 5ml kit

13.10.05 Fibrin sealant (Floseal® Matrix sealant) 
13.10.05 Fibrin sealant (Tisseel Lyo® Fibrin Glue) 
  • 2ml, 4ml & 10ml kit
  • Also approved for use in the treatment of mesh fixation in hernia repair.
05.01.07 Fidaxomicin 
  • Approved for third line use in the treatment of C. difficile. To be initiated on the recommendation of a consultant microbiologist.
09.01.06 Filgrastim (G-CSF) Neupogen®, Ratiograstim®
  • Available as Neupogen (original brand) and Ratiograstim – a
    biosimilar product.
06.04.02 Finasteride 5mg tablets 
06.04.04 Finasteride 5mg tablets 
08.02.04 Fingolimod 
  • Approved for the treatment of highly active relapsing–remitting multiple sclerosis in line with NICE and NHS England Commissioning Policy.
  • Approved for patients who have progressed on glatiramer acetate and for those patients who are at high risk of progressive multifocal leukoencephalopathy (PML) in line with NHS EnglandClinical Commissioning Policy.
01.03 First choice regimen - eradication H.Pylori
  • The most current H.Pylori guidance and treatment regimens can be found here

 

18.03.04 Flaminal ® Hydro Gel  

Alginate with glucose oxidase and lactoperoxidase, for lightly to moderately exuding wounds                                                                  

18.03.04 Flaminal® Forte Gel 

Alginate with glucose oxidase and lactoperoxidase, for moderately to heavily exuding wounds                                                                  

02.03.02 Flecainide 
  • 50mg & 100mg tablets
  • 5mg in 1ml liquid unlicensedunlicensed. 
01.06.05 Fleet Phospho-soda® 
05.01.01.02 Flucloxacillin 
05.02.01 Fluconazole 
07.02.02 Fluconazole 
05.02.05 Flucytosine 
  • 500mg tabletsunlicensedunlicensed.
  • 2.5g in 250ml IV infusion.
08.01.03 Fludarabine Phosphate  
  • Approved for the second line therapy of B-cell CLL in line with NICE.
  • Note: fludarabine is not approved for monotherapy in the first line treatment of CLL - this is in line with NICE.
06.03.01 Fludrocortisone 
13.04 Fludroxycortide  Haelan®

MODERATELY POTENT

15.01.07 Flumazenil 
  • 500 microgram in 5ml injection
12.01.01 Flumetasone 0.02% with Clioquinol 1% ear drops 
  • Alternative choice compound antibacterial/corticosteroid ear drop.
11.04.01 Fluocinolone 190 microgram intravitreal implant 
  • Recommended as a possible treatment for people with chronic diabetic macular oedema who have an artificial lens in their eye if the implant is used in the eye with the artificial lens and their diabetic macular oedema has not got better with other treatments - in line with NICE.
13.04 Fluocinolone Acetonide 0.025% Synalar®

POTENT
Cream, ointment & gel

11.08.02 Fluorescein 
  • 2% minims eye drops
  • 1mg ophthalmic strips
  • Fluorets
  • 10% 5ml & 20% 5ml injections unlicensedunlicensed
11.04.01 Fluorometholone 0.1% Eye drops FML®
  • For use in patients who experience ocular hypertension with other corticosteroids – treatment to be initiated with the advice of an ophthalmologist.
08.01.03 Fluorouracil  
  • A fluorouracil 10mg in 0.4ml subconjunctival injection (unlicensedunlicensed) is also approved for use. 
  • FOLFIRINOX is approved for the management of selected patients with inoperable pancreatic cancer in patients with performance status 0-1.
13.08.01 Fluorouracil Efudix®
  • For the treatment of superficial malignant and premalignant skin lesions. To be initiated with advice of specialists.
04.03.03 Fluoxetine 
  • 20mg capsules
  • 20mg dispersible tablets
    • first choice for patients unable to use the capsules
  • 20mg/5ml oral solution
04.02.01 Flupentixol 
04.02.02 Flupentixol Decanoate 
04.02.02 Fluphenazine 
  • Fluphenazine is to be discontinued in late 2018
    • All patients currently prescribed fluphenazine decanoate should have a medication review
08.03.04.02 Flutamide 
03.02 Fluticasone furoate & vilanterol Relvar Ellipta®
  • Second Choice ICS/LABA combination
    • 22 mcg/92 mcg: Licensed for COPD and asthma.
    • 22 mcg/184 mcg: Licensed for asthma only.

12.02.01 Fluticasone furoate 27.5microgram/dose nasal spray Avamys®
  • Note: take care to avoid confusion with fluticasone propionate.
12.02.01 Fluticasone Propionate 400microgram/dose nasal drops Flixonase Nasule®
  • Note: take care to avoid confusion with fluticasone furoate.
12.02.01 Fluticasone Propionate 50microgram/dose nasal spray Nasofan®
  • Note: take care to avoid confusion with fluticasone furoate.
03.02 Fluticasone propionate and formoterol Flutiform®
  • Second Choice ICS/LABA combination
    • For patients preferring MDIs.
    • Approved the use for maintenance treatment of asthma.

09.01.02 Folic Acid 
  • 400 microgram and 5mg tablets
  • 2.5mg in 5ml sugar-free syrup
  • 15mg in 1ml injection unlicensedunlicensed
  • 30mg in 2ml injection
06.05.01 Follitropin Alfa  
16 Fomepizole 
  • 100mg in 20ml injection unlicensedunlicensed
02.08.01 Fondaparinux 
  • Approved for high risk orthopaedic surgery pateints and as an alternative to enoxaparin in accordance with NICE guidance.
09.06.07 Forceval® 
  • Capsules & junior capsules
    • For limited use as a vitamin and mineral supplement in patients with phenylketonuria The capsules are also approved as an oral supplement in burns patients with malnutrition or alcohol dependency and patients with major burns after discontinuation of IV therapy, and have also been approved for use in patients with severe anorexia nervosa. Treatment initiated with specialist advice.

  • Soluble
    • Approved for short term use in patients who are unable to swallow
      Forceval capsules.

03.01.01.01 Formoterol  
  • Turbohaler® breath actuated DPI 6 mcg & 12 mcg/puff
A2.02.01.02 Fortijuce®  
A2.01.03.03 Fortini 
A2.02.02.03 Fortisip  
05.03.01 Fosamprenavir 
04.06 Fosaprepitant 
  • For the prevention of chemotherapy induced nausea and vomiting (CINV) in high risk patients in accordance with North of England Cancer Network: CINV Guidelines in adult oncology and haematology patients
05.03.02.02 Foscarnet Sodium 
05.01.07 Fosfomycin 
  • 500mg capsules unlicensedunlicensed Red Traffic Light
  • 4g injections Red Traffic Light
  • 3g sachets: sachets can be initiated in primary care for the treatment of UTIs caused by multi-resistant organisms following advice from microbiology only. Most cost effective option to be used Green Traffic Light
18.08.08 Four layer systems  
  • Profore® Kit
  • Profore® Lite Kit
06.01.06 Freestyle Libre® Flash Blood Glucose Monitoring System 
  • Recommended as an option for monitoring in Type 1 diabetic patients only in North East and Cumbria in line with RMOC criteria and NTAG position statement 
04.07.04.01 Frovatriptan 
13.05.02 Fumaric acid esters 
  • 30mg & 120mg tablets
02.02.02 Furosemide 
11.03.01 Fusidic Acid Fucithalmic®
13.10.01.02 Fusidic Acid 2% 

Cream, ointment & gel

04.07.03 Gabapentin 
04.07.03 Gabapentin 
  • Gabapentin is also approved for hospital use  as an adjunct to other treatment in the management of peri/post-operative pain. Red Traffic Light unlicensedunlicensed
  • GPs should not be asked to prescribe gabapentin for this unlicensed indication.
04.08.01 Gabapentin 
  • Note: gabapentin 250mg in 5ml is also approved unlicensedunlicensed.
06.01.05 Gabapentin 
  • Also approved for hospital use as an adjunct to other treatment in
    the management of peri/post-operative pain. GPs should not be asked to prescribe gabapentin for this unlicensedunlicensed indication.
19 Gadobenate dimeglumine Multihance ®
  • for use in the differential diagnosis of liver disease
19 Gadobutrol Gadovist®
  • Gadolinium based MRI Contrast medium for use as an alternative to Magnevist®. One of the safer gadolinium contrast media with regard to the potential risk of nephrogenic systemic fibrosis.
19 Gadofosveset Vasovist®
  • Gadolinium (MRI) contrast agent that binds to albumin for use
    in MRI angiograms
19 Gadoxetic acid Primovist®
  • Gadolinium based MRI Contrast medium for use in:
     The assessment of hepatic vascular structures and biliary system of potential living, related liver donors.
     The detection and characterisation of focal liver lesions using MRI, when standard imaging with other agents has been inconclusive.
  • The detection and characterisation of focal liver lesions which
    potentially communicate with the biliary system e.g. large liver
    cysts.
04.11 Galantamine 
  • Only approved for use in accordance with NICE guidance. 
  • The oral solution is only approved for limited short-term use in the management of hospital patients who are unable to swallow tablets/ capsules. It is not for use in patients whose dementia is so severe that they can no longer swallow tablets.
05.03.02.02 Ganciclovir 
19 Gastrografin 
  • A contrast medium for the radiological examination of the gastrointestinal tract
01.01.02 Gaviscon Infant 
  • Note: each half of the dual-sachet is identified as ‘one dose'.
    To avoid errors prescribe as ‘dual-sachet' with directions in
    terms of ‘dose'
08.01.05 Gefitinib  
  • Approved for first line use in locally advanced or metastatic NSCLC in line with NICE.
09.02.02.02 Gelatin Volplex® or Gelofusine®
  • 4% succinylated gelatin infusion in sodium chloride 0.9% (500ml bags)
09.02.02.02 Gelatin Isoplex®
  • 4%succinylated gelatin infusion in a balanced electrolyte solution containing Na+ 145 mmol, K+ 4 mmol, Mg2+ 0.9 mmol, Cl- 105 mmol, lactate 25 mmol/litre.
    • Mainly for use in critical care areas and other situations where the perceived advantages of a balanced electrolyte plasma substitute are likely to be clinically important. Note Not yet cleared for use in NUTH.

12.03.01 Gelclair® 
08.01.03 Gemcitabine 
  • Approved in combination with paclitaxel for metastatic breast cancer in line with NICE. 
  • NECDAG approved for the second line treatment of women with partially platinum – sensitive, platinum resistant or platinum refractory advanced ovarian cancer (To be used when liposomal doxorubicin [Caelyx] is unavailable). 
  • Approved for pancreatic cancer in line with NICE. 
  • Approved for the treatment of recurrent ovarian cancer in line with NICE.
07.01.01 Gemeprost 1mg pessaries 
19 Gentafleece®  
05.01.04 Gentamicin 
  • For long term therapy in non-cystic fibrosis bronchiectasis usually in patients having > 3 exacerbations per annum with an organism identified as being sensitive to gentamicin.
05.01.04 Gentamicin 
  • 80mg in 2ml & 20mg in 2ml IV/IM injections
  • 5mg in 1ml intrathecal injection
  • bone cement & beads (for use in orthopaedic surgery) unlicensedunlicensed.
12.01.01 Gentamicin 0.3% ear/eye drops 
11.03.01 Gentamicin 0.3% ear/eye drops & 0.3% Minims® 
  • 1.5% eye drops with and with out preservative are also approved -  unlicensedunlicensed and Red Traffic Light
13.11 Gigasept PA 
12.03.05 Glandosane® spray 
08.02.04 Glatiramer Acetate 
  • Approved for treating multiple sclerosis in line with NICE and NHS Engand commissioning policy.
05.03.03.02 Glecaprevir & Pibrentasvir Maviret®
  • Approved for the treatment of chronic hepatitis C in line with NICE and NHS England Commissioning Policy.
06.01.02.01 Glibenclamide 
  • Not used in Newcastle Hospitals. 
06.01.02.01 Gliclazide 40mg & 80mg tablets and 30mg MR tablets 
06.01.02.01 Glimepiride 
06.01.04 Glucagon GlucaGen® HypoKit
08.01 Glucarpidase  
  • Approved for the urgent treatment of methotrexate-induced renal
    dysfunction.
09.02.02.01 Glucose  
  • 5% IV infusion (100ml, 250ml, 500ml & 1000ml)
  • 10% IV infusion (500ml & 1000ml)
  • 20% IV infusion (500ml)
  • 50% Injection (50ml)
A2.07 Glucose 
06.01.04 Glucose 5%, 10%, 25% & 50% 
06.01.04 Glucose 40% Oral Gel GlucoGel®
13.07 Glutaraldehyde 10% paint Glutarol®
A2.06.01 Gluten Free Products 
01.06.02 Glycerol (Glycerin) 
02.06.01 Glyceryl Trinitrate 
  • 400 microgram/metered dose aerosol spray Green Traffic Light.   
    5mg & 10mg/day patches - for use in cardiothoracic critical care unit.Red Traffic Light.
  • 5mg in 5ml , 50mg in 10ml & 50mg in 50ml injections Red Traffic Light.
01.07.04 Glyceryl Trinitrate 0.4% ointment  Rectogesic®
  • 0.2% also available unlicensedunlicensed.
07.04.04 Glycine 1.5% solution 
  • 1.5% large volume solutions (up to 3 litres).
13.12 Glycopyrrolate 1% cream 
  •  To be initiated by specialist.
03.01.02 Glycopyrronium Seebri Breezhaler®
04.06 Glycopyrronium bromide 
  •  1mg/5mL oral solution sugar free
    • Approved for the first line treatment of uncontrolled oral/respiratory secretions/sialorrhoea in Motor Neurone Disease/Home Ventilation patients who have cognitive impairment.
    • Approved for second line treatment of uncontrolled oral/respiratory secretions/sialorrhoea in Motor Neurone Disease/Home Ventilation  patients who have failed other treatment options such as hyoscine patches or who have intolerance to other agents.

  • 2mg/5ml oral solution (Sialanar®)
    • approved for the treatment of severe sialorrhoea in children and adolescents with chronic neurological disorders.

15.01.03 Glycopyrronium injection 
  • 200 microgram in 1ml & 600 microgram in 3ml injections
03.01.04 Glycopyyronium & indacaterol inhaler Ulitbro Breezhaler®
  • First Choice LABA/LAMA for COPD.
01.05.03 Golimumab 
  • Only approved for use in accordance with NICE guidance. 
10.01.03 Golimumab Simponi®
  • Approved for:
    • Rheumatoid arthritis in accordance with NICE.
    • Psoriatic arthritis in accordance with NICE.
    • The treatment of severe active ankylosing spondylitis in adults whose disease has responded inadequately to, or who cannot tolerate, non-steroidal anti-inflammatory drugs in accordance with NICE.
    • Treatment in adults with severe rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed in accordance with NICE.
    • The treatment of non-radiographic axial spondyloarthritis in accordance with NICE
06.05.01 Gonadorelin 100microgram in 1ml 
06.07.02 Goserelin 
  • The following goserelin formulations are approved for use 3.6mg & 10.8mg injections (also see section 8.3.4.2). 
  • Note: leuprorelin is now substantially less expensive than goserelin
08.03.04.02 Goserelin 
  • Approved formulations include 3.6mg and 10.8mg implants.
06.04.04 Goserelin 3.6mg injection 
03.04.02 Grass and Tree Pollen Extract Pollinex Quattro®
  • For use in adults and children by adult and paediatric immunologists only.
  • Less injections than with conventional Pollinex®
03.04.02 Grass and Tree Pollen Extract Pollinex®
  • For use in adults and children by adult and paediatric immunologists only.
03.04.02 Grass pollen extract Grazax®
05.02.05 Griseofulvin 
  • For very limited use where terbinafine is contraindicated.
04.04 Guanfacine Intuniv®
  • 1mg, 2mg, 3mg & 4mg prolonged release tablets
  • Approved for use in children and adolescents when 1st line stimulants and atomoxetine are contraindicated or ineffective.
  • Can also be prescribed in primary care by GPs in adults who started treatment in childhood and wish to continue, for whom stimulants are not suitable, not tolerated or have been shown to be ineffective under specialist supervision
13.05.03 Guselkumab Tremfya®
  • 100mg/1mL solution for injection
  • Approved for the treatment of moderate to severe plaque psoriasis in line with NICE
13.12 Haem-agglutinin complex 
  • For limited use as an alternative to surgery in some patients.
01.07.01 Haemorrhoid relief ointment 
04.02.01 Haloperidol 
04.02.01 Haloperidol 
04.06 Haloperidol 
04.09.03 Haloperidol 
04.02.02 Haloperidol Decanoate 
15.01.02 Haltothane 

unlicensedunlicensed
For use in elective and emergency airway anaesthesia only (mainly paediatrics)

09.06.07 Healthy Start Vitamins 
  • These formulations are prepared for the NHS and recommended in NICE guidance. DOH offers the Healthy Start Vitamins to pregnant women and children less than 4 years. They are only available through clinics and from midwives and are not prescribable on FP10 prescriptions
02.08.01 Heparin 
02.08.01 Heparin 
14.05.02 Hepatitis B immunoglobulin Hepatect CP®
14.05.02 Hepatitis B immunoglobulin HBIG
  • 200 international units - for infant use 
12.03.04 Hexetidine 0.1% mouthwash 
13.10.05 Histoacryl Blue® 
11.08.02.04 Holoclar® 
  • Approved for treating limbal stem cell deficiency after eye burns in line with NICE and NHS England Commissioning Policy as of 14 November 2017
18.08.02 Hospicrepe® 239 

Cotton crepe bandage

18.08.02 Hospilite® 

Cotton, Polyamide and Elastane Bandage

09.02.02.02 Human Albumin Solution 
  • 4.5% (50ml, 100ml & 500ml)
  • 20% (50ml & 100ml)
14.04 Human papilloma virus (HPV) vaccine Gardasil®
  • Also approved for therapeutic vaccination in the treatment of children and adults with recurrent respiratory papillomatosis Red
07.02.01 Hyalofemme® water-based intimate lubricant 
  • For restricted use for the relief of symptoms of atrophic vaginitis, in women who have had treatment for gynaecological malignancyand where topical estriol is not a treatment option
12.03.01 Hyaluronan 
  • 0.2% gel and 0.025% mouthwash.
  • For limited second-line use on specialist advice in the treatment of
    orofacial granulomatosis, severe oral ulceration and mucositis secondary
    to immunosuppression where conventional treatments are unsuitable or
    have failed.
19 Hyaluronic Acid Hydrafil Softline Max®
19 Hyaluronic Acid - Perlane Restylane Perlane®
19 Hyaluronic Acid - Sub Q Restylane Sub Q ®
10.03.01 Hyaluronidase Hyalase®
02.05.01 Hydralazine 
06.03.02 Hydrocortisone 

10mg/5ml

06.03.02 Hydrocortisone 
  • 10mg and 20mg tablets
  • 2.5mg buccal tablets 
  • 10mg in 5ml suspension unlicensedunlicensed.
10.01.02.02 Hydrocortisone acetate 25mg in 1ml injection 
06.03.01 Hydrocortisone sodium succinate 
13.04 Hydrocortisone 0.25% Crotamiton 10% Eurax-HC®

MILD

  • Cream
13.04 Hydrocortisone 0.5%, 1% & 2.5% 

MILD
Cream and ointment

12.01.01 Hydrocortisone 1% Neomycin 0.439% & Polymixin B sulphate 10,000iu/ml ear drops Otosporin®
  • Alternative choice compound antibacterial/corticosteroid ear drop.
13.04 Hydrocortisone 1% with Clotrimazole 1% Canesten HC®

MILD

 

13.04 Hydrocortisone 1% with Miconazole Nitrate 2% Daktacort®

MILD

  • Cream and ointment
06.03.01 Hydrocortisone 10 mg, and 20mg tablets 
  • Hydrocortisone 10mg in 5ml suspension is also approved for use. unlicensed unlicensed
12.03.01 Hydrocortisone 2.5mg Lozenges Corlan®
01.05.02 Hydrocortisone Acetate 
  • 10% foam enema
  • Equal first choice with budesonide foam enema 
13.04 Hydrocortisone Acetate 1% with Fusidic Acid 2% Fucidin H®

MILD

12.01.01 Hydrocortisone Acetate 1% with Gentamicin 0.3% Gentisone® HC
  • First choice compound antibacterial/corticosteroid ear drop.
13.04 Hydrocortisone Butyrate 0.1% cream Locoid®

POTENT

18.02.02 Hydrofilm® Plus 
  • Primary care only
13.11.06 Hydrogen Peroxide Solution BP 
  • 10 volume (3%) & 20 volume (6%) solutions.
13.02.01.01 Hydromol® bath and shower 
13.02.01 Hydromol® ointment 
  • This product is also known locally as ‘Emulsifying Ointment RVI
    Formula’. It is softer than emulsifying ointment BP. Epaderm ointment is
    made to the same formula, but is more expensive.
04.07.02 Hydromorphone 
13.02.01 Hydrous® ointment 
09.01.02 Hydroxocobalamin 1mg in 1ml injection 
08.01.05 Hydroxycarbamide  
  • 100mg tablets
  • 500mg capsules
  • 500mg in 5ml suspension (unlicensedunlicensed) is also approved
10.01.03 Hydroxychloroquine 
11.08.02 Hydroxypropylmethylcellulose HV Oasis®
  • 2% 2.3ml intraocular injection.
03.04.01 Hydroxyzine 
01.02 Hyoscine Butylbromide Buscopan®
04.06 Hyoscine Hydrobromide 
  • For the management of excessive secretions where tablets are unsuitable.
15.01.03 Hyoscine Hydrobromide 400microgram injection 
18.07.03 Hypafix® 

Permeable, Apertured Non-Woven Synthetic Adhesive Tape, BP 1988

03.07 Hypertonic sodium chloride 7% Nebusal®
11.08.01 Hypromellose 
  • 0.3% eye drops
  • 0.3% preservative-free eye drops:
    • 1st line Tear-Lac®;
    • 2nd line PF Drops®
      -treatment to be initiated on the advice of ophthalmologist only

06.06.02 Ibandronic Acid  
  • Ibandronic acid 50mg tablets are approved for use in the reduction of bone damage in patients with metastatic breast cancer. Not approved for use in the treatment of patients with other forms of cancer (e.g. prostate) or for the treatment of osteoporosis. 
  • Ibandronic acid 3mg in 3ml injection is approved for use where oral bisphosphonates are not appropriate (not tolerated, contra-indicated because of upper gastro-intestinal problems or insufficiently effective)
  • Approved for the treatment of osteoporosis in line with NICE
08.01.05 Ibrutinib Imbruvica®
  • Approved for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation in line with NICE and NHS Commissioning Policy.
  • Approved for treating relapsed or refractory mantle cell lymphoma in line with NICE and NHS England Commissioning Policy if:
    • they have had only 1 previous line of therapy
04.07.01 Ibuprofen 
04.07.04.01 Ibuprofen 
10.01.01 Ibuprofen 
02.14 Ibuprofen 10mg injection Pedea®
  • Approved only for use when there is a supply problem with indometacin.
10.03.02 Ibuprofen gel 
03.04.03 Icatibant Firazyr®
  • For use on the advice of immunologist in the treatment hereditary angioedema associated with C1-esterase inhibitor.
13.05.01 Ichthammol 
08.01.02 Idarubicin 
  • Approved formulations include:
    • 5mg and 10mg capsules;
    • 10mg injection.

02.08 Idarucizumab 
  • Approved for use as a rapid reversal agent for dabigatran.
08.01.05 Idelalisib  
  • Approved in combination with rituximab for the treatment of:
    • Untreated chronic lymphocytic leukaemia in adults with a 17p deletion or TP53 mutation; NICE or
    • Chronic lympocytic leukaemia in adults when the disease has been
      treated but has relapsed within 24 months NICE.
08.01.01 Ifosfamide  
02.05.01 Iloprost  
  • Approved for pulmonary hypertension - in accordance with NHS England Commissioning policy. 
02.08.01 Iloprost 
  • Mainly for use in treating pulmonary hypertension - see secton 2.5.1 
08.01.05 Imatinib  
  • Approved for the first-line management of people with KIT (CD117)- positive unresectable and/or KIT (CD117)-positive metastatic gastrointestinal stromal tumours (GISTs) in line with NICE. 
  • Approved for the adjuvant treatment of gastrointestinal stromal tumours (GISTs) after surgery when there is a high risk relapse of tumour NICE. 
  • Approved for Philadelphia-chromosome-positive CML in the accelerated phase or with blast crisis in line with NICE.
  • A standard-dose imatinib is recommended as an option for the first-line treatment of adults with chronic phase Philadelphia-chromosomepositive CML in line with NICE.
09.08.01 Imiglucerase Cerezyme®
  • 400iu injection
04.03.01 Imipramine 
04.07.04.02 Imipramine 
07.04.02 Imipramine  
  • 10mg and 25mg tablets
  • 25mg in 5ml syrup is also approved. unlicensedunlicensed.
13.07 Imiquimod 5% cream Aldara®
  • Second line specialist use for treatment of ano-genital warts (mainly in genitourinary medicine [GUM] clinics).
18.03.02 Inadine® 

Knitted viscose primary dressing impregnated with povidone-iodine ointment

 

02.02.01 Indapamide 2.5mg tablets 
  • First choice for new patients
  • Modified release (MR) indapamide tablets are NON FORMULARY.
13.10.05 Indermil X-Fine® 
19 Indigo Carmine 
05.03.01 Indinavir 
11.08.02 Indocyanine green 

25mg injection.

10.01.01 Indometacin 
02.14 Indometacin 1mg injection 

unlicensedunlicensed

13.11.01 Industrial Methylated Spirit BP 

70% liquid & 70% spray

13.11.03 Infacare Baby Bath Additive 
  • Secondary care use only
01.05.03 Infliximab Inflectra®

Add NICE TA

01.05.03 Infliximab Remicade®, Inflectra®, Remsima®
  • Only approved for use in accordance with NICE guidance.
  • Prescribe by brand only.  
01.05.03 Infliximab Remicade®
10.01.03 Infliximab Remsima®, Inflectra®, Remicade®
  • Prescribe by brand name; Remsima®, Inflectra®, Remicade®. 
  • Approved for:
    • Treatment in adults with severe rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs have failed in accordance with NICE.
    • Rheumatoid arthritis after the failure of a TNF inhibitor in line with NICE.
    • Psoriatic arthritis in accordance with NICE.
    • JIA in patients who have not responded to etanercept.
    • Juvenile dermatomyositis and paediatric onset Behcet’s disease where there has been intolerance or lack of response to 1st and 2nd line therapies.
    • The treatment of severe active ankylosing spondylitis in adults whose disease has responded inadequately to, or who cannot tolerate, non-steroidal anti-inflammatory drugs in accordance with NICE.

13.05.03 Infliximab Remsima®, Inflectra®, Remicade®
  • Approved for psoriasis in line with NICE.
19 Infloran® 
13.08.01 Ingenol mebutate gel Picato®
  • 150 micrograms/g & 500 micrograms/g gel 
  • For the treatment non-hyperkeratotic, non-hypertrophic actinic keratosis
    in adults
19 INRatio2® 
06.01.01.01 Insulin Actrapid®
  • Human Actrapid® 10ml vial approved. 
06.01.01.01 Insulin Insuman® Rapid
  • Approved formulations of Insuman® Rapid include the 5x3ml cartridges.

 

06.01.01.01 Insulin Humulin® S
  • Approved formulations of Humulin® S include:
    • 10ml vials;
    • 5x3ml cartridges.

06.01.01.01 Insulin 500 units in 1mL Humulin R®
  • Humulin R 500units in 1ml (10ml vial) approved for a very small number of insulin resistant patients that require very high doses of insulin. 
06.01.01.01 Insulin Aspart  NovoRapid®
  • Approved formulations for Novorapid® include:
    • 10ml vial;
    • 5x3ml cartridge (for use with Novopen and Novopenmate devices);
    • 5x3ml Flexpen®.

06.01.01.02 Insulin degludec  Tresiba®
  • 100 units/mL only
  • Pre-filled pen and cartridges
  • Approved for use in patients with Type 1 diabetes with
    • Nocturnal/Severe Hypogycaemia (with or without hypoglycaemic unawareness) in patients who would otherwsie progress to insuling pump treatment as per NICE TA151); or
    • Recurrent DKA episodes despite good compliance and who would otherwise progress to insulin pump therapy
    • Paediatric patients who cannot tolerate glargine sting
    • Paediatric patients with poor control on the high HbA1c pathway
    • Patients or Parents/Carers with unpredictable lifestyles such as students or shift workers.
06.01.01.02 Insulin Detemir Levemir®
  • Alternative choice long acting basal insulin.
  • Approved Levemir® formualtions include:
    • 5x3ml cartridges;
    • 5x3ml pens. 

06.01.01.02 Insulin Glargine Lantus®
  • Alternative choice long acting basal insulin. 
  • Approved Lantus® formulations include:
    • 10ml vials;
    • 5x3ml cartridges;
    • 5x3ml pens (Optiset®, OptiClik® and Solostar® - in line with NICE). 

06.01.01.02 Insulin Glargine  Toujeo®
  • Alternative choice long acting basal insulin.
  • Approved Toujeo® formulations include:
    • 3x1.5ml pen (Solostar®).

06.01.01.02 Insulin Glargine biosimilar Abasaglar® 
  • First choice long acting basal insulin in patients eligible for treatment in line with NICE and NTAG
  • Approved Abasaglar® formulations include:
    • 5x3ml cartridge
    • 5x3ml Kwikpen®.

06.01.01.01 Insulin Glulisine Apidra®
  • Approved Apidra® formulations include:
    • 10ml vials;
    • 5x3ml cartridges
    • 5x3ml Solostar® pens.

06.01.01.01 Insulin Lispro 100 units/ml Humalog®
  • Approved formulations for Humalog 100 ® include:
    • 10ml vial;
    • 5x3ml cartridge;
    • 5x3ml Kwiikpen®.

06.01.01.01 Insulin Lispro 200 units/ml Humalog®
  • Approved formulations for Humalog 200® include the 5x3ml Kwikpen®.
19 Integuseal® IS 100 
08.02.04 Interferon Alfa-2b 
08.02.04 Interferon Alfa-2b Roferon-A®
08.02.04 Interferon Beta Rebif®
08.02.04 Interferon Beta Betaferon®
08.02.04 Interferon Beta Avonex®
08.02.04 Interferon beta Extavia®
07.03.04 Intra-uterine Contraceptive Devices 

First choice

  • TT380 Slimline® Intrauterine device – replacement every 10 years.
  • Mini TT380 Slimline® Intrauterine device – replacement every 5 years.
  • T-Safe Cu380A® Intrauterine device – replacement every 10 years.

Alternatives

  • Nova T 380® Intrauterine device – replacement every 5 years.
07.03.02.03 Intra-uterine Progestogen Only System Kyleena®
  • Levonorgestrel 19.5mg intra-uterine system. 
    Low dose long acting reversible contraceptive. Lasts for up to 5 years 
07.03.02.03 Intra-uterine Progestogen Only System Mirena®
  • Levonorgestrel 52mg in a T-shaped intra-uterine system. 
  • For idiopathic menorrhagia. Especially in women requiring (reversible) contraception. Also used for protection with endometrial hyperplasia during oestrogen replacement therapy. Lasts for up to 5 years - for use in accordance with agreed guidelines.
07.03.02.03 Intra-uterine Progestogen Only System Jaydess®
  • Levonorgestrel 13.5mg in a T-shaped intra-uterine system. 
    Low dose long acting reversible contraceptive. Lasts for up to 3 years - not recommended as first line for nulliparous women.
06.02.02 Iodine and Iodide 
  • Oral solution (Lugol’s Iodine) containing 130mg total iodine/ml (5% iodine & 10% potassium iodide).
18.03.02 Iodoflex® 

Iodine 0.9% as cadexomer-iodine in a paste basis with gauze backing

  • Specialist use only
18.03.02 Iodosorb® Ointment 

Iodine 0.9% as cadexomer-iodine in an ointment basis

  • Specialist use only
06.02.02 Iopanoic acid 
  • Approved for use in rapid blockade of thyrotoxicosis in otherwise medically resistant patients prior to surgery/thyroidectomy.
08.01.05 Ipilimumab 
  • Approved for previously treated advanced melanoma in line with NICE.
  • Approved for previously untreated advanced melanoma in line with NICE.

03.01.02 Ipratropium 
12.02.02 Ipratropium Bromide 21 microgram/puff nasal spray Rinatec®
03.01.04 Ipratropium bromide with salbutamol 
02.05.05.02 Irbesartan 
  • Only to be used in the treatment of exisiting patients. 
08.01.05 Irinotecan Hydrochloride  
09.01.01.02 Iron Dextran 100ml in 2ml and 500mg in 10ml injections 
09.01.01.02 Iron Isomaltoside 1000mg in 10ml injection Monofer®
09.01.01.02 Iron Sucrose 100mg in 5ml injection Venofer®
05.02.01 Isavuconazole Cresemba®
  • Approved for use in line with licensed indications and specifically in solid organ transplant and bone marrow transplant recipients.
15.01.02 Isoflurane 
05.01.09 Isoniazid 
  • 50mg & 100mg tablets
  • 50mg in 5ml elixir unlicensedunlicensed
  • 50mg in 2ml injection
06.01.01.02 Isophane Insulin Insulatard®
  • Approved Insulatard® formulations include:
    • 10ml vial;
    • 5x3ml cartridges (for use with Novopen® and Novopenmate® devices);
    • 5x3ml Innolet® pens. 

06.01.01.02 Isophane Insulin Humulin® I
  • Approved Humulin® I formulations include:
    • 10ml vials;
    • 5x3ml cartridges;
    • 5x3ml pens. 

06.01.01.02 Isophane Insulin Insuman® Basal
  • Approved Insuman® Basal formulations include:
    • 5x3ml cartridges;
    • 5x3ml Solostar® pens. 


 

02.07.01 Isoprenaline 
13.11.01 Isopropyl alcohol 70% Skin Preparation Swabs Sterets®
02.06.01 Isosorbide Dinitrate 10mg in 10ml injection 
02.06.01 Isosorbide Mononitrate 10mg, 20mg and 40mg tablets, and 60mg MR tablets 
  • 10mg, 20mg and 40mg tablets
  • 60mg MR tablets - should only be used in patients when the non-modified release tablets are unsuitable Restricted Item
13.06.01 Isotretinoin 0.05% gel Isotrex® gel
13.06.01 Isotretinoin 0.05% with erythromycin 2% Isotrexin®
13.06.02 Isotretinoin capsules 
  • 5mg, 10mg, 20mg & 40mg capsules
  • Isotretinoin is a toxic drug only to be prescribed by or under the supervision of a consultant dermatologist – see BNF and product literature.
01.06.01 Ispaghula Husk 
05.02.01 Itraconazole 
  • 100mg capsules Green Traffic Light.
  • 50mg in 5ml oral solution Green Traffic Light
  • 250mg in 25ml injection for IV infusion Red Traffic Light
02.06.03 Ivabradine 
  • Angina - for intiation on advice from a consultant cariologist in patients with contra-indications to or intolerance of beta-blockers.
  • Heart failure  - approved for use in accordance with NICE guidelines.
03.07 Ivacaftor 
  • Approved for the treatment of cystic fibrosis in patients who have a faulty mutation in the CFTR gene in line with NHS England Clinical Commissioning Policy. 
13.06.01 Ivermectin 1% cream Soolantra®
  • For the treatment of papulopustular rosacea in patients as second line treatment in patient who have failed topical metronidazole.
13.05.03 Ixekizumab Taltz®
  • Approved for the treatment of moderate to severe plaque psoriasis in adults in line with NICE
19 Juvederm® Ultra 3 
19 Juvederm® Ultra 4 
18.08.08 Juxta CURES® 
  • Specialist use only
18.08.02 K-Band® 

Knitted Polyamide and Cellulose Contour Bandage, BP 1988

18.04.02 Kelo-Cote® 15g Gel 

Silicone gel

  • For use by the Burns Team

 

18.02.03 Kendall Telfa Clear® 

Clear non-adherent wound contact layer

18.03.04 Kendall® AMD Antimicrobial Foam 
  • 5cm x 5cm and 8.8cm x 7.5cm only 
18.03.04 Kendall® AMD Foam Discs 
18.01.02 KerraMax® Care 

Super absorbent cellulose primary dressing

18.10 Kerraped® 
18.10 Kerrapro® Pressure Reducing Pads 
15.01.01 Ketamine  
  • 200mg in 20ml (10mg/ml), 500mg in 10ml (50mg/ml) & 1g in 10ml (100mg/ml) injections
  • 50mg in 5ml oral solution unlicensedunlicensed
    • Often used as an analgesic in the management of neuropathic pain by specialist pain teams Red Traffic Light
    • Also for palliative care Amber Traffic Light
13.10.02 Ketoconazole 
  • 2% cream
  • shampoo
13.09 Ketoconazole 2% shampoo Nizoral®
11.08.02 Ketorolac Acular®
  • 0.5% eye drops.
15.01.04.02 Ketorolac injection 
  • 10mg/1ml & 30mg/1ml injection
    • the use of this is no longer recommended, other parenteral analgesics are now preferred

09.06.07 Ketovite® 
18.08.04 Knitted Elastomer and Viscose Bandage K- Lite®
02.04 Labetalol 
04.08.01 Lacosamide  
  • Only approved on advice from consultant neurologists, in patients that are refractory to treatment with other drugs.
01.06.04 Lactulose 
  • Not for PRN use - not effective.
05.03.01 Lamivudine 
  • 150 mg and 300 mg tablets
  • 50 mg/5ml oral solution
05.03.03.01 Lamivudine 
04.08.01 Lamotrigine 
08.03.04.03 Lanreotide 
  • Approved formulation include lanreotide 30mg long-acting injection and lanreotide 60mg, 90mg, and 120mg autogel injections.
    Existing patients 
    Green Traffic Light  for acromegaly, neuroendocrine tumour and carcinoid. 
    New patients
    Red Traffic Light  for acromegaly, neuroendocrine tumour and carcinoid.
01.03.05 Lansoprazole 
  • Orodispersible tablets should only be used in patients who cannot swallow capsules or tablets and for NG/PEG/PEJ use. Omeprazole capsules are currently cheaper than lansoprazole capsules in primary care.
09.05.02.02 Lanthanum Fosrenol ®
08.01.05 Lapatinib 
11.06 Latanoprost 0.005% with Timolol 0.5% eye drops 
  • For use as a second/third-line agent in patients insufficiently responsive
    to monotherapy with a prostaglandin analogue or beta blocker.
11.06 Latanoprost eye drops 
  • 50 microgram/ml drops
  • 50 microgram/ml preservative free SDU (Monopost)
10.01.03 Leflunomide 
08.02.04 Lenalidomide 
  • Approved for multiple myeloma in line with NICE - approved for myelodysplastic syndrome with 5q deletion in line with NICE (subject to NHS England funding).
09.01.06 Lenograstim (rHuG-CSF) Granocyte®
  • 263 microgram (33.6 million units) injection vials
08.01.05 Lenvatinib Kisplyx®
  • 4mg & 10mg capsules
  • Approved with everolimus for previously treated advanced renal cell carcinoma in accordance with NICE
02.06.02 Lercanidipine 
  • For use as a second line calcium channel blocker where amlodipine is not tolerated. 
08.03.04.01 Letrozole 
06.07.02 Leuprorelin 
  • Approved formualtions include 3.75mg and 11.25mg pre filled syringes (also see section 8.3.4.2).
06.04.04 Leuprorelin 11.25mg injection 
08.03.04.02 Leuprorelin Acetate 
  • Approved formulations include leuprorelin 3.75mg & 11.25mg prefilled syringes.
04.08.01 Levetiracetam 
15.02 Levobupivacaine Chirocaine®
  • 0.25%, 25mg in 10ml & 0.5%, 50mg in 10ml & 0.75%, 75mg in 10ml injections 
  • 0.625mg/ml & 1.25mg/ml infusion bags Red Traffic Light
    - for local infiltration in hip and knee replacement surgery.
15.01.04.03 Levobupivacaine with Fentanyl 
  • 2 micrograms/ml with levobupivacaine 0.1% in sodium chloride 0.9% infusion, 100ml, 250ml & 500ml unlicensedunlicensed
  • 4 micrograms/ml with levobupivacaine 0.125% in sodium chloride 0.9% infusion, 500ml (RVI) unlicensedunlicensed
05.01.12 Levofloxacin 
04.02.01 Levomepromazine 
  • For use in palliative care.
  • Note: Methotrimeprazine 6mg tablets are unlicensedunlicensed
04.06 Levomepromazine 
  • Levomepromazine 6mg tablets unlicensedunlicensed.
  • Levomepromazine 25mg in 1ml injection is approved for use in palliative care. 
07.03.05 Levonorgestrel 1.5mg tablet Levonelle 1500 ®
  • Levonorgestrel is recommended for patients who present at up to 72 hours following unprotected intercourse, and the use of ulipristal should be second-line to the use of a copper containing IUCD.
02.07.01 Levosimendan 
  • Approved for use in weaning paediatric and adult patients off extracorporeal membrane oxygenation (ECMO).
  • Approved for use in paediatrics and adults where additional intravenous inotropic support is considered appropriate.
06.02.01 Levothyroxine 
  • 25microgram, 50microgram, 75microgram & 100 microgram tablets
  • 25microgram in 5ml sugar-free oral solution
  • 100microgram in 5ml sugar-free suspension is also approved unlicensedunlicensed.
02.03.02 Lidocaine 
02.03.02 Lidocaine 
15.02 Lidocaine 
  • Injections (plain)
  • 0.5% 10ml
  • 1% 2ml, 5ml, & 10ml (10mg/ml)
    • approved for use in post-operative pain management subject to local protocols with a review of adverse events to be submitted by October 2018

  • 2% 2ml, 5ml & 20ml injection (20mg/ml)
  • 5% 2ml Heavy injection (50mg/ml)
  • 5% 10ml injection (50mg/ml) unlicensedunlicensed
  • Injections (with Adrenaline)
  • 1% & adrenaline 1 in 200,000, 20ml
  • 2% & adrenaline 1 in 200,000, 20ml
  • 2% & adrenaline 1 in 80,000, 2ml cartridges
    Topical preparations
  • 1% & 2% gel with chlorhexidine 0.25%
  • 4% topical solution (some packs unlicensed)
  • 5% ointment
  • Metered dose spray (10mg/spray)
  • 2% spray unlicensedunlicensed
  • 100mg lollipops unlicensedunlicensed
  • Lidocaine 4%, adrenaline 0.1% & tetracaine 0.5% (LAT gel®) unlicensedunlicensed
    - approved for use in anaesthetising lacerations particularly in the paediatric population – not to be used in children
    weighing under 15kg.
15.02 Lidocaine 2.5% with Prilocaine 2.5% EMLA®
15.02 Lidocaine 4% cream LMX4®
11.07 Lidocaine 4% with Fluorescein 0.25% Minims® 
15.02 Lidocaine 5% and Phenylephrine 0.5% 
  • 5% lidocaine & 0.5% phenylephrine solution with
    applicator
04.07.03 Lidocaine 5% medicated plasters (700mg lidocaine/plaster) 
  • For use in the treatment of post-herpetic neuralgia only, on the advice of pain specialists and subject to an appropriate trial of efficacy in each individual patient.
13.03 Lidocaine 5% ointment 
12.02.03 Lidocaine and Phenylephrine Nasal spray 
13.03 Lidocaine and prilocaine EMLA®
13.03 Lidocaine, Adrenaline, Tetracaine Pliaglis®
18.10 Limbo® Waterproof Protector 
01.06.07 Linaclotide 
  • Approved for specialist initiation for the symptomatic treatment of moderate-to-severe irritable bowel syndrome with constipation (IBS-C).
06.01.02.03 Linagliptin 
05.01.07 Linezolid 
  • Restricted for use on microbiology/infectious diseases advice, or as agreed in Trust Guidelines.
09.01.06 Lipegfilgrastim (G-CSF) 
13.10.05 LiquiBand Optima® 
13.10.05 LiquiBand® 
11.08.01 Liquid Paraffin eye ointment 
06.01.02.03 Liraglutide Victoza®
  • Only approved for the treatment of type 2 diabetes mellitus in accordance with NICE guidance . 

 

 

04.04 Lisdexamfetamine 
  • 20mg, 30mg, 40mg, 50mg, 60mg & 70mg capsules
  • For third line use and specialist initiation. Should only transferred to GPs after at least three month stable symptom control
  • Approved for the treatment of ADHD in adults
02.05.05.01 Lisinopril 
11.08.02 Lissamine Green  1.5mg ophthalmic strips
04.02.03 Lithium Carbonate 
  • Prescribe by brand name.
04.07.04.03 Lithium carbonate 
  • Lithium should be prescribed by brand name.
04.02.03 Lithium Citrate 
  • Prescribe by brand name.
04.07.04.03 Lithium citrate 
  • Lithium should be prescribed by brand name.
06.01.02.03 Lixisenatide 
19 l-lysine 2.5%, l-arginine 2.5%  
18.03.01 L-Mesitran® Ointment 

Medical grade honey

  • Specialist use only
18.03.01 L-Mesitran® Ointment S 

Medical grade honey

  • Specialist use only
04.03.01 Lofepramine 
  • Safer than amitriptyline in overdosage, but not as effective.
04.10.03 Lofexidine BritLofex®
08.01.01 Lomustine  
  • Note: 10mg capsules are unlicensedunlicensed.
01.04.02 Loperamide 2mg Capsules 
01.04.02 Loperamide 2mg Orodispersible tablets and 1mg in 5ml sugar-free syrup 
  • 2mg Orodispersible tablets: approved for use in primary care following specialist initiation in secondary care for patients with high output stoma only.
  • 1mg in 5ml sugar-free syrup: to relieve diarrhoea post-surgery following extensive gastrointestinal surgery. A therapeutic test should be carried out and if there is inappropriate response after 5 days, and it should be stopped.
05.03.01 Lopinavir and Ritonavir Kaletra®
03.04.01 Loratadine 
04.01.02 Lorazepam 
04.08.02 Lorazepam 
  • For intitation by neurologists only.
  • Lorazepam  2mg/ml suspension & 4mg/ml suspension are also approved but are unlicensedunlicensed.
  • Buccal administration of lorazepam suspensions are only approved for use in paediatrics in children with status epilepticus in whom buccal midazolam, rectal paraldehyde or rectal diazepam are ineffective.Red Traffic Light
15.01.04.01 Lorazepam 
  • See section 04.01.02.
02.05.05.02 Losartan 
  • To be used as first line treatment in all new patients.
  • 2.5mg in 1ml suspension is approved as an alternative to crushing tablets for paediatric and adult patients. 
11.04.01 Loteprednol Eye drops 
  • Approved as a second line agent to conventional corticosteroid eye drops, treatment to be imitated with the advice of an ophthalmologist only.
01.06.07 Lubiprostone 
  • Only approved for use in accordance with NICE guidance.
13.11 Lubricating jelly 
05.01.03 Lymecycline 
02.05.01 Macitentan 
  • Approved for pulmonary hypertension - in accordance with NHS England Commissioning policy. 
01.06.04 Macrogol Movicol liquid®

Approved as a second line macrogol laxative for care home residents only.

01.06.04 Macrogol oral powder 
01.06.04 Macrogol oral powder, Compound 
  • Macrogol oral powder, Compound
  • Macrogol oral powder, Compound, Half
  • Macrogrol Paediatric Plain
01.06.05 Macrogols Klean-Prep®
01.06.05 Macrogols Moviprep®
13.11.06 Magenta Paint BPC Castellani's paint

Paint containing magenta 0.4%, boric acid 0.8%, phenol 0.004%, resorcinol 8%, acetone and alcohol (or industrial methylated spirit).

09.05.01.03 Magnesium Aspartate 
  • 6.5g (10 mmol) sachets - first line for the treatment and prevention of magnesium deficiency.
  • 614.8mg (2.5mmol) tablets unlicensedunlicensed - for second line treatment in patients with short bowel syndrome.
09.05.01.03 Magnesium chloride  
  • 10 mmol magnesium in 1 litre sodium chloride 0.9% with potassium chloride 0.15% (20 mmol) unlicensedunlicensed
  • 64mg sustained release tablets (2.6mmol magnesium) unlicensedunlicensed
09.05.01.03 Magnesium Glycerophosphate 
  • 1g (4mmol) chewable tablets 
    • Use preparation with cheapest acquisition cost.
    • Yourmag®
    • Magnaphate® unlicensedunlicensed

  • 1mmol/ml suspension -available if supply problems with tablets unlicensedunlicensed.
09.05.01.03 Magnesium Sulphate 
  • 50% 2ml (4 mmol), 50% 10ml (20 mmol) & 10% 10ml (4mmol) injections 
  • 60 mmol in 500ml sodium chloride 0.9% infusion unlicensedunlicensed
13.10.05 Magnesium Sulphate Paste BP 
13.10.04 Malathion 0.5% solution (aqueous & alcoholic) 
12.03.05 Malic acid  Salivix®
02.02.05 Mannitol 
03.07 Mannitol inhalation 
  • Approved for bronchial provocation testing in patients unable to tolerate the taste of methacholine.
03.07 Mannitol inhalation Bronchitol ®
  • Only approved for use in accordance with NICE guidance. 
05.03.01 Maraviroc 
  • Approved for use in the treatment of patients with HIV infections that are resistant to standard therapy in accordance with British HIV Association and EACS guidelines.
05.05.01 Mebendazole 
01.02 Mebeverine 
18.10 Medi Derma® S  
  • sachet
  • 28g
  • 90g 

 

18.10 Medi Derma® S  
  • 1ml applicator
  • 3ml applicator
  • 50ml aerosol
  • 30ml pump spray
18.09.01 Medi® hosiery 
13.11.03 Mediscrub®  
06.04.01.02 Medroxyprogesterone Acetate 

Approved Medroxyprogesterone formulations include:

  • 2.5mg, 5mg, and 10mg tablets (sometimes used as a progestogen component of HRT).
  • 100mg & 200mg tablets (for use in malignant disease see section 8.3.2).
  • 50mg in ml injection - see sections 7.3.2.2 for use of  medroxyprogesterone acetate injection in contraception.
08.03.02 Medroxyprogesterone Acetate 
  • Approved formualtion include 100mg, 200mg, and 400mg tablets. 
  • Medroxyprogesterone acetate 500mg in 2.5ml injection is also approved. Green Traffic Light
07.03.02.02 Medroxyprogesterone Acetate injection 
  • Approved formulations include:
    • Depo-Provera® - 150mg in 1ml depot injection;
    • Sayana Press® - 104mg/0.65ml S/C injection.

10.01.01 Mefenamic Acid 
18.07.03 Mefix® 

Permeable, Apertured Non-Woven Synthetic Adhesive Tape, BP 1988

 

05.04.01 Mefloquine 

Note: not approved on the NHS for prophylaxis. Not NHS 

08.03.02 Megestrol Acetate 
18.02.06 Meglisorb®  

Calcium sodium alginate fibre, highly absorbent, gelling dressing, non-woven 

19 Meglumine gadoterate Dotarem®
  • Gadolinium MRI contrast medium that is licensed for use in children. Gadoterate is considered to be much less likely to cause nephrogenic systemic fibrosis than dimeglumine gadopentetate (Magnevist®), which has previously been used in children.
04.01.01 Melatonin  
  • First line: melatonin 2mg modified release tablets. 
  • Second line: melatonin 2mg modified release tablets (crushed).
  • Third line: Melatonin 1mg in 1ml solution (unlicensedunlicensed).

Approved Indications

Melatonin can be used to facilitate the induction of sleep, and increase the duration of sleep on the advice of an appropriate secondary care specialist, in the following situations:

1) Visually impaired or blind people with disturbed sleep wake cycles. Green plus
2) Delayed sleep phase syndrome and other circadian rhythm disorders.Green plus
3) Children with neurological or behavioural disorders including: Amber

  • Attention deficit hyperactivity disorder (ADHD).*
  • Chronic sleep onset insomnia.*
  • Neurodevelopmental disabilities (e.g. involving delayed brain maturation, sensory dysfunction - especially visual and dysfunction of sleep centres).*

4) Treatment of children and young adults with chronic fatigue syndrome / myalgic encephalomyelitis who have sleep difficulties (as recommended in NICE clinical guideline no. 53).* Amber
5) Prior to examinations such as a sleep encephalogram (EEG) in children and sedation prior to scans in paediatric oncology. Green plus
6) Patients with REM sleep behaviour disorder (RBD) - e.g. associated with degenerative conditions such as Parkinson’s disease or dementia, as a second line treatment to clonazepam. Green plus
7) To improve nocturnal sleep in critically ill patients (to aid weaning from mechanical ventilation) Green plus

*Note that for indications 3 and 4 in children and young people melatonin is classified as an ‘amber’ drug by the NoT APC therefore subject to formal shared care guidance.  Please follow link below for the most recent guideline

 

18.01.02 Melolin® 

Absorbent, Perforated Plastic Film Faced, Dressing

  • Podiatry use only
10.01.01 Meloxicam 
08.01.01 Melphalan 
04.09.03 Memantine  
  • Approved for use as last line drug after other alternatives have been considered, in the treatment of congenital and acquired nystagmus.
04.11 Memantine 
  • Only approved for use in accordance with NICE guidance. 
09.06.06 Menadiol Sodium Phosphate 
  • 10mg tablets - water soluble derivative of vitamin K for use in patients with fat malabsorption, especially in hepatic disease or biliary obstruction including cystic fibrosis patients.
06.05.01 Menotrophin (75 units FSH & 75 units LH activity) injection  
13.03 Menthol and aqueous cream  

- available as Dermacool

05.04.04 Mepacrine Hydrochloride 
18.04.02 Mepiform® 

Silicone gel sheet

  • Burns Team initiation only
18.02.03 Mepilex® Border  

Absorbent soft silicone dressing with polyurethane foam and adhesive border

18.02.03 Mepilex® Border lite  

Thin absorbent soft silicone dressing with polyurethane foam and adhesive border

  • Paediatrics only 
18.02.03 Mepilex® Border Post-op 
18.02.03 Mepilex® ST 

Absorbent soft silicone dressing with polyurethane foam film backing 

15.02 Mepivacaine 
  • 3% 2.2 ml cartridges
03.04.02 Mepolizumab Nucala®
  • Approved for the treatment of severe refractory eosinophilic asthma in line with NICE and NHS England Commissioning Policy.
09.08.01 Mercaptamine 
01.05.03 Mercaptopurine 
08.01.03 Mercaptopurine  
  • A mercaptopurine 20mg in 1ml suspension (unlicensedunlicensed) is also approved for use. 
  • Note: when prescribed for inflammatory bowel disease. Amber Traffic Light
12.03.03 Merocaine 
05.01.02.02 Meropenem 
  • Restricted for use on microbiology/infectious diseases advice, or as agreed in Trust Guidelines.
01.05.01 Mesalazine Rectal Preparations
  • 250mg & 500mg & 1g suppositories
  • 1g in 100ml retention enema, 2g in 59ml enema
  • 1g foam enema
01.05.01 Mesalazine 

First Choice

  • Octasa MR® (400mg e/c m/r tablets): approved as first choice 400mg e/c m/r preparation for all new patients. Patients receiving Asacol® and Mesren® should be switched to Octasa® when appropriate.
  • Asacol® (400mg e/c m/r tablets) - to be used for existing patients who are unable to change to Octasa MR®.
  • Pentasa® (500mg m/r tablets).
  • Mezavant® XL (1.2g e/c m/r tablets).
  • Salofalk® 1g m/r granules/sachet - only to be used in patients with difficulty in swallowing.
08.01 Mesna 
  • Approved formulations include 1gram in 10ml injection and 400mg tablets.
13.02.02 Metanium® 
02.07.02 Metaraminol 
06.01.02.02 Metformin 
  • Metformin oral solution sachets are preferred to the ready-made oral solution (more cost effective).
  • Metformin MR (once daily - Glucophage® SR) are only approved for use in patients who have failed to tolerate the conventional tablets despite careful dose titration.
  • Note: metformin is also approved for use in Polycystic Ovary Syndrome.
04.07.02 Methadone 
  • The following preparations are approved:
    • 5mg tablets;
    • 2mg in 5ml linctus;
    • 5mg in 5ml mixture DTF & 5mg in 5ml sugar free solution
    • 20mg in 1ml concentrated oral solution (unlicensedunlicensed)
    • 10mg in 1ml injection

04.10.03 Methadone 
  • Methadone 5mg in 5ml oral solution and 5mg in 5ml sugar free solution are both approved for the management of opioid dependence in line with NICE.
05.01.13 Methenamine Hippurate 
  • Approved as second line agent for prophylaxis in patients with recurrent UTI’s who have failed long-term antibiotic prophylaxis, have contraindications to antibiotics or breakthrough infection with resistant organisms.
16 Methionine 250mg and 500mg tablets 

Paracetamol overdose

 

01.05.03 Methotrexate 
01.05.03 Methotrexate 
10.01.03 Methotrexate 
13.05.03 Methotrexate 
08.01.03 Methotrexate 2.5mg tablets 
  • Other approved formulations include:
    • Methotrexate 10mg in 5ml oral solution. unlicensedunlicensed
    • Methotrexate injections (various strengths) – including prefilled syringes.
    • Methotrexate 5mg in 2ml intrathecal injection.

  • Note: when used in chronic inflammatory conditions, e.g. Crohn’s disease, rheumatoid arthritis.Amber Traffic Light
09.01.03 Methoxy Polyethylene Glycol-Epoetin Beta Mircera®, Pegzerepoetin® alfa
  • 30, 50, 100, 120, 150, 200 & 250 microgram in 0.3ml and 360 microgram in 0.6ml injections in prefilled syringes.
  • Approved for use as a longer-acting alternative to darbepoetin in a
    small number of patients receiving peritoneal dialysis.
13.05.02 Methoxypsoralen 1.2% bath additive 
01.06.01 Methycellulose Celevac®
02.05.02 Methyldopa 
04.04 Methylphenidate 
  • Please prescribe by brand name
  • Approved for ADHD and the treatment of narcolepsy in paediatrics.
  • 5mg & 10mg tablets
  • 5mg, 10mg, 20mg, 30mg and 40mg m/r capsules (Medikinet® XL)
  • 10mg, 20mg & 30mg m/r capsules (Equasym® XL)
  • 18mg, 27mg & 36mg m/r tablets (Xaggitin® XL) -
    • Existing patients who are prescribed Concerta® XL should be reviewed and switched to Xaggitin® XL as appropriate
    • Xaggitin® XL is bioequivalent to Concerta® XL
07.04.02 Methylphenidate 
  • Methylphenidate is approved for use as a third line option (after e.g. antimuscarinics, imipramine, and pelvic floor exercises) in the treatment of giggle incontinence. Its use should be subject to a therapeutic trial to be reviewed after two months and considered for Shared Care if patients have been shown to respond after the trial period. 
  • The following methylphenidate formulations are approved for giggle incontinence:
    • 5mg & 10mg tablets.
    • 10mg, 20mg & 30mg m/r capsules (Equasym XL®).
    • 18mg, 27mg & 36mg m/r tablets (Xaggitin® XL) 
      • Existing patients who are prescribed Concerta® XL should be reviewed and switched to Xaggitin® XL as appropriate
      • Xaggitin® XL is bioequivalent to Concerta® XL
  • The effects of Equasym® XL lasts for about 8 hours compared with about 12 hours for Xaggitin® XL.

 

 

10.01.02.02 Methylprednisolone Acetate 40mg in 1ml injection 
10.01.02.02 Methylprednisolone Acetate 40mg with lidocaine 1% injection 
06.03.02 Methylprednisolone Acetate 40mgin 1ml and 120mg in 3ml (depot) 
06.03.02 Methylprednisolone sodium succinate 2mg, 4mg, and 16mg tablets
06.03.02 Methylprednisolone sodium succinate 40mg, 125mg, 500mg & 1000mg injection
19 Methylthioninium Chloride 
01.02 Metoclopramide 
04.06 Metoclopramide 
04.07.04.01 Metoclopramide 
  • Used to help promote absorption of analgesics.
02.02.01 Metolazone 
  • Treatment should only be on advice from cardiology.
02.04 Metoprolol 
04.07.04.02 Metoprolol 
05.01.11 Metronidazole 
  • 200mg & 400mg tablets Green Traffic Light.
  • 200mg in 5ml suspension Green Traffic Light.
  • 500mg & 1g suppositories Green Traffic Light.
  • 50mg in 10ml injection & 500mg in 100ml IV infusion Red Traffic Light.
05.04.02 Metronidazole 
05.04.04 Metronidazole 
13.10.01.02 Metronidazole 0.75%  

Cream & gel

07.02.02 Metronidazole 0.75% vaginal gel 
06.07.03 Metyrapone Metopirone®
  • 250mg capsules
02.03.02 Mexiletine 
04.07.03 Mexiletine 
  • For use in the treatment of neuropathic pain. ECG monitoring is required to be carried out by pain clinic consultants as part of the initiation process of mexiletine, as patients are required for cardiac arrhythmias.
05.02.04 Micafungin 
13.10.02 Miconazole 0.16% spray 
13.10.02 Miconazole 2% cream 
12.03.02 Miconazole 24mg/ml sugar-free oral gel Daktarin®
12.03.02 Miconazole 50mg muco-adhesive buccal tablets Loramyc®
  • Restricted to use in immunocompromised patients with severe oropharyngeal candidiasis, where the use of other antifungal agents e. g. nystatin, fluconazole is not appropriate and for use on the advice of microbiologists.
04.08.02 Midazolam 
  • Buccolam® 5mg/ml alcohol-free buccal solution, and Buccolam® 2.5mg, 5mg, 7.5mg and 10mg prefilled oral syringes are approved as first choice for status epilepticus in children aged 3 months to 18 years.
  • Epistatus® 10mg in 1ml oromucosal solution pre-filled oral syringes is approved for use in the treatment of epileptic seizures in infants under 3 months and adults over 18 years of age. 
    Injection solutions (section 15.1.4) can also be given buccally
  • Midazolam 2.5mg in 5ml oral solution is approved for use as a sedative. To be used in preference to administering the injection orally (more cost effective).unlicensedunlicensed
15.01.04.01 Midazolam 
  • 5mg in 5ml (1mg/ml) injection – for general use
  • 10mg in 2ml & 10mg in 5ml injections
    • these higher strengths are restricted to use in general anaesthesia, intensive care, palliative medicine and where its use has been formally risk assessed and agreed, for example, where syringe drivers are used

  • 50mg in 50ml prefilled syringes Red Traffic Light - ITU use only 
  • 2.5mg in 1ml oral solution unlicensedunlicensed
  • Intranasal midazolam 40mg/ml + lidocaine 20mg/ml Red Traffic Light
    • approved for use prior to cannulation for adult patients with
      special needs receiving dental treatment under IV sedation.

02.07.02 Midodrine 
  • For specialist initiation in treating symptomatic hypotension that has not responsed to conventional therapies. 
08.02.04 Mifamurtide 
  • Approved for high-grade resectable non-metastatic osteosarcoma in line with NICE.
07.01.02 Mifepristone 200mg tablets 
09.08.01 Migalastat Galafold ®
  • Approved for the treatment of Fabry's disease in line with NICE 
02.01.02 Milrinone 
05.01.03 Minocycline 
10.01.03 Minocycline 
  • Only approved for use in patients with rheumatoid arthritis who are unable to tolerate biologics and other DMARDs.
02.05.01 Minoxidil 
  • Treatment should only be on the advice of a cardiologist/nephrologist.
07.04.02 Mirabegron 
  • Approved for use when antimuscarinics don’t work, are not suitable or side effects are unacceptable, in line with NICE guidance. 
11.09 Miraflow® daily cleaner 
04.03.04 Mirtazapine 
  • Orodispersible mirtazapine tablets should only be prescribed for use when other formulations are unsuitable (more expensive).
01.03.04 Misoprostol 
  • Note: 100 microgram tablets (unlicensedunlicensed) are also on formulary - mainly for use in paediatric nephrology at the RVI.
07.01.01 Misoprostol 
08.01.02 Mitomycin  
  • Also approved for treatment in combination with 5-Fluorouracil for bladder cancer concurrent with radiotherapy.
  •  Mitomycin 0.04% preservative free eye drops  are also approved for useGreen Traffic Light - this is unlicensedunlicensed.
08.01.05 Mitotane 
08.01.02 Mitoxantrone  
15.01.05 Mivacurium Mivacron®
  • 10mg in 5ml injection
  • 20mg in 10ml injection
04.03.02 Moclobemide 
  • For use on advice from psychiatrists only.
04.04 Modafinil 
  • Only approved for limited use in the treatment of patients with narcolepsy.
12.02.01 Mometasone Furoate 50microgram/metered dose nasal spray 
03.03.02 Montelukast 
  • Review treatment after 6 weeks of initiation and discontinue if no evidence of improvement. Should typically only be initiated by hospital specialist.
  • Montelukast is 2nd line after an inhaled corticosteroid for asthmatic children < 5 years old.
04.07.02 Morphine 
  • Zomorph is the preferred formulation. 
  • Morphine 20mg, 30mg, 60mg, 100mg & 200mg sachets of MR granules for preparing oral  suspensions are only approved for use when other formulations are unsuitable. 
  • Note: the following unlicensedunlicensed preparations are also approved for use:
    • morphine 5mg in 1ml injection;
    • 10mg in 1ml preservative free injection;
    • 2mg in 5ml epidural
    • 50mg in 50ml PCA injection. 

12.03.04 Mouthwash solution tablets 
05.01.12 Moxifloxacin 
02.05.02 Moxonidine 
12.02.03 Mupirocin 2% Bactroban Nasal®
  • First choice the treatment of MRSA
13.10.01.01 Mupirocin 2% Ointment Bactroban®
09.06.07 Mutivitamins BPC 
  • Capsules containing ascorbic acid 15mg, nicotinamide 7.5mg, riboflavin 500 micrograms, thiamine HCl 1mg, vitamin A 2,500 units, & vitamin D 300 units
08.02.01 Mycophenolate Mofetil 
08.02.01 Mycophenolate Sodium Myfortic®
  • Approved as second-line therapy in patients who do not tolerate mycophenolate mofetil.
11.05 Mydricaine ® No.2 
  • 0.3ml injection containing procaine HCl 6mg, atropine sulphate 1mg and adrenaline solution (1:1,000)
11.05 Mydricaine® No.2 
  • 0.3ml injection containing procaine HCL 6mg, atropine sulphate 1mg and adrenaline solution (1 in 1,000).
18.01.01 N/A Ultra® (Silicone-coated) 
04.06 Nabilone 
  • Also approved for very limited use in the treatment of chronic pain (unlicensedunlicensed) that has not responded to other treatments. Treatment must be initiated by pain consultants and reviewed after about one month. Treatment must be stopped immediately in non-responders.
  • Note: Nabilone 250 microgram capsules unlicensedunlicensed.
10.01.01 Nabumetone 
02.04 Nadolol 
  • Limited to use by cardiologists in patients with long QT syndrome/idiopathic ventricular fibrillation.
  • Liquid formulations (unlicensedunlicensed) can be obtained for use in children if necessary. Treatment should only be on the advice of a cardiologist.
06.07.02 Nafarelin 
02.06.04 Naftidrofuryl 
  • Approved for the treatment of intermittent claudication in people with peripheral arterial disease. 
04.10.01 Nalmefene 
  • Only approved for use in accordance with NICE guidance. 
01.06.06 Naloxegol 
  • Only approved for use in accordance with NICE guidance.
15.01.07 Naloxone 
  • 400 microgram in 1ml injection (ampoules).
  • 2mg/2ml pre-filled syringes (as per ACMD guidance).
16 Naloxone 
  • 400 microgram injection – ampoules and prefilled syringes
04.10.01 Naltrexone 
04.10.03 Naltrexone 50 mg tablets Nalorex®
  • Approved for the management of opioid dependence in detoxified formerly opioid-dependent people in line with NICE.
  • Also approved for use in reducing agitation and/ or selfinjurious behaviour in patients with learning disabilities or autism (unlicensedunlicensed indication). Treatment must be initiated by an appropriate hospital specialist and GPs should only be asked to prescribe it for responders in accordance with a shared care guidelineAmber Traffic Light
04.07.01 Naproxen tablets 
04.07.04.01 Naproxen tablets 
10.01.01 Naproxen tablets 
  • Note: a naproxen 125mg in 5ml suspension (unlicensedunlicensed) is also approved. 
08.02.04 Natalizumab 
  • Approved for rapidly evolving severe relapsing remitting multiple sclerosis in line with NICE and NHS England commissioning policy.
11.03.02 Natamycin 5%  
02.04 Nebivolol 
  • For specialist use in the treatment of patients who cannot tolerate other beta-blockers. Treatment should only be on the advice of a cardiologist.
12.02.02 NeilMed® Sinus Rinse 
  • Sachets containing powder for preparing a buffered saline solution for nasal irrigation using the NeilMed Irrigation device. Available as kits containing the irrigation device and sachets and separate (isotonic) sachets.
  • Note: NeilMed Sinus Rinse is classified as a medical device and, as it is not currently included in the Drug Tariff, it cannot be prescribed on the NHS in primary care.
05.03.01 Nelfinavir 
A2.03.01 Neocate LCP 
05.01.04 Neomycin 
  • 500mg tablets
  • 1g in 10ml syrup unlicensedunlicensed.
10.02.01 Neostigmine 
15.01.06 Neostigmine 
  • 2.5mg in 1ml injection
15.01.06 Neostigmine with Glycopyrronium 
  • Glycopyrronium 500 microgram & neostigmine 2.5mg in 1ml injection (Robinul – neostigmine)
04.06 Netupitant & Palonosetron Akynzeo®
  • To be used in accordance with Northern England Strateigc Clincial Cancer Network (NCCN) Guidelines
05.03.01 Nevirapine 
02.06.02 Nicardipine 1mg in 1ml injection 
  • Approved as a second line agent for the treatment of aortic dissection and pre-eclampsia.
02.06.03 Nicorandil 
04.10.02 Nicotine 
  • The following nicotine replacement treatments are approved:
    • Nicotine gum -  2mg & 4mg sugar-free chewing gum (Nicorette® is the gum of choice).
    • Nicotine 16 hour patch - 10mg, 15mg, and 25mg/16 hour patches (Nicorette® Invisi). 
    • Nicotine 24 hour patch - 7mg & 14mg, and 21mg /24 hour patches (Nicotinell® is the patch of choice as potential savings to be made).
    • Nicotine lozenges - 2mg and 4mg lozenges (Niquitin® is the lozenge of choice), 1.5mg and 4mg mini lozenges (NiQuitin® Minis Lozenges).
    • Nicotine 2mg sublingual tablets.
    • Nicotine inhalator -  5mg cartridges for use in inhalator.
    • Nicotine oromucosal spray - Nicorette® Quickmist 1mg per dose.

02.06.02 Nifedipine 
  • Once daily formualtions are preferred
  • 20mg controlled release tablets (Adalat LA), 30mg & 60mg m/r capsules (Coracten XL)
  • 5mg & 10mg capsules
  • 10mg & 20mg retard tablets
  • 20mg in 1ml (1mg/drop) nifedipine oral solution is also approved for use unlicensedunlicensed.
02.06.02 Nimodipine 
  • 30mg tablets -treatment should be on the advice of the stroke team or a cardiologist.
  • 10mg in 50ml for IV infusion Red Traffic Light
03.11 Nintedanib Ofev®
  • Only approved for use in accordance with NICE guidance. 
08.01.05 Nintedanib  
  • Approved for the treatment of locally advanced, metastatic or locally recurrent non-small-cell lung cancer who have previously been treated been with first-line chemotherapy in accordance with NICE.
  • Approved for treating idiopathic pumonary fibrosis in line with NICE
05.01.13 Nitrofurantoin 
  • Note: Liquid presentations of nitrofurantoin are very expensive compared to
    other solid dosage formulation. Please consider whether capsules can be used.
13.10.01.01 Nitrofurazone 0.2% Ointment 
  • For limited use in burns/plastic surgery patients only.
15.01.02 Nitrous oxide 
08.01.05 Nivolumab  
  • For the treatment of locally advanced or metastatic squamous nonsmall cell lung cancer (NSCLC) after prior chemotherapy in adults.
  • Approved for the treatment of advanced (unresectable or metastatic) melanoma in adults in line with NICE.
  • Approved in combination with ipilimumab for treating advanced melanoma in line with NICE and NHS England Commissioning Policy (SSC1664)
  • Approved for the treatment of advanced renal cell carcinoma in adults in line with NICE and NHS England Commissioning Policy
  • Approved for the treatment of relapsed of refractory classical Hodgkin lymphoma in line with NICE and NHS England Commissioning Policy 
18.07.02 Non-woven Fabric Swab 

Non-woven fabric folded 4-ply

07.03.03 Nonxynol ’9’ - 2% gel Gygel®
02.07.02 Noradrenaline / Norepinephrine 
08.03.02 Norethisterone 
06.04.01.02 Norethisterone 5mg tablets 
06.04.01.02 Norethisterone 5mg tablets 
14.05.01 Normal Immunoglobulin Kiovig®
  • 10% - 1g, 2.5g, 5g, 10g, 20g & 30g
14.05.01 Normal Immunoglobulin Flebogamma®DIF
  • 5% - 2.5g, 5g, 10g & 20g
14.05.01 Normal Immunoglobulin Subcuvia®
  • 16% - 0.8g & 1.6g
14.05.01 Normal Immunoglobulin Privigen®
  • 10% - 2.5g, 5g, 10g & 20g
14.05.01 Normal Immunoglobulin Gammunex®
  • 10% - 5g, 10g & 20g
14.05.01 Normal Immunoglobulin Iqymune®
  • 10% - 2g, 5g, 10g & 20g
14.05.01 Normal Immunoglobulin Intratect®
  • 5% - 1g, 2.5g, 5g & 10g
  • 10% - 1g, 5g, 10g & 20g
14.05.01 Normal Immunoglobulin Cuvitru®
  • 20% - 1g, 2g, 4g & 8g
14.05.01 Normal Immunoglobulin Gammanorm®
  • 16.5% - 1g, 1.65g, 2g, 3.3g, 4g & 8g
14.05.01 Normal Immunoglobulin Octagam®
  • 5% - 5g & 10g
  • 10% - 2g, 5g, 10g & 20g
14.05.01 Normal immunoglobulin for Intramuscular use 
18.07.01 Nurse It® Dressing Pack 

Contains latex-free, powder-free nitrile gloves, sterile laminated paper sheet, large apron, non-woven swabs, paper towel, disposable bag, compartmented tray, disposable forceps, paper measuring tape

A2.05.02 Nutilis Clear Nutilis®
A2.03.01 Nutramigen Puramino 
A2.01.03.02 Nutrini® 
A2.01.01.01 Nutrison®  
13.04 Nystaform-HC® 

MILD

  • Cream and ointment
05.02.03 Nystatin 
  • 100,000 units/ml suspension Green Traffic Light.
  • 100,000 unit pessaries unlicensedunlicensed Red Traffic Light
    • Second line treatment for vaginal non albicans infection, for patients who have not responded to standard treatments such as azoles. Prescribing is restricted to the GUM clinics.

13.10.02 Nystatin 
12.03.02 Nystatin 1000,000units/ml suspension Nystan®
01.09.01 Obeticholic acid 
  • 5mg & 10mg tablets
    • Approved for the treatment of primary biliary cholangitis in line with NICE and NHS England Commissioning Policy.

08.02.03 Obinutuzumab 
  • Approved for use in chronic lymphocytic leukaemia in combination with chlorambucil in patients who have co-morbitities that make full‑dose fludarabine‑based therapy unsuitable for them, only if bendamustine‑based therapy is not suitable and the company provides obinutuzumab with the discount agreed in the patient access scheme in line with NICE (subject to NHS England funding).
  • Approved for the treatment of rituximab-refractory follicular lymphoma in combination bendamustine in line with NICE and NHS England Commissioning Policy
11.08.02 Ocriplasmin Jetrea®
  • Approved for use in patients with vitreomacular traction who also have no epiretinal membrane and a hole (up to 400 micrometres) in the centre of their retina or severe sight problems in line with NICE.
02.11 Octanate 
  • Approved for patients with severe Haemophilia A and an inhibitor and in whom there is agreement to undertake immune tolerance induction with a plasma derived product. 
02.11 Octaplas and Octaplas LG 
  • Solution for infusion containing 45-75mg/ml human plasma proteins.
13.11.03 Octenisan® wash 
  • Used in some trusts as an alternative to chlorhexidine scrub and Triclosan skin cleanser in MRSA prophylaxis/eradication.
08.03.04.03 Octreotide 
  • Approved formulations include octreotide 50microgram, 100microgram, and 500 microgram in 1ml, and 1mg in 5ml injections, and octreotide 10mg, 20mg and 30mg long-acting injections.
    Existing patients 
    Green Traffic Light  for acromegaly, neuroendocrine tumour and carcinoid. 
    New patients
    Red Traffic Light  for acromegaly, neuroendocrine tumour and carcinoid.
  • Green Traffic Light Approved for the management of GI secretions in end of life care
06.04.01.01 Oestrogen conjugated tablets 625microgram and 1.2mg Premarin®
08.02.03 Ofatumumab 
  • Approved for use in chronic lymphocytic leukaemia in combination with chlorambucil if the person is ineligible for fludarabine‑based therapy and bendamustine is not suitable and the company provides ofatumumab with the discount agreed in the patient access scheme in line with NICE (subject to NHS England funding)
05.01.12 Ofloxacin 
  • For use in the treatment of pelvic inflammatory disease and chlamydia genital tract infections in accordance with local primary care guidelines.
11.03.01 Ofloxacin 0.3% Eye drops 
13.09 Oilatum shampoo 
13.02.01 Oilatum® cream 
13.02.01 Oilatum® Junior cream 
13.02.01.01 Oilatum® Plus emollient bath additive 
13.02.01.01 Oilatum® shower emollient gel 
01.07.03 Oily phenol injection BP 
04.02.01 Olanzapine 
  • Olanzapine orodispersible tablets should only be used in situations where the plain tablets are unsuitable. 
  • Olanzapine orodispersible tablets and injection are also approved for 2nd/3rd- line use in the management of delirium in critical care patients unlicensedunlicensed indication.
08.01.05 Olaparib 50mg capsules 
  • Approved for the maintenance treatment of BRCA 1 or 2 mutated, relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer in people whose relapsed disease has responded to platinum-based chemotherapy in line with NICE.
08.01.05 Olaratumab Lartuvo®
  • 10 mg/mL concentrate for solution for infusion
  • Approved for the treatment of advanced soft tissue sarcoma in combination with doxorubicin in line with NICE
18.04.02 Oleeva® 

Silicone gel sheet

  • Burns Team initiation only
12.01.03 Olive Oil Ear Drops 
11.04.02 Olopatadine Opatanol®
03.04.02 Omalizumab 
  • Only approved for use in accordance with NICE guidance. 
05.03.03.02 Ombitasvir & paritaprevir & ritonavir Viekirax®
  • Approved for the treatment of chronic hepatitis C in line with NICE and NHS England Commissioning Policy.
02.12 Omega-3-Acid Ethyl Esters Omacor®
  • For the treatment of hypertriglyceridaemia following specialist advice. 
01.03.05 Omeprazole 
  • Dispersible tablets (Losec® MUPS) should only be used in patients who cannot swallow capsules or tablets and where lansoprazole orodispersible tablets are unsuitable.
  • 10mg in 5ml oral suspension (unlicensedunlicensed) can be obtained for use in very small children and where a suspension has to be given down a very fine NG tube (below French Size 8) .
  • For acute Gastrointestinal bleeding see North of Tyne and Gateshead Acid suppression guidelines.
04.06 Ondansetron 
  • The cheapest available formulation should be used.
  • Ondansetron 4mg and 8mg oro-dispersible tablets/films are approved for the treatment of post-operative nausea and vomiting in patients who do not require IV access or are nil by mouth Red Traffic Light   

04.09.01 Opicapone 
  • Approved as an alternative to tolcapone in patients with Parkinson's disease in whom entacapone has not been tolerated or failed.
18.02.02 Opsite® Post-Op 
07.03.02.01 Oral progestrogen-only contraceptive  

First choice

  • Cerelle® (desogestrel 75 microgram tablets).
  • Cerazette® (desogestrel 75 microgram tablets).
  • Zelleta® (desogestrel 75 microgram tablets).


Alternatives

  • Femulen® (ethynodiol diacetate 500 microgram tablets).
  • Micronor® (norethisterone 350 microgram tablets).
  • Norgeston® (levonorgestrel 30 microgram tablets).
09.01 Oral Rehydration Salts Dioralyte®
04.05.01 Orlistat 
  • Only approved for use in accordance with NICE guidance. 
04.09.02 Orphenadrine 
  • 5mg/5ml Liquid
05.03.04 Oseltamivir 
  • Only approved for use in accordance with NICE guidance. 
09.05.02.02 Osvaren® 
  • Tablets containing calcium acetate 435mg & Magnesium carbonate heavy 235mg.
  • For use, after calcium carbonate and calcium acetate, but before the
    much more expensive sevelamer and lanthanum.
08.01.05 Oxaliplatin  
  • Approved for Dukes C colon cancer in combination with 5-fluorouracil
    and folinic acid in line with NICE.
  • Approved for advanced and metastatic colorectal cancer in line with NICE.
03.04.03 Oxandrolone 2.5mg and 10mg capsules 
  • For use on the advice of an immunologist in the prophylaxis treatment hereditary angioedema associated with C1-esterase inhibitor deficiency when danzol and stanozolol are not available.
04.08.01 Oxcarbazepine 
11.07 Oxybuprocaine 0.4% Minims®  
07.04.02 Oxybutynin  
  • 2.5mg and 5mg tablets
  • 2.5mg in 5ml oral solution. 
  • Immediate release oxybutinin is not appropriate for frail elderly people or those with cognitive impairment. 
  • Please note both first choice agents (oxybutinin and tolerodine) should be tried sequentially, unless contraindicated, before moving on to second choice treatment options.
07.04.02 Oxybutynin Hydrochloride - patch 
  • Oxybutinin patch 36mg (releases approximately 3.6mg in 24 hours). 
  • Approved for patients in whom two antimuscarinics have proved to be efficacious butthe side effects are intolerable, or for patients who cannot swallow tablets.
04.07.02 Oxycodone 
  • Oxycodone is only approved for use in patients who are intolerant of morphine. 
  • The Longtec® branded generic is preferred (most cost effective option).
  • The oral solution should be used instead of immediate release tablets. 
  • Note: Oxycodone 50mg in 1ml injection  is also approved for use, but is restricted to controlled circumstances in palliative patients following risk assessment by individual organisations.Green Traffic Light


11.09 Oxysept® 1 Step 
05.01.03 Oxytetracycline 
13.06.02 Oxytetracycline 
07.01.01 Oxytocin 
  • The following formulations are approved for use:
    • 10 units in 1ml injection
    • 5 units in 50ml syringes unlicensedunlicensed.

08.01.05 Paclitaxel 
  • The following formulations are approved:
  • 30mg in 5ml, 100mg in 16.7ml, and 150mg in 25ml concentrate for preparing IV infusion.
  • Approved for the treatment of recurrent ovarian cancer in line with NICE.
08.01.05 Paclitaxel - Albumin Bound Formulation Abraxane®
  • Note: Abraxane® 5mg in 1ml powder for suspension for infusion is restricted for use within its current license for metastatic breast cancer patients who cannot tolerate standard taxanes. 
  • Approved in combination with a platinum-based compound or platinum-based therapy alone (cisplatin or carboplatin) for first line therapy in ovarian cancer in line with NICE.
  • Approved in combination with a platinum-based drug (carboplatin or cisplatin) for second-line (or subsequent) therapy in ovarian cancer in line with NICE
  • Approved metastatic breast cancer in line with NICE.
  • Abraxane is not recommended for the adjuvant treatment of women with early node-positive breast cancer NICE.
  • Approved in combination with gemcitabine for untreated metastatic pancreatic cancer in line with NICE and NHS England Commissioning Policy as of 5th December 2017
08.03.04.01 Palbociclib Ibrance®
  • 75mg, 100mg & 125mg capsules
  • Approved for use with an aromatase inhibitor for the treatment of previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer in line with NICE and NHS England Commissioning Policy
04.02.02 Paliperidone 
  • NTAG approved for the treatment of schizophrenia as per its licensed indication and as outlined in the Guidance on the Use of Antipsychotic Long-acting Injections in the North of England.
05.03.05 Palivizumab 
  • To be used in accordance with NHS England Commissioning Policy.   
04.06 Palonosetron 
  • Only approved for the second line treatment of chemotherapy induced nausea vomiting only.
01.09.04 Pancreatin Creon®
01.09.04 Pancreatin Pancrex® V
01.09.04 Pancreatin Creon® Micro
15.01.05 Pancuronium 
  • 4mg in 2ml injection
08.01.05 Panitumumab Vectibix®
  • Approved for previously untreated metastatic colorectal cancer in line with NICE.
08.01.05 Panobinostat  
  • Approved in combination with bortezomib and dexamethasone as an option for the treatment of multiple myeloma in line with NICE.
15.01.05 Papaverine 
  • 30mg/2ml injection unlicensedunlicensed
04.07.01 Paracetamol 
  • Paracetamol 1gram injection for IV infusion
    This is approved for limited short-term use where oral and rectal routes cannot be used and NSAIDs are not appropriate. 
  • In paediatric areas only, the 50ml formulation should be stocked.

 

  • Paracetamol suppositories
    unlicensedunlicensed preparations include 15mg, 30mg, 60mg, 120mg, 240mg, and 500mg. These are used in NUTH.
  • Licensed preparations include 60mg, 125mg, 250mg, and 500mg suppositories are available in primary care.
04.07.04.01 Paracetamol 
04.08.03 Paracetamol 
04.07.01 Paracetamol and codeine Co-codamol 8/500
  • While co-codamol 8/500 is commonly used, no advantages over paracetamol have been substantiated. The low dose of codeine may be enough to cause opioid side-effects (in particular, constipation) and can complicate the treatment of overdosage, yet may not provide significant additional relief of pain. Use is therefore discouraged
18.01.01 Paraffin Gauze Dressing BP Sterile Paranet®
13.02.01 Paraffin sterile liquid 
04.08.02 Paraldehyde rectal liquid 
  • For intiation by neurologists only.
15.01.04.02 Parecoxib 40mg injection Dynastat®
  • For peri-operative use only.
09.05.01.02 Paricalcitol 
  • Approved for use in patients with PTH levels < 800mcg/l but  whose treatment with alfacalcidol is restricted due to a high calcium level.
04.03.03 Paroxetine 
08.03.04.03 Pasireotide Signifor®
  • Approved for the treatment of Cushing’s disease in line with NHS England Policy.
19 Patent Blue V Sodium 
08.01.05 Pazopanib 
  • Approved for advanced renal cell carcinoma in line with NICE
08.01 Pegaspargase 3750iu vial 
09.01.06 Pegfilgrastim (G-CSF) 
08.02.04 Peginterferon Alfa Pegasys®, ViraferonPeg®
  • Approved  for hepatitis B and C in accordance with NICE guidelines and NHS England Commissioning Policies. 
08.02.04 Peginterferon Beta-1a Plegridy®
08.01.05 Pembrolizumab  
  • Approved for the treatment of advanced melanoma after disease
    progression with ipilimumab in accordance with NICE. 
  • Approved for the treatment of advanced melanoma not previously treated with ipilimumab in accordance with NICE.
  • Approved for treating PD-L1-positive non-small-cell lung cancer
08.01.03 Pemetrexed  
  • Approved for:
    • Mesothelioma in line with NICE (funding has to be agreed on an individual patient basis if treatment is not in line with NICE).
    • Combination with cisplatin for the first line treatment of locally advanced or metastatic NSCLC (non-squamous cell histology) in line with NICE.
    • Maintenance treatment of locally advanced or metastatic NSCLC (non-squamous cell histology) in line with NICE.
    • Maintenance treatment of non-squamous non-small lung cancer after pemetrexed and cisplatin in line with NICE and NHS England Commissioning Policy.

  • Note: pemetrexed is not approved for locally advanced or metastatic NSCLC as per NICE. 
09.08.01 Penicillamine 
  • 125mg & 250mg tablets - also used for the treatment ofcystinuria and rheumatoid arthritis – section 10.1.3
10.01.03 Penicillamine 
16 Penicillamine 
  • 125mg & 250mg tablets
05.04.08 Pentamidine Isetionate 
07.04.03 Pentosan Polysulphate Sodium  
  • 50mg and 100mg capsules
08.01.05 Pentostatin Nipent®
01.02 Peppermint Oil Colpermin®
01.02 Peppermint water 
01.01.02 Peptac 
  • Preferred antacid for treating reflux. Use instead of Gaviscon®.
04.08.01 Perampanel 
  • NETAG approved for partial (focal) seizure epilepsy only when other treatment  options recommended by NICE have been tried or fully considered.
02.05.05.01 Perindopril  
  • Perindopril erbumine/tert-butylamine 
  • Perindopril is third line for all indications including prevention of stroke.
  • Perindopril arginine is Non-Formulary   
13.10.04 Permethrin 1% Lyclear® Creme Rinse
13.10.04 Permethrin 1% Lyclear® Creme Rinse
13.10.04 Permethrin 5% Lyclear® Dermal Cream
13.10.04 Permethrin 5% Lyclear® Dermal Cream
04.02.01 Perphenazine 
19 Personal Best Peak Flow Meter 
08.01.05 Pertuzumab Perjeta®
  • Approved for the neoadjuvant treatment of HER2-positive breast cancer in line with NICE and NHS Commissioning Policy
  • Approved with trastuzumab and docetaxel for treating HER2-positive breast cancer in line with NICE and NHS Commissioning Policy
04.07.02 Pethidine 
04.03.02 Phenelzine 
  • For use on advice from psychiatrists only.
02.08.02 Phenindione 
04.08.01 Phenobarbital 
04.12 Phenol 5% in Glycerol Injection 
  • Approved for intrathecal neurolysis treatment of intractable pain due to cancer in terminally ill patients
02.05.04 Phenoxybenzamine  
05.01.01.01 Phenoxymethylpenicillin 
02.05.04 Phentolamine 
10.01.01 Phenylbutazone 
  • Approved for use in ankylosing spondylitis.
02.07.02 Phenylephrine 
11.05 Phenylephrine 
  • 2.5% eye drops unlicensedunlicensed
  • 2.5% single use Minims®
11.05 Phenylephrine Hydrochloride 
  • 2.5% eye drops unlicensedunlicensed.
  • 2.5% single use Minims®.
04.07.03 Phenytoin 
04.08.01 Phenytoin 
  • Note: phenytoin 30mg in 5ml suspension (base) – 90mg (15ml) is equivalent to one 100mg phenytoin sodium capsule 250mg in 5ml injection (sodium salt).
04.08.02 Phenytoin sodium 250mg in 5ml injection 
  • For intiation by neurologists only.
03.09.01 Pholcodine 
  • 5mg in 5ml sugar-free linctus.
09.05.02.01 Phosphate  
  • 4.15 mmol phosphate in 10ml oral solution unlicensedunlicensed
09.05.02.01 Phosphate Polyfusor 
  • 500ml intravenous infusion containing 50mmol phosphate
    per 500ml (PO4 3- 100 mmol, K+ 19 mmol, and Na+ 162 mmol/litre).
01.06.04 Phosphate soda  Fleet Phospho-Soda®
01.06.04 Phosphates  
09.05.02.01 Phosphate-Sandoz® 
  • Effervescent tablets (phosphate 16.1 mmol, sodium 20.4mmol & potassium 3.1 mmol / tablet)
09.02.02.02 Phoxilium 1.2mmol/l phosphate 
  • A haemofiltration and haemodialysis fluid containing Na+ 140 mmol, K+ 4 mmol, Mg2+ 0.6 mmol, Ca2+ 1.25mmol/l, Cl- 115.9 mmol/l, HCO3 - 30.0mmol/l, HPO4 2- 1.20mmol/l.
    • Approved for use in CRRT in patients not requiring reduced potassium or low bicarbonate.

15.01.06 Physostigmine 
  • 1mg in 1ml injection unlicensedunlicensed
09.06.06 Phytomenadione 
  • 50 microgram in 0.25ml drops (NeoKay®) unlicensedunlicensed
  • 1mg capsule- preferred product for use in neonates
  • 10mg in 1ml injection unlicensedunlicensed
  • 2mg in 0.2ml mixed micelles injection (Konakion® MM
    Paediatric) – may be taken by mouth as well as being given by IM or IV injection
08.01.05 Picibanil  
18.06.01 PICO® Single Use NPWT System 
11.06 Pilocarpine 
  • 0.5%, 1%, 2% and 4% eye drops.
  • 1%, 2% and 4% unit dose eye drops.
11.06 Pilocarpine 1% and 2% eye drops 
12.03.05 Pilocarpine 5mg tablets 
  • Treatment to be initiated with specialist advice.
13.05.03 Pimecrolimus cream Elidel®
  • Approved for moderate disease on face and neck for those between 2 and 16 years in line NICE.
06.01.02.03 Pioglitazone 
05.01.01.04 Piperacillin and Tazobactam 
  • Restricted for use on microbiology/infectious diseases advice, or as agreed in Trust Guidelines.
05.05.01 Piperazine 
03.11 Pirfenidone Esbriet®
  • Approved for the treatment of idiopathic pulmonary fibrosis in line with NICE and NHS England Commissioning Policy
10.01.01 Piroxicam 20mg orodispersible tablets 
  • Piroxicam 20mg orodispersible 'Melt' tablets are approved for use in operating theatres and for use in children with juvenile idiopathic rheumatoid arthritis. Older children should be changed to another NSAID when they reach the age of 14 (or earlier if considered appropriate).
10.03.02 Piroxicam gel 
05.01.01.05 Pivmecillinam 
08.01.02 Pixantrone  
  • Approved as a possible treatment for adults with multiply relapsed or refractory aggressive non-Hodgkin's B cell lymphoma if they have previously been treated with rituximab and they are having third- or fourth-line treatment in line with NICE. 
04.07.04.02 Pizotifen 
09.02.02.02 Plasma-lyte 148 with Glucose 5% 
  • Infusion in a balanced electrolyte solution containing Na+ 140 mmol, K+ 5 mmol, Mg2+ 1.5 mmol, acetate 27 mmol/litre. Gluconate 23 mmol/litre. Note calcium free.
    • Approved for use in paediatric theatres only.

13.11 Plaster remover 
09.01.07 Plerixafor Mozobil®
  • Approved by NHS England Specialist Services for stem cell mobilisation for patients with Hodgkin’s disease, Non-Hodgkins lymphoma or multiple myeloma and meet the policy for Haematopoietic Stem Cell Transplantation.
13.07 Podophyllotoxin 0.15% cream Warticon®
13.10.01.01 Polyfax® Ointment 
18.07.01 Polyfield ® Nitrile Patient Pack 

Contains powder-free nitrile gloves, laminate sheet, non-woven swabs, towel, polythene disposable bag, apron

  • First choice on FP10
11.03.01 Polyhexamethylene biguinide (PHMB) 0.02% Eye drops 
13.09 Polytar® liquid 
  • Shampoo containing a mixture of tar preparations & 0.3% Cade oil
08.02.04 Pomalidomide Imnovid®
  • For the treatment of multiple myeloma previously treated with lenalidomide and bortezomib in line with NICE and NHS Commissioning Policy
08.01.05 Ponatinib Iclusig®
  • 15mg, 30mg & 45mg film-coated tablets
  • Approved for the treatment of chronic myeloid leukaemia and acute lymphoblastic leukaemia in line with NICE and NHS England Commissioning Policy
03.05.02 Poractant Alfa 
05.02.01 Posaconazole  Noxafil®
  • Approved for the prevention of invasive fungal infection in immunocompromised patients in whom there is a specific risk of aspergillus infection or where fluconazole and itraconazole are not tolerated or are unlikely to be sufficiently effective (largely for secondary prevention).
  • Approved for patients with invasive fungal infections that are not responding to other treatments or where they are not tolerated (largely in place of liposomal amphotericin/ voriconazole).
09.02.01.01 Potasium Chloride 
  • 600mg m/r tablets – (8 mmol potassium) Green Traffic Light
    • For use where the effervescent tablets or syrup are unsuitable

  • 5mmol in 5ml sugar-free syrup (Kay-Cee-L) Green Traffic Light
  • 1mmol in 1ml carbohydrate free oral solution Red Traffic Light 
    • Approved for use in children with intractable epilepsy being
      treated with a ketogenic diet.

09.02.01.01 Potassium Chloride Sando-K®
  • Effervescent tablets (12mmol potassium 8 mmol chloride)
09.02.02.01 Potassium Chloride  
  • 15% injection Restricted Item Restricted
09.02.02.01 Potassium Chloride and Glucose  
  • 0.15%/5% IV infusion (1000ml - Steriflex 13)
  • 0.3%/5% IV infusion (1000ml - Steriflex 16)
  • 0.15%/10% IV infusion (500ml - Steriflex 106)
  • 0.3%/10% IV infusion (500ml - Steriflex 132)
  • 0.6%/5% IV infusion (500ml) - high strength
09.02.02.01 Potassium Chloride and Sodium Chloride  
  • 0.15%/0.9% IV infusion (1000ml - Steriflex 12)
  • 0.3%/0.9% IV infusion (500ml & 1000ml - Steriflex 15)
  • 0.45%/0.9% IV infusion (1000ml) - high strength
  • 0.6%/0.9% IV infusion - high strength
09.02.02.01 Potassium Chloride, Sodium Chloride and Glucose  
  • 0.15%/0.45%/5% IV infusion (500ml - Intraven GV332)
  • 0.15%/0.18%/4% IV infusion (1000ml - Steriflex 14)
  • 0.3%/0.18%/4% IV infusion (1000ml - Steriflex 17)
  • 0.3%/0.45%/5% IV infusion (500ml) Paediatrics only
07.04.03 Potassium Citrate Mixture (potassium citrate 3g & citric acid 500mg in 10ml) 
06.02.02 Potassium Iodate 85mg tablets 
  • Mainly used by medical physics.
13.11.06 Potassium Permanganate 
  • 400mg solution tablets
  • 5% solution unlicensedunlicensed - under review
09.02.02.01 Potassium Phosphate 
  • 17.42% injection Restricted Item Restricted
11.03.01 Povidone iodine 5% 
11.08.02 Povidone iodine 5% eye drops 
  • For use in eye surgery only. 
13.11.04 Povidone-Iodine 
  • 2.5% dry powder spray
  • 10% alcoholic solution
  • 7.5% surgical scrub
  • 10% antiseptic solution (aqueous)
  • 0.35% sterile aqueous solution Red Traffic Light
    • approved for use in the prevention of surgical site infection in arthroplasty. 

18.03.02 Povitulle® 

Knitted viscose primary dressing impregnated with povidone-iodine ointment

  • First choice in primary care 
15.02 PR Freeze Spray 
16 Pralidoxime Mesylate 
  • 1g in 5ml injection
04.09.01 Pramipexole 
  • Approved for second line use in Parkinson's disease. 
02.09 Prasugrel 
  • Only approved for use in accordance with NICE guidance.
02.12 Pravastatin  
05.05.05 Praziquatel Biltricide  
02.05.04 Prazosin 
07.04.01 Prazosin 500microgram and 1mg tablets 
01.05.02 Prednisolone 
  • 5mg suppositories only
01.05.02 Prednisolone 

First Choice

06.03.02 Prednisolone  
  • The lowest cost formulation should be used when clinically appropriate.  
  • Other formulations approved include:
  • 1mg, 5mg, 25mg & 50mg tablets;
  • 2.5g mg E/C tablets;
  • 5mg soluble tablets;
  • 1mg in 1ml oral solution (Prednisolone Dompé®);
  • 5mg suppositories.
12.01.01 Prednisolone 0.5% ear/eye drops 
  • Second choice corticosteroid ear drops.
11.04.01 Prednisolone 0.5% Single Use Minims® 
11.04.01 Prednisolone 0.5% with Neomycin 0.5% Predsol-N®
10.01.02.02 Prednisolone Acetate 25mg in 1ml  
11.04.01 Prednisolone eye drops 
  • The following formulations are approved
    • 0.5% eye drops and 1% (Pred-Forte).
    • 0.1% and 0.3% eye drops - both unlicensedunlicensed.

  • Approved preservative free formulations include
    • 0.5% minims.
    • 0.1%, 0.3%, 0.5% and 1% - all unlicensedunlicensed.

04.08.01 Pregabalin 
  • Approved for specialist advice in the management of treatment resistant epilepsy. 
  • Also approved as a second line agent for General Anxiety Disorder. Although treatment can be given 2-3 times daily, it is more cost effective to give as a twice daily dose. 
04.07.03 Pregbalin 
  • Pregbalin is restricted to use in the management neuropathic pain as a second choice where treatment with gabapentin has been unsuccessful or not tolerated.
15.02 Prilocaine Hydrochloride 
  • 0.5% 10ml injection unlicensedunlicensed, 1% 20ml injection.
  • 4% 2ml injection (cartridges).
  • 2% 5ml injection (cartridges) Red Traffic Light
    • Only to be used in patients undergoing spinal anaesthesia for day surgery where the procedure is anticipated to last less than 90 minutes.
  • 3% & felypressin injection (cartridges).
05.04.01 Primaquine 
19 PrimsOcal® B22 
19 Primsocitrate® 18/0 
10.01.04 Probenecid 
02.03.02 Procainamide 
15.02 Procaine Hydrochloride 
  • 1% 5ml injection unlicensedunlicensed.
  • 2% 2ml injection.
  • 0.1% 500ml infusion unlicensedunlicensed.
05.01.01.01 Procaine Penicillin 
08.01.05 Procarbazine  
04.02.01 Prochlorperazine 
04.06 Prochlorperazine 
  • Note: Buccastem® 3mg tablets are only approved for the treatment of nausea associated with migraine when the oral route cannot be used due to vomiting.
01.07.02 Proctofoam®HC 
04.09.02 Procyclidine 
13.10.05 Proflavine Cream, BPC  
06.04.01.02 Progesterone 
  • Approved formulations include:
    • 200mg & 400mg pessaries;
    • 50mg in 1ml injection.

03.04.01 Promethazine 
04.01.01 Promethazine Hydrochloride 
04.06 Promethazine Hydrochloride Phenergan
13.11.02 Prontosan 
  • Solution containing Betaine 0.1% (surfactant) and Polyhexanide 0.1% (a chlorhexidine polymer). Mainly for use from 40ml plastic ampoules.
    Also available as a gel. 
  • To be prescribed/used only on the advice of tissue viability specialists.
18.03.04 Prontosan® Wound Gel 30ml 

Hydrogel containing betaine surfactant and polihexanide

  • Specialist use only
18.03.04 Prontosan® Wound Irrigation Solution  

Aqueous solution containing betaine surfactant and polihexanide

  • Specialist use only
02.03.02 Propafenone 
11.03.01 Propamidine Isetionate 
  • For use in the treatment of acanthamoeba keratitis – used with PHMB.
01.02 Propantheline 
07.04.02 Propantheline 
15.01.01 Propofol 
  • 1% (10mg/ml) injections (Propofol Lipuro®) available as 200mg in 20ml ampoules.
  • 500mg in 50ml and 1g in 100ml bottles.
  • 1% (10mg/ml) 50ml (500mg) prefilled syringes for use in Diprifusor pumps (Diprivan®).
  • 2% (20mg/ml) injection - 1g in 50ml bottles for ITU use only.
02.04 Propranolol 
04.07.04.02 Propranolol 
06.02.02 Propranolol 80mg MR capsules 
  • Propranolol 80mg MR capsules is the preferred formulation for relief of thyrotoxic symptoms.
06.02.02 Propylthiouracil 
02.08.03 Protamine Sulphate 
06.05.01 Protirelin (TRH) 
11.07 Proxymetacaine 0.5% Minims® 
01.06.07 Prucalopride 
  • Only approved for use in accordance with NICE guidance.
03.10 Pseudoephedrine Hydrochloride 
05.01.09 Pyrazinamide 
10.02.01 Pyridostigmine Bromide 
09.06.02 Pyridoxal Phosphate 
  • 25mg tablets unlicensedunlicensed
  • 50mg capsules unlicensedunlicensed
09.06.02 Pyridoxine Hydrochloride 
  • 10mg unlicensedunlicensed
  • 50mg tablets
05.04.01 Pyrimethamine Darprim®
04.02.01 Quetiapine 
  • 25mg, 100mg, 150mg 200mg & 300mg tablets 
  • 50mg, 200mg, 300mg & 400mg prolonged release tablets 
    • Prolonged release tablets are approved for use in patients who require an outside carer to administer their medicines, and for short term use when rapid dose titration is considered important e.g. where its use might avoid the need to admit the patient to hospital.


06.07.01 Quinagolide 
05.04.01 Quinine Dyhydrochloride 
05.04.01 Quinine sulphate 
10.02.02 Quinine sulphate 200mg tablets  
  • MHRA advice states that quinine should not be used routinely in the treatment of nocturnal leg cramps, and should only be considered when cramps cause regular disruption of sleep. After a period of 4 weeks, treatment should be discontinued if no benefit is gained.
13.02.01 QV® 
  • Approved for used in radiotherapy only.
19 Radiesse Voice® 
08.03.04.02 Radium-223 dichloride 
  • Provided by radiotherapy department in accordance with NICE
06.04.01.01 Raloxifene Hydrochloride 
  • For use on the advice of specialists in the prevention and treatment of osteoporosis where alternative treatments are inappropriate.
05.03.01 Raltegravir 
  • Approved for use in the treatment of patients with HIV infections that are resistant to standard therapy in accordance with British HIV Association and EACS guidelines.
02.05.05.01 Ramipril 
  • Most cost effective formulation to be prescribed
11.08.02 Ranibizumab 10mg/1ml injection Lucentis®
  • Approved for wet age related macular degeneration in line with NICE/.
  • Approved for diabetic macular oedema in line with NICE.
  • Approved for visual impairment caused by macular oedema secondary
    to retinal vein occlusion in line with NICE.
  • Approved as a possible treatment for sight problems caused by choroidal neovascularisation in people who also have pathological myopia in line with NICE.
01.03.01 Ranitidine 
  • Injection mainly used for prophylaxis of stress ulceration.
02.06.03 Ranolazine 
  • For use in the treatment of angina in those patients for whom other treatments have been unsuccesful.
  • Initial prescribing should be by a consultant cardiologist only. 
04.09.01 Rasagiline 
10.01.04 Rasburicase 
  • Only approved for prophylactic use in high risk patients.
04.03.04 Reboxetine 
  • Not licensed in the elderly
02.03.02 Regadenoson 
  • For radionuclide myocardial perfusion imaging in patients who are unable to undergo adequate exercise stress (e.g. COPD and asthma patients where dobutamine is indicated, and obese patients who require several vials of adenosine).
20 Regadenoson 
08.01.05 Regorafenib Stivarga®
  • 40mg tablets
  • Approved for treating unresectable or metastatic gastrointestinal stromal tumours in adults whose disease has progressed on, or who are intolerant to, prior treatment with imatinib and sunitinib in line with NICE and NHS England Commissioning Policy (Cancer Drug Fund until 13th February 2018)
15.01.04.03 Remifentanil 
  • 1mg, 2mg & 5mg injections.
18.06.01 Renasys® Go  
09.06.07 Renavit® tablets 
  • Water soluble vitamin supplementation therapy for maintenance haemodialysis patients only.
03.04.02 Reslizumab Cinquil®
  • 10 mg/mL concentrate for solution for infusion
  • Approved for the treatment of severe eosinophilic asthma in line with NICE and NHS England Commissioning Policy as of 2 January 2018
09.02.01.01 Resonium A® 
  • Powder (Sodium polystyrene sulphonate)
A2.05.02 Resource® Thickened Drink 
A2.05.02 Resource® ThickenUp Clear 
02.10.02 Reteplase 
  • Preferred for acute treatment of myocardial infarction where streptokinase is unsuitable; used in NUTH.
04.08.01 Retigabine 
  • Only approved for use in accordance with NICE guidance. 
11.08.01 Retinol palmitate 250iu/g, liquid paraffin, white soft paraffin, wool fat  
  • 5g eye ointment
05.03.03.02 Ribavirin 
05.03.05 Ribavirin Virazole®
08.03.04.01 Ribociclib Kisqali®
  • 200mg tablets
  • Approved for use with an aromatase inhibitor for the treatment of previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer in line with NICE and NHS England Commissioning Policy
05.01.09 Rifabutin 
05.01.09 Rifampicin 
  • 150mg & 300mg capsules Green Traffic Light
  • 100mg in 5ml syrup Green Traffic Light
  • 600mg injection Red Traffic Light  
05.01.09 Rifampicin and Isoniazid 
05.01.09 Rifampicin and Isoniazid and Pyrazinamide 
05.01.07 Rifaximin 
  • 550mg Tablets: Only approved for use in accordance with NICE guidance. 

 

05.03.01 Rilpivirine hydrochloride 
  • For patients who, due to renal impairment, require reduced doses that are not able to be accommodated by the fixed combination product.
04.09.03 Riluzole 
  • Approved for motor neurone disease in line with NICE. 
  • Note: riluzole oral suspension approved only when other preparations (including crushing tablets) are not suitable.
11.04.01 Rimexolone 
  • For use where Fluorometholone (FML) drops (which are much cheaper) are likely to be insufficiently effective.

02.05.01 Riociguat 
  • Approved for Chronic Thromboembolic Pulmonary Hypertension - in accordance with NHS England Commissioning policy. 
06.06.02 Risedronate 
  • Approved risedronate formulations include:
    • 5mg tablets (taken daily);
    • 35mg tablets (taken once weekly for osteoporosis) -preferred.

  • Risedronate is approved for the primary prevention of osteoporosis in line with NICE, and for for the secondary prevention of osteoporotic fragility fractures in postmenopausal women who are confirmed to have osteoporosis in line with NICE. 
  • Risedronate 30mg tablets are also approved for Paget’s disease.
  • Approved for the treatment of osteoporosis in line with NICE
04.02.01 Risperidone 
  • Note: risperidone orodispersible tablets should only be used in situations where the plain tablets are unsuitable.
04.02.02 Risperidone Risperdal Consta®
  • Only for use by psychiatrists in accordance with NTAG guidelines.
07.01.03 Ritodrine 
05.03.01 Ritonavir 
08.02.03 Rituximab 
  • NICE have approved rituximab for the following indications:
  • First line use in NHL in combination with CHOP.
  • Maintenance therapy in follicular NHL that has responded to first line induction therapy with rituximab in combination with chemotherapy.
  • Stage III and IV follicular lymphoma in previously untreated people.
  • Replased or refractory follicular NHL.
  • Post-transplant lymphoproliferative disease.
  • First line use in CLL in combination with fludarabine and cyclophosphamide. 
  • Combination with fludarabine and cyclophosphamide for relapsed or refractory CLL.
  • Autoimmune haematological conditions (where conventional treatments have failed)
  • Autoimmune haemolytic anaemia (AIHA), Evans syndrome, pure red cell aplasia (PRCA), & thrombocytopenia purpura (TTP).
  • Combination with bendamustine for first line use in CLL (Binet stage B or C) in patients for whom fludarabine combination chemotherapy is not appropriate.
  • Vasculitis (including Wegener’s granulomatosis in adults and children) that has not responded adequately to conventional treatment (e.g. corticosteroids, cyclophosphamide) in line with NICE and additional NHS England criteria.
  • NECDAG have approved rituximab for the following indications:
  • Treatment of NLPHL
  • Newly diagnosed mantle cell NHL in patients aged
  • In combination with bendamustine for patients with CLL not fit for FCR chemotherapy or for patients who relapse within 2 years of FCR chemotherapy and not fit for alemtuzumab.
  • Salvage chemotherapy for patients relapsing > 12 months post 1st line therapy with R-CHOP.
  • Standard NHL induction regimen in patients who cannot be given an anthracycline. Rituximab with other chemotherapy regimens is an alternative treatment option e.g. DECC, CVP for this group of patients, as part of their first line therapy. Also in addition to the MACOP-B regimen for the small number of young patients with DLBCL, subtype Primary Mediastinal B cell Lymphoma.
  • Treatment of Hairy Cell Leukaemia (HCL) or  HCL varian (HCL-v) who:
    - relapse early after purine analogue therapy (< 2 years post treatment)
    - are refractory to purine analogues.
  • NTAG have approved rituximab for the following indications:
  • Treatment of immune (idiopathic) thrombocytopenic purpura (ITP) in adults and children.
  • NHS England have approved rituximab for the following indications:
  • Treatment of immunobullous disease
  • Steroid Sensitive Nephrotic Syndrome in Children
  • Steroid Resistant Nephrotic Syndrome in Children
  • Acquired Haemophilia
  • Cytopenia Complicating Primary Immunodeficiency
  • Maintenance single agent therapy in FL, mantle cell lymphoma, marginal zone lymphoma and lymphoplasmacytic lymphoma in line with (SSC1434) - 1.4g solution for sc injection.
  • Second line treatment for anti-NMDAR auto-immune encephalitis (all ages)

 

For musculoskeletal indications see chapter 10

10.01.03 Rituximab  
  • Approved for:
    • Adults with severe systemic lupus erythematosus who have failed conventional therapies.
    • Rheumatoid arthritis after the failure of a TNF inhibitor in line with NICE.
    • Combination with methotrexate as first-line biological therapy in cases where there is an absolute contraindication to tumour necrosis factor inhibitors (NETAG approval).
    • Combination with other (non-methotrexate) disease modifying antirheumatic drugs and as monotherapy in cases in which conventional treatment with tumour necrosis factor inhibitors or methotrexate is deemed unsafe (NETAG approval).
    • For immunoglobulin G4-related disease (IgG4-RD) in accordance with NHS England Commissioning Criteria
    • Myositis in accordance with NHS England Commissioning Criteria
    • Juvenile Idiopathic Arthritis (JIA) in accordance with NHS England Commissioning Criteria
02.08.02 Rivaroxaban 
  • Only approved for use in accordance with NICE guidance. 
04.11 Rivastigmine 
  • Only approved for use in accordance with NICE guidance. 
  • Rivastigmine patches are approved for patients unable to tolerate treatment with oral rivastigmine due to nausea and vomiting, and for patients requiring treatment with an acetylcholinesterase inhibitor who are unable to take oral medication e.g. due to swallowing difficulties or ‘nil by mouth’ prior to surgery.
15.01.05 Rocuronium Esmeron®
  • 50mg in 5ml injection
03.03.03 Roflumilast Daxas®
  • 500microgram film-coated tablets
  • Approved for the treatment of chronic obstructive pulmonary disease in line with NICE
09.01.04 Romiplostim 
  • For the treatment of adults with chronic immune (idiopathic) thrombocytopenia purpura in line with NICE.
04.09.01 Ropinirole 
  • Ropinirole once daily formulation is only approved for use in Parkinson’s disease patients with proven compliance.
  • Approved for first line use in patients with restless legs syndrome.
02.12 Rosuvastatin 
  • Strickly limited for use on the advice of specialists working in lipid clinics for patients with familial hypercolesterolaemia who do not respond adequately to, or do not tolerate the maximum doses of other statins. 
04.09.01 Rotigotine 
  • For use on the advice of specialists in the treatment of Parkinson's disease. Mainly for use in patients who have difficulty with swallowing.
  • Approved for second line use in patients with restless legs syndrome.
04.08.01 Rufinamide 
  • Approved for limited use as a second or third-line treatment in patients with Lennox-Gastaut syndrome and related encephalopathies.
  • Should only be used on the advice of paediatric neurologists and other neurologists specialising in the treatment of epilepsy.
08.01.05 Ruxolitinib 
  • Approved for the treatment of disease-related splenomegaly or symptoms in adults with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemiaa myelofibrosis, only in people with intermediate-2 or high-risk disease in line with NICE.
02.05.05.02 Sacubitril & valsartan Entresto®
  • Only approved for use in accordance with NICE guidance. 
04.09.01 Safinamide 
  • 50mg and 100mg tablets
  • Approved for use in Parkinson's Disease patients on levodopa who are having motor fluctuations affecting their quality of life as an alternative to rasagiline.
03.01.01.01 Salbutamol 
  • 100 mcg/puff CFC-free metered dose inhaler (MDI) & breath actuated CFC-free MDI (Airomir® Autohaler & Salamol® Easi-Breathe).
  • Accuhaler® breath actuated dry powder inhaler (DPI) 200 mcg/puff.
  • Easyhaler® breath actuated DPI 100 mcg/puff: For use in children only, as a second line treatment after the Accuhaler®.
  • 2.5mg in 2.5ml & 5mg in 2.5ml nebules
  • 2mg in 5ml sugar-free oral solution
  • 500 mcg in 1ml & 5mg in 5ml injections Red Traffic Light - parenteral use is rarely indicated
13.07 Salicylic Acid 

See section 13.5.2

13.07 Salicylic Acid 11% with Lactic Acid 4% Salactol®
13.07 Salicylic Acid 16.7% with Lactic Acid 16.7% Paint Salactol®

In flexible collodion

13.05.02 Salicylic Acid in emulsifying ointment 
  • 2%, 5%, 10% and 20%.
03.01.01.01 Salmeterol 
  • MDI 25 mcg/puff
  • Accuhaler® breath actuated DPI 50 mcg/puff
09.05.01.01 Sandocal-1000® 
  • Sandocal 1000 tablets (calcium lactate gluconate, calcium carbonate & citric acid providing 1000mg, 25 mmol calcium).
05.03.01 Saquinavir 
10.01.03 Sarilumab  Kevzara®
  • 150mg/1.14mL & 200mg/1.14mL injection
  • Approved as an option for treating active rheumatoid arthritis in adults whose disease has responded inadequately to intensive therapy with a combination of conventional disease-modifying antirheumatic drugs (DMARDs) in line with NICE
A2.04.01.02 Scandishake® Mix 
18.07.03 Scanpor® 

Permeable Non-woven Synthetic Adhesive Tape, BP 1988 

  • Primary care only
18.04.02 Scar FX® 

Silicone gel sheet

  • Burns Team initiation only
01.07.02 Scheriproct® 
01.07.02 Scheriproct® suppositories 
18.10 Seal Tight® Wound Care Protector 
13.05.02 Sebco® scalp ointment 
10.01.03 Secukinumab Cosentyx®
  • Approved for active ankylosing spondylitis in line with NICE.
  • Approved for psoriatic arthritis in line with NICE.
13.05.03 Secukinumab Cosentyx®
  • Approved for the treatment of plaque psoriasis in line with NICE.
04.09.01 Selegiline Hydrochloride 
13.09 Selenium Sulphide 2.5% shampoo Selsun®
01.06.02 Senna 
  • Avoid 15mg strength, this is an OTC product. 
06.04.01.01 Sequential combined cyclical HRT patch Evorel® Sequi
06.04.01.01 Sequential combined tablets Elleste-Duet®, Femoston, Prempak-C
  • First choice - Prempak-C®
04.03.03 Sertraline 
09.05.02.02 Sevelamer Carbonate 
  • 800mg f/c tablets.
  • 2.4g powder for oral suspension.

15.01.02 Sevoflurane 
18.08.07 Short Stretch Compression Bandages 
  • Comprilan®
  • Actico®
02.05.01 Sildenafil 
  • 20mg tablets
  • 25mg, 50mg & 100mg tablets unlicensedunlicensed indication
  • Approved for pulmonary hypertension - in accordance with NHS England Commissioning policy. 
  • Approved for systemic sclerosis with ongoing digital ulcer disease (to reduce number of new digital ulcers) - in accordance with NHS England Commissioning policy.
  • Approved for secondary Raynaud's.

 

07.04.05 Sildenafil 
  • Also approved for specialist use in treating:
  • Pulmonary hypertension (see section 2.5.1a)Red Traffic Light
  • Secondary Raynaud’s disease. Red Traffic Light
18.04.02 Silgel® 

Silicone gel sheet

  • Burns Team initiation only
13.11.06 Silver nitrate 0.5% Solution 
13.07 Silver Nitrate 75% & 95% applicators 
  • 6 inch applicator
  • 95% pencils
  • 0.5% solution 
13.10.01.01 Silver Sulfadiazine 1% cream Flamazine®
01.01.01 Simeticone 
  • Approved for use in endoscopy procedures.
03.09.02 Simple Linctus 
  • Simple linctus and Paediatric simple linctus.
13.09 Simple shampoo 
02.12 Simvastatin 
08.02.02 Sirolimus 
  • Approved for renal transplantation in children and adolescents in line with NICE.
06.01.02.03 Sitagliptin 
10.01.03 Sodium Aurothiomalate 
10.01.03 Sodium aurothiomalate (Gold) 
09.02.01.03 Sodium Bicarbonate 
  • 500mg capsules (500mg contains approx. 6 mmol each ofsodium and bicarbonate)
  • 1mmol/ml oral solution unlicensedunlicensed
09.02.02.01 Sodium Bicarbonate 
  • 1.26% IV infusion Polyfusor®
  • 1.4% IV infusion Polyfusor®
  • 2.74% IV infusion Polyfusor®
  • 8.4% IV infusion Polyfusor®
  • 8.4% injection (10ml & 50ml)
12.01.03 Sodium Bicarbonate ear drops 
16 Sodium calcium edetate 
09.02.01.02 Sodium Chloride 
  • 600mg m/r tablets (Slow Sodium) - approx. 10 mmol sodium & chloride per tablet
  • 1mmol / ml oral solution Green Traffic Light 
    • Treatment should only be initiated with the advice of a specialist.

09.02.02.01 Sodium Chloride  
  • 0.9% injection (5ml, 10ml & 20ml)
  • 0.9% IV infusion (100ml, 250ml, 500ml & 1000ml)
  • 0.9% irrigation (1000ml & 3000ml)
  • 0.45% IV infusion (500ml - Steriflex 2)
  • 1.8%, 2.7% & 5% Polyfusor infusion (500ml)
  • 30% injection (10ml)
11.08.01 Sodium Chloride 
  • 0.9% eye drops and single dose unit eye drops.
  • 5% eye drops and preservative-free eye drops.
  • 5% eye ointment unlicensedunlicensed.
12.02.02 Sodium Chloride 0.9%  
  • Nasal drops and UDV's.
13.11.01 Sodium Chloride 0.9% 
  • Sterile solution – bottles
  • 25ml & 100ml sachets(Normasol®)
  • 45ml plastic ampoules/pods (Miniversol®)
18.11.01 Sodium chloride 0.9% 
  • Irrippod® (20mL & 100ml sachets)
  • Miniversol® (45ml)
07.04.04 Sodium chloride 0.9% solution 
  • Large volume solutions (up to 3 litres).
09.02.02.01 Sodium Chloride and Glucose  
  • 0.9%/5% IV infusion (500ml - Sterfilex 3)
  • 0.18%/4% IV infusion (500ml & 1000ml)
  • 0.18%/10% IV infusion (500ml - Steriflex 19)
  • 0.45%/5% IV infusion (500ml - Steriflex 45)
01.06.04 Sodium Citrate 
15.01.09 Sodium citrate 
  •  0.3 molar peppermint falvoured solution.
11.08.02.04 Sodium Citrate 10.11% eye drops 
06.06.02 Sodium Clodronate  
  • 520mg and 800mg tablets
09.05.01.02 Sodium Clodronate 
  • 520mg & 800mg tablets
11.04.02 Sodium Cromoglicate 2% Eye drops 
  • A 2% preservative free preparation is also approved unlicensedunlicensed -  treatment to be imitated with the advice of an ophthalmologist only.
13.14 Sodium dichloroisocyanurate 
  • 500mg & 5g tablets and granules
09.01.01.01 Sodium Feredetate Sodium ironedetate, Sytron®
  • 190mg in 5ml sugar-free elixir (27.5mg iron/5ml).
09.05.03 Sodium Fluoride 
  • Sodium fluoride 0.619% (75ml) toothpaste (Duraphat® 2800 ppm) prescription only medicine
  • Sodium fluoride 1.1% (51g) toothpaste (Duraphat® 5000 ppm) prescription only medicine
  • Sodium fluoride 0.05% mouthwash - approved for use within the dental hospital. 
05.01.07 Sodium fusidate 
11.08.01 Sodium Hyaluronate 
  • 0.1% eye drops & preservative-free eye drops
  • 0.2% eye drops & preservative-free eye drops
  • 0.4% unit dose vials (Clinitas) & 0.4% preservative-free eye drops (Clinitas Multi) Green+ Traffic Light  - specialist recommendation for the treatment of Keraconjunctiva sicca, post refractive surgery and Corneal healing disorders.
11.08.02 Sodium Hyaluronate 
  • 10mg in 1ml bag (Z-Hyalin®, formerly Ophthalin Gelbag®)
  • 14mg in 1ml syringe (Healon GV®)
07.04.04 Sodium hyaluronate (1.6%)/sodium chondroitinsulphate (2%) Ialuril®
  • Ialuril® is a 50ml solution for instillation into the bladder approved as second line treatment in patients who have failed Cystistat.
07.04.04 Sodium hyaluronate 40mg in 50ml solution Cystistat®
  • For instillation into the bladder.
13.11.04 Sodium Hypochlorite Solution 1% 
  • 1% sterilising solution.
09.02.02.01 Sodium Lactate IV infusion 
  • 500ml & 1000ml
16 Sodium nitrite 
  • 3% 10ml injection (30mg/ml) unlicensedunlicensed
02.05.01 Sodium nitroprusside 
  • unlicensedunlicensed import
04.01.01 Sodium Oxybate 500mg/1ml oral solution Xyrem®
  • Approved for the treatment of narcolepsy with cataplexy in children only in accordance with NHS england clinical commissioning policy.
  • Must be prescribed by Dr Kirstie Anderson (specialist sleep service at NUTH).
  • The Northern (NHS) Treatment Advisory Group only recommends the use of sodium oxybate in adult patients who have received and benefited from treatment with sodium oxybate as commissioned by NHS England. i.e. continuing treatment for those >19 years old
  • The use of sodium oxybate in new adult patients is not recommended.
09.08.01 Sodium Phenylbutyrate 
  • 500mg tablets - Licensed formulation marketed as Ammonaps
  • 1g in 5ml & 2g in 10ml injections
01.06.02 Sodium Picosulfate 
  • For use as a second line agent in paediatric patients with constipation when Movicol, lactulose and senna are ineffective as single agent therapy.
01.06.05 Sodium Picosulfate with Magnesium Citrate  Picolax®Citrafleet®
05.04.05 Sodium Stibogluconate 
02.13 Sodium Tetradecyl Sulphate 
16 Sodium thiosulphate 
  • 25% injection unlicensedunlicensed
  • 50% injection
  • Approved for the treatment of caliciphylaxis in patients with End Stage Renal Disease (ESRD)
04.07.04.02 Sodium valproate 
  • Note: sodium valproate 500mg & 1000mg MR granules (Episenta®) are also approved for use in those who have difficulty swallowing sodium valproate tablets. MR granules may be more convenient to use than large volumes of liquid formulations.
04.08.01 Sodium Valproate 
  • Note: sodium valproate 500mg & 1000mg MR granules (Episenta®) - for possible use in those who have difficulty swallowing sodium valproate tablets. May be more convenient to use than large volumes of liquid formulations.
04.02.03 Sodium valproate 200mg, 300mg, and 500mg tablets Epilim Chrono®
  • Sodium valproate 200mg, 300mg, and 500mg (Epilim Chrono®) tablets are approved for the prevention and treatment of manic episodes associated with bipolar disorder (unlicensedunlicensed indication). May be useful in patients unresponsive to lithium. 
  • Valproate must no longer be prescribed to women and girls of childbearing potential unless there is no alternative and they are on the Pregnancy Prevention Programme (PPP)
05.03.03.02 Sofosbuvir Sovaldi®
  • Approved for the treatment of chronic hepatitis C in line with NICE and NHS England Commissioning Policy.
05.03.03.02 Sofosbuvir & Ledipasvir  Harvoni®
  • To be used in accordance with NHS England Commissiong Policy  
05.03.03.02 Sofosbuvir & velpatasvir  Epclusa®
  • Approved for the treatment of chronic hepatitis C in line with NICE and NHS England Commissioning Policy.
05.03.03.02 Sofosbuvir, Velpatasvir & Voxilaprevir  Vosevi®
  • Approved for the treatment of chronic hepatitis C in line with NICE and NHS England Commissioning Policy.
18.07.01 Softdrape® Universal Dressing Pack 

Latex free; includes Vitrex gloves

  • Northumbria only
07.04.02 Solifenacin 
  • Specialist Initiation or GP Initiation (in patients who do not wish to be referred  to secondary care and have failed first/second line treatments).
18.01.02 Solvaline N® 

Absorbent, Perforated Plastic Film Faced, Dressing

  • Podiatry use only
06.05.01 Somatropin - adults 
  • Genotropin® cartridges for use in Genotropin pens - 16 unit (5.3mg) & 36 unit (12mg) in 1ml. 
  • Genotropin Miniquick® syringes - 0.2mg (0.6 units), 0.8mg (2.4 units), 1.4mg (4.2 units) 0.4mg (1.2 units) 1mg (3 units) 1.6mg (4.8 units) 0.6mg (1.8 units) 1.2mg (3.6 units) 2mg (6 units) - to be used for patients when travelling.
06.05.01 Somatropin (children) 
  • First line
  • Omnitrope® 5-mg (15-unit) vial (powder with diluent) for use with Omnitrope Pen L® device, 3.3 mg (10 units)/ml, 1.5 ml (5-mg, 15-unit) cartridge & 6.7 mg (20 units)/ml, 1.5 ml (10-mg, 30-unit) cartridge - for use with Omnitrope Pen 5® & Omnitrope Pen 10® devices respectively. 
  • Note: Omnitrope is the least expensive formulation of somatropin and should be used in all de novo paediatric patients where possible. 
  • Second line 
  • Norditropin SimpleXx® 1.5ml cartridges for use in Nordipen® devices - 5mg (15 units), 10mg (30 units) and 15mg (45 units). Note: norditropin is the second least expensive alternative formulation for patients who cannot tolerate omnitrope. 
  • Saizen® 8mg vials (powder with diluent), Saizen® 5.83 mg/ml solution for injection (6mg cartridges), 8 mg/ml solution for injection (12mg and 20mg cartridges) - for use in EasyPod® device (to be used in patients with compliance issues).
  • Third line
  • Genotropin Miniquick® syringes - 0.2mg (0.6 units) 0.8mg (2.4 units) 1.4mg (4.2 units), 0.4mg (1.2 units) 1mg (3 units) 1.6mg (4.8 units) 0.6mg (1.8 units), 1.2mg (3.6 units) 2mg (6 units). To be used for patients when travelling.
  • Zomacton® (needle free presentation) 12 unit (4mg) injection; 1st line: 75% to 85% of total mg usage; 2nd line: 15% to 25% of total mg usage; 3rd line: up to 5% of total mg usage.
08.01.05 Sorafenib Nexavar®
  • 200mg tablets
  • Approved for treatment of advanced hepatocellular carcinoma only for people with Child-Pugh grade A liver impairment in line with NICE and NHS Commissioning Policy
13.02.02 Sorbaderm® cream 
  • 2g, 28g & 92g barrier cream, 28ml pump spray, sterile 1ml no
    sting barrier film foam applicator, sterile 3ml no sting
    barrier film foam applicator
18.02.06 Sorbsan ® Ribbon  

Calcium alginate fibre, highly absorbent

02.03.02 Sotalol 
02.04 Sotalol 
  • Treatment should only be intiated on the advice of a cardiologist. 
05.01.04 Spectinomycin 
  • Only approved for the treatment of gonorrhoea in adults.

 

02.02.03 Spironolactone 
  • Use is also extended for treatment in post-acute myocardial infarction patients and patients with mild heart failure. Treatment should only be initiated on the advice of a cardiologist. (Spironolactone is considerably cheaper than eplerenone).
  • A spironolactone 10mg and 50mg in 5ml suspension is also approved unlicensedunlicensed.
02.02.04 Spironolactone and chlorothiazide capsules 
  • For use in paediatric cardiology. 
  • Capsules are manufactured to have 1:10 ratio of spironolactone to chlorothiazide - formulations available include:
    • 1mg/10mg 
    • 2mg/20mg
    • 3mg/30mg
    • 5mg/50mg
    • 10mg/100mg

02.02.04 Spironolactone and chlorothiazide capsules 
03.04.03 Stanozolol 50mg tablets 
  • For use on the advice of an immunologist in the prophylaxis treatment hereditary angioedema associated with C1-esterase inhibitor deficiency.

05.03.01 Stavudine 
09.02.02 Steriflex 165® 
  • Potassium chloride 0.3% (20mmol); sodium chloride 0.9%; and glucose 5% (500ml bag).
    • Approved for diabetic ketoacidosis in paediatric patients unlicensedunlicensed.

18.07.01 Sterile Gloves 
18.11.07 Sterile Larvae Biobag®
  • Specialist use only
18.11.07 Sterile Larvae Larvae 300®
  • Specialist Use Only
13.11.07 Sterile Larvae (Maggots) LarvE®
  • Used for the management of sloughy wounds.
09.02.02.01 Sterile oral water 
  • 100ml
04.08.01 Stiripentol 
  • For use as adjunctive therapy of refractory generalised tonicclonic seizures in children with severe myoclonic epilepsy in infancy.
02.10.02 Streptokinase 
05.01.09 Streptomycin  
08.01.05 Streptozocin  
  • Named patient supply only.
18.08.07 Sub-compression wadding bandage 
  • Profore®
  • Flexi-Ban®
  • FormFlex natural (not on FP10)  
09.05.02.02 Sucroferric oxyhydroxide Velphoro®
  • Approved for use by haemodialysis or peritoneal dialysis patients who cannot tolerate alternative phosphate binders or where these have been ineffective
19 Sucrose 24% solution 
13.02.02 Sucrulfate cream 
  • For limited use around gastrostomies when wound breakdown is thought to be aggravated by leakage of gastric acid.
13.02.02 Sudocrem® 
04.07.02 Sufentanil Zalviso®
  • 15microgram sublingual tablets
  • Approved only for Gateshead Health NHS Foundation Trust whose patients have had total knee replacement and are part of an enhanced recovery programme.
15.01.06 Sugammadex Bridion®
  • 200mg in 2ml & 500mg in 5ml injections
    • Approved for the emergency reversal of blockade in cases of failed intubation in patients who are undergoing rapid sequence induction anaesthesia with rocuronium because of contra-indications to suxamethonium.
    • Approved for the reversal of rocuronium blockade in obstetric general anaesthesia for caesarean sections.

01.05.01 Sulfasalazine 

Alternative

10.01.03 Sulfasalazine E/C tablets 
19 Sulphur hexafluoride Sonovue ®
  • Sulphur hexafluoride. Available as a kit including one vial of gas, one vial of powder and one pre-filled syringe containing 5ml of solvent. On reconstitution, 1 ml of the resulting dispersion contains 8 microliters of sulphur hexafluoride in the microbubbles, equivalent to 45 microgrammes
    - approved for use in visualising blood vessels in liver and diagnosing cancer, and used for the diagnosis of pancreatic cancers, and also for use when echocardiography images are unsatisfactory for answering the clinical question due to poor definition.
04.02.01 Sulpiride 
04.02.01 Sulpride 
04.07.04.01 Sumatriptan 
08.01.05 Sunitinib  
  • Approved for gastrointestinal stromal tumours (GISTs) in line with NICE. 
  • Approved for advanced and/or metastatic renal cell carcinoma in line with NICE.
  • Sunitinib not approved for second line use in advanced and/or metastatic renal cell carcinoma NICE.
  • Approved for the treatment of unresectable or metastatic neuroendocrine tumours in people with progressive disease in line with NICE and NHS England Commissioning Policy
13.08.01 Sunsense Ultra® 
15.01.05 Suxamethonium Chloride 
  • 100mg/2ml injection
11.08.01 Systane® 
  • 10ml multidose bottles 0.8ml preservative-0free vials Contains hydroxypropyl guar, polyethylene glycol 400, propylene glycol (and other ingredients).
  • Long-acting ocular lubricant used for the treatment of dry eye syndrome. Liquid formulation which turns into a gel on contact with eyes providing fast and long lasting relief. The multidose bottle may be used for up to six months after opening in primary care. In contact lens wearers, Systane should be applied before inserting lenses and after removal to extend comfortable wearing times.
11.09 Systane®  
13.10.05 TachoSil® 
  • 4.8 & 9.5 cm 2 Haemostatic (collagen sponge coated with fibrinogen and thrombin) - for use in liver and renal surgery.
08.02.02 Tacrolimus 

Approved tacrolimus formulations include:

  • 500 microgram, 1mg & 5mg capsules (Prograf® & Adoport®).
  • 1mg in 1ml oral suspension (unlicensedunlicensed) - this replaces 0.5mg/ml oral
    suspension. 
  • 5mg in 1 ml concentrate for preparing IV infusion - approved for renal transplantation in children and adolescents in line with NICE.
  • 500microgram, 1mg, 3mg & 5mg MR capsules (Advagraf®) approved for use for prophylaxis of organ rejection in kidney and liver transplantation. Advagraf® is also approved for use in patients who are currently prescribed Prograf®, and de novo patients should be prescribed Adoport®.
  • 750microgram, 1 mg and 4 mg m/r tablets (Envarsus®)
    • approved for the treatment of renal and liver transplant patients who are suffering from neurotoxicity with other formulations or for patients requiring large doses of tacrolimus. 

13.05.03 Tacrolimus ointment Protopic®
  • Approved for moderate to severe disease atopic eczema in patients over 2 years in line with NICE.
02.05.01 Tadalafil 
  • Approved for pulmonary hypertension in adults for whom treatment with sildenafil is not tolerated or effective (in accordance with NHS England Commissioning policy).
  • Approved for systemic sclerosis with ongoing digital ulcer disease (to reduce number of new digital ulcers) - in accordance with NHS England Commissioning policy.
  • Approved for secondary Raynaud's.
07.04.05 Tadalafil 
  • 10mg and 20mg tablets 
  • Also approved for specialist use in treating secondary Raynaud's disease. Red Traffic Light
11.06 Tafluprost (Preservative Free) 15micrograms/ml unit dose eye drops 
  • Approved for use in children and adults. To be initiated by ophthalmologists only and is to be used third line after preservative containing latanoprost and preservative free timolol. The ophthalmologists must clearly document that signs and symptoms of preservative intolerance/ allergy have been demonstrated in their patient prior to initiation.
11.06 Tafluprost 15microg with timolol 0.5% eye drops 
08.01.05 Talimogene laherparepvec 
  • Approved for the treatment of unresectable metastatic melanoma in line with NICE and NHS England Commissioning Policy (SSC1679).
08.03.04.01 Tamoxifen 
  • Approved formulations include:
    • 10mg and 20mg tablets;
    • 10mg in 5ml sugar free oral solution.

07.04.01 Tamsulosin 400microgram MR capsules 
04.07.02 Tapentadol 
  • Approved for use by chronic pain specialist in adults with severe pain who have been screened for a neuropathic element to their pain and are uncontrolled or experiencing GI side effects on existing therapy.
13.05.02 Tar Pomade (6% coal tar solution & 2% salycylic acid in emulsifying ointment) 
02.08.01 TauroHep® 
  • Approved for use in the prevention of central intravenous line infections
    in; haemodialysis patients, adult parenteral nutrition patients, patients with recurrent line infections, and immune deficiency unit patients.
19 Tauroldine 2% solution 
02.08.01 TauroLock® 
  • Approved for use in the prevention of central intravenous line infections in; haemodialysis patients, adult parenteral nutrition patients, patients with recurrent line infections, and immune deficiency unit patients.
18.02.02 Tegaderm Film 
  • IV/sc dressing and podiatry use only
18.03.03 Tegaderm® Alginate Ag 

Calcium alginate and carboxymethylcellulose dressing with silver

18.02.02 Tegaderm® with pad 
08.01.03 Tegafur with Uracil 
  • Approved for metastatic colorectal cancer in line with NICE.
05.01.07 Teicoplanin 
  • Restricted for use on microbiology/infectious diseases advice, or as agreed in Trust Guidelines.
04.01.01 Temazepam 
15.01.04.01 Temazepam 
  • see section 04.01.01
05.01.01.02 Temocillin 
  • Restricted for use on microbiology/infectious diseases advice, or as agreed in Trust Guidelines.
08.01.05 Temozolomide  
  • Approved for the treatment of recurrent malignant glioma in line with NICE.
  • Approved for newly diagnosed glioblastoma multiforme (GBM) in line with NICE.
05.03.01 Tenofovir alafenamide & Cobicistat & Emtricitabine & Elvitegravir  Genvoya®
  • To be used in accordance with NHS England Clinical Commissioning Policy.
05.03.01 Tenofovir alafenamide & Emtricitabine 
  • Film coated tablets containing:
    • emtricitabine 200mg & tenofovir alafenamide (as fumarate) 10mg
    • emtricitabine 200mg & tenofovir alafenamide (as fumarate) 25mg

  • To be used in accordance with NHS England Clinical Commissioning Policy.
05.03.01 Tenofovir alafenamide & Emtricitabine & Rilpivirine  Odefsey®
  • Film coated tablets containing rilpivirine 25mg, emtricitabine 200mg & tenofovir alafenamide (as fumarate) 25mg
  • To be used in accordance with NHS England Clinical Commissioning Policy.
05.03.01 Tenofovir Disoproxil 
05.03.01 Tenofovir Disoproxil & Emtricitabine 
05.03.01 Tenofovir Disoproxil & Emtricitabine & Rilpivirine 
05.03.03.01 Tenofovir Disproxil Viread®
05.03.01 Tenofovir Disproxil & Cobicistat & Elvitegravir & Emtricitabine 
  • To be used in accordance with NHS England Clinical Commissioning Policy.
05.03.01 Tenofovir Disproxil & Efavirenz & Emtricitabine 
02.05.04 Terazosin 
07.04.01 Terazosin 2mg, 5mg, and 10mg tablets  
05.02.05 Terbinafine 
13.10.02 Terbinafine 1% cream 
03.01.01.01 Terbutaline 
  • Turbohaler® 500 mcg/puff
  • 500 mcg in 1ml injection
07.01.03 Terbutaline 
08.02.04 Teriflunomide 
  • Approved as a option for treating adults with active relapsing-remitting multiple sclerosis that isn’t highly active or rapidly evolving severe relapsing-remitting multiple sclerosis NICE and NHS England Commissioning Policy.
06.06.01 Teriparatide 250microgram in 1ml prefilled pen 
  • Approved for the secondary prevention of osteoporotic fragility fractures in postmenopausal women who are confirmed to have osteoporosis primary in line with NICE.
06.05.02 Terlipressin 1mg injection 
06.04.02 Testosterone 50mg in 5gram (1%) gel Testim®
  • For use on advice from endocrinologists.
06.04.02 Testosterone 1ml injection Sustanon 250®
  • Sustanon® 250 1ml injection contains testosterone propionate 30mg, testosterone phenylpropionate 60mg, testosterone isocaproate 60mg and testosterone decanoate 100mg.
06.04.02 Testosterone 50mg in 5ml (1%) sachets Testogel®
  • For use on advice of endocrinologist.
06.04.02 Testosterone gel pump 10mg in 0.5ml (2%)/metered dose Tostran®
  • For use on advice from endocrinologist.
06.04.02 Testosterone undecanoate 1gram in 4ml oily injection Nebido®
06.04.02 Testosterone undecanoate 40mg capsules 

 

 

14.05.02 Tetanus immunoglobulin 
04.09.03 Tetrabenazine 
  • For use on the advice of neurologists. 
15.02 Tetracaine (Amethocaine) Ametop®
  • 4% gel
11.07 Tetracaine 1% Minims® 
06.05.01 Tetracosactide Synacthen®
  • Approved formulations include:
    • 250microgram in 1ml injection;
    • 1mg in 1ml depot injection. 

09.02.02.02 Tetrastarch Volulyte®
  • 6% tetrastarch infusion in a balanced electrolyte solution containing Na+ 137 mmol, K+ 4 mmol, Mg2+ 1.5 mmol, Cl110 mmol, acetate 34 mmol/litre.
    Contains calcium.
    • Mainly for use in indications where calcium containing fluids are unsuitable

09.02.02.02 Tetrastarch Tetraspan®
  • 6% & 10% tetrastarch infusions in a balanced electrolyte solution containing Na+ 140 mmol, K+ 4 mmol, Mg2+ 1 mmol, Cl- 118 mmol, Ca2+ 2.5 mmol, acetate 24 mmol, malate 5 mmol/litre.
    Contains calcium
08.02.04 Thalidomide 
  • Approved in combination with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma in line with NICE. 
  • Approved for the treatment of bleeding from bowel angiodysplasia in patients with an inherited/acquired bleeding disorder on specialist advice only.
  • Approved for the treatment of severe epistaxis as a result of hereditary haemorrhagic telangiectasia (HHT) who have failed all other treatments.
03.01.03 Theophylline 
09.06.02 Thiamine 
  • 50mg & 100mg tablets
15.01.01 Thiopental Sodium 500mg/20ml injection 
08.01.01 Thiotepa  
06.04.01.01 Tibolone 
02.09 Ticagrelor 
  • Only approved for use in accordance with NICE guidance. 
05.01.03 Tigecycline 
13.04 Timodine® 

MILD

  • Cream
11.06 Timolol 
  • 0.25% and 0.5% eye drops.
    0.25% and 0.5% unit dose eye drops.
11.06 Timolol LA 
  • 0.25% and 0.5% long-acting eye drops.
02.08.01 Tinzaparin 
08.01.03 Tioguanine  
  • 50mg in 1ml suspension is also approved.unlicensedunlicensed
09.08.01 Tiopronin 
  • 500mg tablets - for use as 2nd line treatment for cystinuria in
    patients who fail to tolerate/respond to penicillamine unlicensedunlicensed.
03.01.02 Tiotropium Handihaler®

COPD

  • Handihaler® breath actuated DPI 18 mcg capsules.
    • For existing COPD patients only and those unable to use the other LAMA devices. Consideration should be given to switching at next review, providing adequate training / counselling is provided in device use.

Asthma

  • Step 4 of BTS/SIGN guidelines. Treatment should be stopped if not effective. 
  • 2.5mg Respimat® inhaler
  • Handihaler® device for patiernts who cannot use the Respimat inhaler (off label use).
05.03.01 Tipranavir 
02.09 Tirofiban 
10.02.02 Tizanidine 
  • Approved for use on advice from neurologists when other treatments are unsuitable.
05.01.04 Tobramycin 
  • Restricted for use on microbiology/infectious diseases advice, or as agreed in Trust Guidelines.
    • 80mg in 2ml & 240mg in 6ml injections.
    • 300mg in 4ml (Bramitob®).
    • 300mg in 5ml (Tobi®).
    • TOBI Podhaler.

  • Inhaled preparations to be used for treatment of Cystic Fibrosis in accordance with NHS England Commissioning Policy/NICE Guidance.   
10.01.03 Tocilizumab RoActemra®
  • IV preparations approved for:
    • Systemic JIA in children and young people aged 2 years and older in line with NICE.
    • People aged 2 years and older to treat polyarticular juvenile idiopathic arthritis (JIA) whose diease has responded inadequately to previous therapy with methotrexate in line with NICE.
    • An alternative treatment to anakinra for patients with systemic onset JIA who have already received treatment with etanercept and adalimumab (NETAG approval). Not recommended for polyarticular JIA.
    • Rheumatoid arthritis in accordance with NICE.
    • Treatment in adults with severe rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed in accordance with NICE.
  • 162mg SC injection is approved:
    • For rheumatoid arthritis in accordance with NICE.
    • Treatment of giant cell arteritis in adults only if:
      • they have relapsing or refractory disease
      • they have not already had tocilizumab
      • tocilizumab is stopped after 1 year of uninterrupted treatment at most.
10.01.03 Tofacitinib Xeljanz®
  • 5mg tablets
  • Approved as an option for treating active rheumatoid arthritis in adults whose disease has responded inadequately to intensive therapy with a combination of conventional disease-modifying anti-rheumatic drugs (DMARDs)in line with NICE
06.01.02.01 Tolbutamide 
04.09.01 Tolcapone 
07.04.02 Tolterodine 1mg and 2mg tablets 
06.05.02 Tolvaptan 
  • 15mg, 30mg, 45mg, 60mg and 90mg tablets (Jinarc®) - approved for the treatment of autosomal dominant polycystic kidney disease in line with NICE.
  • 15mg and 30mg tablets (Samsca®) - approved for the treatment of hyponatraemia secondary to the Syndrome of Inappropriate Antidiuretic Hormone (SIADH) in patients requiring cancer chemotherapy in accordance with NHS England Policy.
04.07.04.02 Topiramate 
04.08.01 Topiramate 
08.01.05 Topotecan  
  • Approved for relapsed NSCLC in line with NICE.
  • Approved for recurrent or stage IVB cervical cancer in line with NICE.
  • Approved for second-line (or subsequent) treatment in advanced ovarian cancer in line with NICE.
  • Approved for the treatment of recurrent ovarian cancer in line with NICE.
02.02.02 Torasemide 
08.01.05 Trabectedin  

Approved for the treatment of recurrent ovarian cancer in line with NICE.

04.07.02 Tramadol 
  • 50mg capsules, 50mg dispersible tablets & 100mg/2ml injection
  • Only approved for use as a second-line weak opioid analgesic for use in patients where treatment with possible alternatives such as paracetamol, NSAIDs, and codeine is insufficiently effective, not tolerated or considered unsuitable for other reasons.
  • Note: modified release tramadol is not approved or recommended. 
06.01.05 Tramadol  
  • 50mg capsules, 50mg dispersible tablets & 100mg/2ml injection
08.01.05 Trametinib  
  • Approved in combination with dabrafenib for the treatment of unresectable or metastatic melanoma in line with NICE and NHS England Commissioning Policy.
02.11 Tranexamic Acid 
  • Also available as a 500mg in 5ml syrup unlicensedunlicensed.
18.07.03 Transpore® 

Permeable Non-woven Synthetic Adhesive Tape, BP 1988 

  • Secondary care only
08.01.05 Trastuzumab 
  • Approved for metastatic or locally advanced inoperable gastric cancers in line with NICE.
  • Approved for early stage HER2-positive breast cancer in line with NICE.
  • Approved for advanced HER2-positive breast cancer in line with NICE.
  • Note: trastuzumab is not recommended in combination with an aromatase inhibitor for the first-line treatment in postmenopausal women with metastatic hormonereceptor- positive breast cancer that overexpresses HER2 - in line with NICE.
  • Trastuzumab 600mg subcutaneous injection is approved by NHS England for HER2-positive breast cancer in line with NECN guidance.
08.01.05 Trastuzumab emtansine Kadcyla®
  • 100mg & 160mg powder for concentrate for solution for infusion
  • Approved for the treatment of HER2-positive advanced breast cancer after trastuzumab and a taxane in line with NICE and NHS England Commissioning Policy
04.03.01 Trazodone 
  • Trazodone is widely used off-license for night sedation and behavioural symptoms of dementia.
03.02 Trelegy Ellipta® 
  • First choice triple therapy ICS/LABA/LAMA inhaler
  • Fluticasone furoate 92 microgram/umeclidinium bromide 65 microgram/vilanterol (as Vilanterol trifenatate) 22 microgram per dose

  • Patients on other triple therapy combinations should be given the opportunity to change to a triple therapy preparation to potentially improve compliance and realise savings. This must be done following a face to face review.
08.01.01 Treosulfan  
02.05.01 Treprostinil 
  • Approved for pulmonary hypertension - in accordance with NHS England Commissioning policy. 
08.01.05 Tretinoin  
13.06.01 Tretinoin 0.025% with Clindamycin 1% gel Treclin®
11.08.02.04 Tretinoin 0.05% eye drops 
10.01.02.02 Triamcinolone Acetonide 
  • The following triamcinolone acetonide preparations are approved:
    • Kenalog® - 40mg in 1ml and 80mg in 2ml intramuscular/intra-articular injection.
    • Adcortyl® - 10mg in 1ml and 50mg in 5ml intradermal/intra-articular injection. 

06.03.02 Triamcinolone acetonide 40 mg in 1ml 
12.02.01 Triamcinolone Acetonide 55microgram metered dose nasal spray Nasacort®
10.01.02.02 Triamcinolone hexacetonide 20mg in 1ml 
  • Only approved for paediatric use. 
13.07 Trichloroacetic Acid 
  • 10%, 75% & 90% solution.
13.11.05 Triclosan Aquasept® & Manusept®
  • 1% or 2% skin cleanser
  • 0.5% hand rub
12.03.04 Triclosan toothpaste Mentadent P®
09.08.01 Trientine Dihydrochloride 
  • 300mg capsules
    • Approved for the treatment of Wilsons disease in line with NHS England Commissioning Policy. NHS England will commission the treatment for patients who are currently being treated (April 2017)

04.02.01 Trifluoperazine 
04.02.01 Trifluoperazine 
11.03.03 Trifluorothymidine 1% Eye drops 
08.01.03 Trifluridine and tipiracil 
  • Approved for previously treated metastatic colorectal cancer in adults in line with NICE and NHS England Commissioning Policy (SSC1662). 
04.09.02 Trihexyphenidyl 
03.02 Trimbow® 
  • Second choice triple therapy ICS/LAMA/LABA inhaler
  • Beclometasone dipropionate 87 microgram/formoterol fumarate dihydrate 5 microgram/glycopyrronium (as glycopyrronium bromide) 9 microgram per dose.

  • A spacer should be used

  • Patients on other triple therapy combinations should be given the opportunity to change to a triple therapy preparation to potentially improve compliance and realise savings. This must be done following a face to face review.
05.01.08 Trimethoprim 
13.04 Trimovate® cream 

MODERATELY POTENT

  • Containing clobetasone 0.5%, oxytetracycline3% and nystatin 100,000units/g
01.03.03 Tripotassium Dicitratobismuthate De-Noltab®
  • Discontinued by the manufacturer in December 2015. No alternative product available once supplies have been used
06.07.02 Triptorelin 
  • The following formualtions are approved for use in treating precocious puberty:
    • Gonapeptyl Depot® 3.75mg injection;
    • Decapeptyl SR®11.25mg injection.

08.03.04.02 Triptorelin 
  • Approved formulations include triptorelin 3mg, 11.25mg and 22.5mg IM injection.
11.05 Tropicamide single use Minims®  
09.08.01 Ubiquinone Coenzyme Q10, Ubidecarenone
  • 10mg, 30mg, & 100mg capsules 
  • 50mg in 5ml & 30mg in 1ml (150mg in 5ml) oral solution
    • nutritional supplement and antioxidant approved for use in the
      management of mitochondrial disorders.
    • approved for use under specialist consultant supervision in the
      management of patients with severe hyperlipidaemia who are not tolerating statins due to myopathy. Use in statin induced myopathy is subject to treatment being initiated by a consultant.

      Lipid clinic initiation only

18.05 UCS® Debridement 
06.04.01.02 Ulipristal 
  • Approved for the pre-operative treatment of uterine fibroids up to a maximum of four 3 month intermittent courses, as per its product license and reviewed regularly.
  • Approved for the medical treatment of uterine fibroids up to a maximum of four 3 month intermittent courses, as per its product license and reviewed regularly.
07.03.05 Ulipristal 30mg tablet ellaOne®
  • Recommended by NETAG as the preferred drug treatment option for post-coital contraception for patients who present between 72 and 120 hours following unprotected intercourse.
03.01.02 Umeclidinium Incruse Ellipta®
03.01.04 Umeclidinium & vilanterol Anoro Ellipta®
  • Alternative LABA/LAMA for COPD.
08.01.05 upoNilotinib 
  • Approved for the first-line treatment of adults with chronic phase Philadelphia-chromosome-positive CML in line with NICE and NHS Commissioning Policy
18.02.03 Urgotul® 

Non-adherent soft polymer wound contact dressing

18.03.03 Urgotul® SSD 

Non-adherent, soft polymer wound contact dressing with silver sulfadiazine.

  • Specialist use only.
02.10.02 Urokinase 
01.09.01 Ursodeoxycholic acid 
01.05.03 Ustekinumab Stelara®
  • 130 mg concentrate for solution for infusion
  • Approved for previously treated moderately to severely active Crohn’s disease in adults in line with NICE
10.01.03 Ustekinumab Stelara®
  • Approved for psoriatic arthritis in accordance with NICE.
13.05.03 Ustekinumab Stelara®
  • 45mg & 90mg SC injections approved for psoriasis and psoriatic arthritis in line with NICE.
  • Approved for the treatment of plaque psoriasis in children and young people in line with NICE
13.08.01 Uvistat Ultrablock® 
18.06.01 V.A.C.® Dressing 
05.03.02.01 Valaciclovir 
05.03.02.02 Valganciclovir Valcyte®
04.02.03 Valproic Acid  Depakote®
  • Licensed alternative to sodium valproate MR tablets. 
  • Valproate must no longer be prescribed to women and girls of childbearing potential unless there is no alternative and they are on the Pregnancy Prevention Programme (PPP)
02.05.05.02 Valsartan 
  • Only to be used in the treatment of existing patients.
05.01.07 Vancomycin 
  • Restricted for use on microbiology/infectious diseases advice, or as agreed in Trust Guidelines.
    • 125mg capsules Green Traffic Light.
    • 500mg and 1g injections Red Traffic Light
    • 20mg in 4ml intrathecal injection unlicensedunlicensed Red Traffic Light.

04.10.02 Varenicline 
  • Only approved for use in accordance with NICE guidance. 
14.04 Varicella Zoster vaccine Zostavax®
14.05.02 Varicella-Zoster immunoglobulin VZIG
14.04 Varicella-zoster vaccine 
13.02.02 Vasogen® 
15.01.05 Vecuronium Norcuron®
  • 10mg in 5ml injection
01.05.03 Vedolizumab 
  • Only approved for use in accordance with NICE guidance. 
08.01.05 Vemurafenib  
  • Approved melanoma (BRAF V600 mutation positive, unresectable metastatic) in line with NICE.
08.01.05 Venetoclax 
  • Approved for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) in the presence of 17p deletion or TP53 mutations, and who are unsuitable for or have failed a B-cell receptor pathway inhibitor; and for the treatment of adult patients with CLL in the absence of 17p deletion ot TP53  mutation, and who are unsuitable for or have failed both chemo-immunotherapy and a B-cell receptor pathway inhibitor in line with MHRA Early Access to Medicines Scientific Opinion.
04.03.04 Venlafaxine 
  • For patients on doses of 300mg/day or more. Green Traffic Light
  • Patients who are deemed stable on doses of up to 225mg daily of MR venlafaxine should be switched to the equivalent dose of immediate release venlafaxine.
  • MR tablets are only to be used in patients currently prescribed doses of 300mg and over and for whom there is no suitable alternative, those who have experienced discontinuation reactions (at any dose), and for patients who need to take the once daily formulation in order to facilitate care visits.
02.06.02 Verapamil 
11.08.02 Verteporfin 15mg Injection Visudyne®

Approved for photodynamic therapy in wet age-related macular degeneration in line NICE.

04.08.01 Vigabatrin 
08.01.04 Vinblastine Sulphate  
08.01.04 Vincristine Sulphate 
08.01.04 Vindesine Sulphate  
08.01.04 Vinorelbine 
  • The following formulations are approved for use:
    • 20mg & 30mg capsules;
    • 10mg in 1ml injections;
    • 50mg in 5ml injections.

09.06.01 Vitamin A 
  • 20,000 unit injection - for the treatment of night blindness/ vitamin A deficiency as a result of malabsorption in patients with short bowel syndrome, ileal resection or pancreatic insufficiency unlicensedunlicensed.
09.06.02 Vitamin B & C injection Pabrinex®
  • IVHP injection (ascorbic acid 500mg, nicotinamide 160mg, pyridoxine
    hydrochloride 50mg, riboflavin 4mg & thiamine hydrochloride 250mg &
    1g anhydrous glucose / pair of ampoules) 
  • IMHP injection also used
09.06.02 Vitamin B Tablets, Compound Strong 
  • Tablets (nicotinamide 20mg, pyridoxine hydrochloride 2mg, riboflavin 2mg & thiamine hydrochloride 5mg per tablet).
    • For short term use in refeeding syndrome only.

09.06.01 Vitamins A and D 
  • Capsules containing vitamin A 4000 units, vitamin D 400 units
03.01.05 Volumatic® 
05.02.01 Voriconazole 
11.03.02 Voriconazole 
  • 100microgram in 0.1ml (0.1%) - preservative-free eye drops.
04.03.04 Vortioxetine 
  • Only approved for use in accordance with NICE guidance. 
01.10 VSL#3® 
  • Probiotic containing high concentration of lyophilised bacteria 
  • approved for use under the supervision of a physician for the maintenance of remission of ileoanal pouchitis in patients with ulcerative colitis who have undergone proctocolectomy with ileal pouch-anal anastomosis
    • Adult patients Green Traffic Light
    • Paediatric patients Red Traffic Light

02.08.02 Warfarin 
  • 500 microgram, 1mg, 3mg & 5mg tablets Green Traffic Light.
  • 1mg/1ml oral suspension - - for use in paediatric patients on mechanical support using ventricular assistance devices, and for patients with mechanical heart valves or irregular heart rythms who have not been weaned Green Traffic Light.
07.04.04 Water 
  • Large volumes  - up tp 3 litres.
09.02.02.01 Water for Infusion (Viaflo® - FE0304) 
  • Approved for use by the North-East Assisted Ventilation Service (NEAVS).
09.02.02.01 Water for Injection 
  • 2ml, 5ml, 10ml, 20ml, 100ml & 500ml
09.02.02.01 Water for Irrigation 
  • 1000ml
13.11.01 Water for Irrigation 
13.02.01 White Soft Paraffin BP 
07.04.04 Whitmore cocktail 
  • Whitmore cocktail is a 60ml bladder installation containing hydrocortisone 100mg, heparin Sodium 10,000units, and bupivacaine 50mg in Sodium Chloride 0.9%.
19 Xelma® 
12.02.02 Xylometazoline Otrivine®
  • 0.05% and 0.1% nasal drops.
  • 0.1% nasal spray.
01.07.02 Xyloproct® 
  • Recommended for short-term use only.
13.02.01 Yellow Soft Paraffin BP 
05.03.04 Zanamivir inhalation Relenza®
  • Only approved for use in accordance with NICE guidance. 
13.02.01 ZeroAQS® 
  • SLS free alternative to Aqueous Cream.
13.02.01 Zerobase® 
  • Alternative to Diprobase
13.02.01 Zerocream® 
  • Alternative to E45® Cream.
13.02.01 Zerodouble® Gel  
  • Alternative to Doublebase gel.
13.02.01.01 Zerolatum® Bath Emollient 
  • Alternative to Oilatum®.
13.02.01.01 Zeroneum® Bath Emollient  
  • Alternative to Balneum®.
13.02.01 Zeroveen® cream 
  • Alternative to Aveeno
18.01.02 Zetuvit Plus® 

Super absorbent cellulose primary dressing

18.01.02 Zetuvit® E  

Absorbent Cellulose Dressing with Fluid Repellent Backing 

05.03.01 Zidovudine 
05.03.01 Zidovudine & Lamivudine 
13.02.02 Zinc and caster oil ointment BP 
13.05.02 Zinc and Coal Tar Paste White's Tar Paste
13.05.02 Zinc and Salicylic Acid Compound Paste  Half Strength Lassar's Paste
13.05.01 Zinc oxide bandage  Viscopaste®
18.08.09 Zinc Paste and Ichthammol Bandage, BP 1993 Ichthopaste®
18.08.09 Zinc Paste Bandage, BP 1993 Viscopaste® PB7
09.05.04 Zinc Sulphate Solvazinc®
09.05.04 Zinc Sulphate 220mg capsules 
09.05.01.02 Zoledronic Acid Zometa®
  • 4mg injection
    For hypercalcaemia of malignancy and the prevention of skeletal events in patients with metastatic breast cancer. Prescribe by brand name (Zometa®) to avoid confusion with a different strength product used to treat osteoporosis and Paget’s disease
06.06.02 Zoledronic Acid 4mg injection 
  • Approved for use in treating hypercalcaemia of malignancy and the prevention of skeletal events in patients with metastatic breast cancer.
  • Approved for the adjuvant treatment of post-menopausal  women with early breast cancer (subject to agreement with the CCGs and provider trusts regarding the extra activity). 
  • Not approved for preventing skeletal events in patients with prostate cancer.
  • To avoid confusion it is recommended that this product is prescribed by brand name i.e. Zometa®
06.06.02 Zoledronic Acid 5mg injection 
  • Prescribe by brand name
  • Approved for the treatment of osteoporosis in line with NICE
04.07.04.01 Zolmitriptan 2.5mg tablets 
04.08.01 Zonisamide 
  • For specialist use only in patients that are refractory to treatment with other drugs
  • Use in children is unlicensedunlicensed.
04.01.01 Zopiclone 
  • To be used in accordance with NICE criteria
04.02.01 Zuclopenthixol 
04.02.02 Zuclopenthixol Acetate Clopixol Acuphase®
  • For short-term use by NTW.
04.02.02 Zuclopenthixol Decanoate 
North of Tyne and Gateshead Area Prescribing Committee